email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
all 3612 products
View All
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
Next
China Medical Technologies Inc. Has "No Assets" according to Liquidators
$5.00
Available
Sanjiu Medical Buys Zhongyi Pharma for $209 Million
$5.00
Available
Sino Biological Pays $48 Million to Acquire Vancouver’s SignalChem
$5.00
Available
Biocytogen Signs Evaluation/Licensing Agreement for TCR-mimic with BioCopy
$5.00
Available
Leads Biolabs Begins Phase III Trial of PD-L1/4-1BB Bispecific for Solid Tumors
$5.00
Available
Eluminex Starts Trials of Novel Trispecific Fusion mAb for Macular Edema
$5.00
Available
SCG and A*STAR to Develop better Stem Cell Manufacturing in Singapore
$5.00
Available
WuXi AppTec Says Q1 Revenues Hit Targets, Clients not Leaving Company
$5.00
Available
Brise Pharma Closes $20 Million in A Rounds for Novel Pain Drugs
$5.00
Available
Transcenta and Agilent Collaborate on Companion Diagnostic for Claudin18.2 mAb
$5.00
Available
Abbisko Completes Enrollment in Global Phase III Trial for Tenosynovial Giant Cell Tumor
$5.00
Available
Kelun/Merck Release Positive Early Data on TROP-2 ADC for Gastric Cancer
$5.00
Available
Kexing Biopharm’s Phase III Trial of Inhaled RSV Therapy for Children
$5.00
Available
VesiCURE Says Stem Cell Derived Extracellular Vesicles Effective in UC
$5.00
Available
Sino Biopharm to Partner China Development of Boehringer Ingelheim Portfolio
$5.00
Available
Junshi's Eighth China Approval of PD-1 is for Renal Cell Carcinoma
$5.00
Available
D3 Bio Raises $62 Million in Series A+ Round for Next-Gen KRAS G12C Inhibitor
$5.00
Available
Visen Pharma Plans Hong Kong IPO to Support Endocrine Therapies
$5.00
Available
Aurisco Pharma Expands Yangzhou CRDMO Facility for Generic GLP-1 Peptides
$5.00
Available
Insilico Medicine, an AI Drug Company, Files for Hong Kong IPO
$5.00
Available
RemeGen Granted US Fast Track for Dual-Target Candidate in Sjögren's Syndrome
$5.00
Available
ProfoundBio, a Seattle-Suzhou ADC Company, Acquired by Genmab for $1.8 Billion
$5.00
Available
Innovent and HutchMed File Combination Therapy NDA for Endometrial Cancer
$5.00
Available
PharmaEssentia Publishes Results for Polycythemia Vera Therapy
$5.00
Available
CMS Acquires JAK1 Inhibitor from Incyte for Autoimmune/Dermatology Diseases
$5.00
Available
WuXi AppTec Passed Client Data to China Officials, Reuters Says
$5.00
Available
InnoCare Doses First Patient in Combination Trial of SHP2 Inhibitor
$5.00
Available
Sperogenix Files for Approval of Duchenne Muscular Dystrophy Therapy in China
$5.00
Available
GenFleet Starts Combo Trial of CDK9 Inhibitor with BeiGene’s BTK Inhibitor
$5.00
Available
Avenzo, Alleron's Partner, Raises $150 Million to Develop Their Partnered Cancer Drug
$5.00
Available
Biocytogen Signs BiSpecific ADC Discovery Deal with Korea’s ABL Bio
$5.00
Available
Biocytogen Signs BiSpecific ADC Discovery Deal with Korea’s ABL Bio
$5.00
Available
Bio-Thera Cleared for US Trial of FRα ADC for Solid Tumor Cancers
$5.00
Available
AriBio Out-Licenses China Rights To Alzheimer’s Candidate in $770 Million Deal
$5.00
Available
Alphamab Publishes Trial Data on Bispecific for Non-Small Cell Lung Cancer
$5.00
Available
WuXi Biologics Begins Construction of $1.4 Billion Singapore CRDMO Facility
$5.00
Available
Merck KGaA to Build $326 Million Bioprocessing Production Center in Korea
$5.00
Available
Novo Nordisk Invests $556 Million In Tianjin Manufacturing Plant for Weight Loss Drug
$5.00
Available
Antengene Starts Dose Expansion in Trial of Claudin 18.2 ADC
$5.00
Available
WuXi AppTec Reports 2023 Results; US Biopharmas Are 65% of Its Business
$5.00
Available
Innovent Reports Positive Data from Phase II Trials of nAMD Therapy
$5.00
Available
BeiGene PD-(L)1 Inhibitor Approved in US for Esophageal Carcinoma
$5.00
Available
KeChow Approved to Launch Tunlametinib for Melanoma Patients in China
$5.00
Available
Boehringer Options Schizophrenia Candidate from Japan’s Sosei in $822 Million Deal
$5.00
Available
Hansoh Adds Global Rights for Zhuhai’s Bispecific in $700 Million Deal
$5.00
Available
PegBio Plans Hong Kong IPO to Support Long Acting GLP-1 for Diabetes/Obesity
$5.00
Available
Aslan Pharma Offers Data Showing Eblasakimab Effective in COPD
$5.00
Available
Ranok to Start China Trial of Protein Degrader for Solid Tumors and Lymphomas
$5.00
Available
RemeGen Says anti-HER2 ADC Effective for Cervical Cancer
$5.00
Available
EurekaBio Raises $40 Million for New Lentiviral Vector Production System
$5.00
Available
Zylox-Tonbridge Acquires China Rights to Vascular Devices for $15 Million
$5.00
Available
Chengdu Maxvax Bio Raises $40 Million for Vaccines and Immunotherapies
$5.00
Available
Chengdu Maxvax Bio Raises $40 Million for Vaccines and Immunotherapies
$5.00
Available
Akeso Starts China Phase III Trial of PD-1/CTLA-4 Bispecific for NSCLC
$5.00
Available
TransThera to Start European Arm of Global Trial for Bile Tube Cancer
$5.00
Available
Innovent/AnHeart File China NDA for ROS1 Inhibitor to Treat NSCLC
$5.00
Available
Haihe Out-Licenses Japan/Asia Rights for NSCLC Therapy to Taiho Pharma
$5.00
Available
Qilu Says PD-1/CTLA-4 Combo Effective Against Cervical Cancer
$5.00
Available
CARsgen Approved to Launch BMA CAR-T in China for Multiple Myeloma
$5.00
Available
Innovent Starts Trials of Bispecific Antibody for Severe Asthma
$5.00
Available
Mabwell Out-Licenses Rare Disease Therapy to Disc in $412 Million Deal
$5.00
Available
AstraZeneca to Build Global Strategic Center in Shanghai
$5.00
Available
Biotheus to Develop Antibodies With Bitterroot for Cardio-Immunology
$5.00
Available
AstraZeneca to Continue Roxadustat Sales in China; Returns Other Rights
$5.00
Available
Everest Medicines Approved to Start China Phase IIb Trial of Lupus Therapy
$5.00
Available
Nhwa to Distribute Teva’s Movement Disorder Therapies in China
$5.00
Available
BioCity Completes Enrollment of ETA Agonist Trial in Patients with IgA Nephropathy
$5.00
Available
Longbio of Suzhou Says LP-003 Effective in Patients with Allergic Rhinitis
$5.00
Available
CHMP Recommends Approval of Legend’s CAR-T as Second-Line Multiple Myeloma Therapy
$5.00
Available
Immunofoco to Start US Trial of CAR-T for Gastrointestinal Tumors
$5.00
Available
Simcere Announces Positive Data from Phase III Trial of Dual-Drug Oral Therapy for Stroke
$5.00
Available
Innovent’s IGF-1R Antibody Meets Endpoint for Thyroid Eye Disease
$5.00
Available
AlphaGen and ArtBio Form China-US Partnership for Radioligand Therapies
$5.00
Available
Mabwell OK’d to Begin US Clinical Trials of ADC for Solid Tumors
$5.00
Available
Biocytogen Signs Three-Year Antibody Discovery Pact with Gilead Sciences
$5.00
Available
Jacobio to Start Phase III Trial of Novel Combination in NSCLC with KRAS G12C Mutations
$5.00
Available
CASI Launches Pralatrexate in China for R/R Peripheral T-cell Lymphoma
$5.00
Available
AusperBio Updates Clinical Progress of Antisense Oligonucleotide Therapy for HBV
$5.00
Available
LianBio to Shut Down Operations; Will Distribute $528 Million to Shareholders
$5.00
Available
Chugai Pharma Approved for China Launch of Complement Inhibitor 5 for NPH
$5.00
Available
Yiviva Signs MOU with AstraZeneca to Develop New Drugs based on TCM Therapies
$5.00
Available
Hengrui Launches Antifungal in China for Vulvovaginal Candidiasis
$5.00
Available
Bayer Signs Letter of Intent to Market Trinity’s Glucose Monitor in China and India
$5.00
Available
Eisai Launches Leqembi, an Alzheimer’s Drug, in China for Early-Stage Disease
$5.00
Available
China Medical System Acquires China Rights to Phosphate Binder from Winhealth
$5.00
Available
I-Mab Divests China Operations to Become Fully US-Based Biopharma
$5.00
Available
Innovent Says NDA for Dual Agonist Obesity Therapy Accepted for China Review
$5.00
Available
Wuhan iRegene Therapeutics Starts China Trial of iPSC Cell Therapy for Parkinson’s
$5.00
Available
Fermion OK’d to Start China Trials of Novel JAK inhibitor for Autoimmune Diseases
$5.00
Available
Anbogen Raises $12.5 Million to Develop Precision Oncology Portfolio
$5.00
Available
Sirius Starts Phase I Trial in Australia of siRNA Aimed at Thromboembolic Disorders
$5.00
Available
Inmagene Exercises Option for Two HutchMed Candidates in $460 Million Deal
$5.00
Available
Biosyngen Nabs US Fast Track Status for TIL Cell Therapy in Liver Cancer
$5.00
Available
Sanofi Invests in Graviton and its Lead Product, a ROCK2 Inhibitor in-licensed from Beijing Tide
$5.00
Available
Biosion Cleared to Start US Trials of Novel anti-SIRPα mAb for Solid Tumor Cancers
$5.00
Available
DualityBio and BioNTech announce US Fast Track Status for ADC in Ovarian Cancer
$5.00
Available
US Legislators Target WuXi Bio and BGI; Aim to Prevent Transfer of US Genomic Data
$5.00
Available
Data from Qilu Pharma’s Approved ALK Inhibitor for NSCLC Published in Journal
$5.00
Available
Gracell Approved for US Trial of FasTCAR in Early Multiple Myeloma
$5.00
Available
Vesicure Announces Positive Early Results of Exosome Technology for siRNA Delivery
$5.00
Available
ArriVent Completes $175 Million NASDAQ IPO to Bring Assets from China to the US
$5.00
Available
Jiuzhou Pharma Earmarks $42 Million for New CDMO Site in Japan
$5.00
Available
Refreshgene’s siRNA Therapy Enables Children with Genetic Deafness to Hear
$5.00
Available
Alphamab and 3D Medicines Out-License PD-L1 to India’s Glenmark
$5.00
Available
Biocytogen Launches New Division to Partner Antibodies and License Mice Platforms
$5.00
Available
Guangzhou’s Baird Medical Completes its First Thyroid Microwave Ablation in the US
$5.00
Available
Duality and BioNTech Start China Arm of Phase III Trial of ADC for HER2 Breast Cancer
$5.00
Available
InnoCare Launches Early Access to CD19 Immunotherapy in China for B-cell Lymphoma
$5.00
Available
SineuGene Reports Positive Initial Results of RNA Therapy for ALS
$5.00
Available
AstraZeneca Signs $26.5 Million Deal to Build Production Line in China for Type-2 Diabetes Drug
$5.00
Available
CARsgen Cleared to Stage China Trial of CAR-T for Hepatocellular Carcinoma
$5.00
Available
Lee’s Pharma in $138 Million Deal for China Rights to Heart Failure Treatment
$5.00
Available
Adagene Reports Positive Early Results from its anti-CTLA-4 for Colorectal Cancer
$5.00
Available
Chipscreen NewWay Starts China Trial of PD-1/CD40 Bispecific for Solid Tumor Cancers
$5.00
Available
Henlius In-licenses Novel ESR1 Antagonist Therapy for Breast Cancer in $58 Million Deal
$5.00
Available
WuXi Biologics to Discover mAbs for BioNTech for $20 Million Upfront
$5.00
Available
GSK Pays $1.4 Billion to Acquire Aiolos, which In-Licensed a Hengrui Asthma Candidate
$5.00
Available
Bayer Joins $162 Million Round for Ji Xing; Has Preferential Rights for In-Licensings
$5.00
Available
OnCusp Completes $100 Million Series A Round for In-Licensed Cancer Candidates
$5.00
Available
Kanghua Out-Licenses Norovirus Vaccine Candidate to HilleVax in $270 Million Deal
$5.00
Available
Insilico Sells Global Rights for KAT6A Inhibitor to Menarini in $500 Million Deal
$5.00
Available
Argo Signs $4.2 Billion Agreement Selling Four RNA Candidates to Novartis
$5.00
Available
Tenacia Acquires China Rights to Tremor Therapy from Praxis in $279 Million Deal
$5.00
Available
Avistone Closes $140 million Series B Round for Precision Medicine Oncology Portfolio
$5.00
Available
Novartis Acquires SanReno Therapeutics, a Shanghai Company with Two IgAN Candidates
$5.00
Available
Allorion Out-Licenses ex-China Rights for CDK2 Inhibitor to Avenzo in $1 Billion Deal
$5.00
Available
IASO and Umoja Partner to Develop Off-the-Shelf CAR-T Gene Therapies
$5.00
Available
Ribo Life Science Forms $2 Billion siRNA Collaboration with Boehringer Ingelheim
$5.00
Available
Belief BioMed Starts China Registrational Trial of Gene Therapy for Hemophilia A
$5.00
Available
JW Therapeutics Extends Development Collaboration with 2seventy for Autoimmune CAR-T
$5.00
Available
Elpiscience Out-licenses Bispecific Macrophage Engage to Astellas in $1.7 Billion Deal
$5.00
Available
Qilu In-Licenses siRNA Targeting PCSK9 from Ribo in $100 Million Agreement
$5.00
Available
Innovent Will Trial its PD-1 With Xuanzhu’s HER-2 ADC for Solid Tumor Cancers
$5.00
Available
Innovent And Sanegene Collaborate to Develop siRNA for Hypertension
$5.00
Available
Biocytogen and CtM Biotech Identify Tri-Specific T Cell Engager for Cancers
$5.00
Available
Gracell, a CAR-T Company, to be Acquired by AstraZeneca for $1.2 Billion
$5.00
Available
LianBio Sells China Rights for Radioenhanced Drug to Janssen for $30 Million
$5.00
Available
Huadong to Promote Impact’s PARP Inhibitor in China in $40 Million Agreement
$5.00
Available
Ablaze Medicine Partners with Oncoshot for AI-based Optimization of Clinical Trials
$5.00
Available
CStone Sells China Rights for IDH1 Inhibitor to Servier Pharma for $50 Million
$5.00
Available
CellOrigin Starts China Trial of Macrophage-based CAR Therapy
$5.00
Available
GSK Acquires ex-China Rights to Second ADC from Hansoh in $1.7 Billion Deal
$5.00
Available
InxMed Licenses Rights to Escugen’s Linker-Payload Platform for ADC Candidates
$5.00
Available
RNAimmune Approved to Start US Trials of mRNA Vaccine for RSV
$5.00
Available
Nona Out-licenses MSLN-targeting ADC to Pfizer in $1 Billion Agreement
$5.00
Available
GeneQuantum and BioMap Form AI Collaboration to Discover Novel ADC Candidates
$5.00
Available
Fosun Pharma Receives Support for Phase III Trial of Triple Artemisinin Therapy for Malaria
$5.00
Available
Alebund Reports Positive Phase II Data for Novel Therapy Aimed at Dialysis Side Effects
$5.00
Available
Evive and Nona Partner Up to Develop Antibody Drugs
$5.00
Available
SystImmune Out-Licenses Rights for ADC to BMS in $8.4 Billion Agreement
$5.00
Available
Connect Reports Positive Data from Phase IIb Trial of IL-4Rα Inhibitor for Asthma
$5.00
Available
Yingli Reports Positive Data from Phase III Trial of Linperlisib for T-cell Lymphoma
$5.00
Available
Xtalpi, a Quantum Physics-AI Drug Discovery Company, Files for Hong Kong IPO
$5.00
Available
AbelZeta Forms a China CAR-T Collaboration with AstraZeneca
$5.00
Available
Aspen Pharma Buys Sandoz’s China Operations for $120 Million
$5.00
Available
Innovent Adds Second ADC to Collaboration with Synaffix, an ADC CRO
$5.00
Available
Adcentrx Adds $13 Million to A+ Round for Novel Antibody Drug Conjugates
$5.00
Available
Ractigen Files to Start Australian Trials of saRNA Therapy for Bladder Cancer
$5.00
Available
Singapore’s CytoMed Plans to Start Investigator Initiated Trials in China of Novel T Cell Therapies
$5.00
Available
Abbisko Sells China Rights for CSF-1R Inhibitor to Germany’s Merck in a $605 Million Agreement
$5.00
Available
WuXi Biologics’ Stock Price Falls 24% after Company Reduces H2 Revenue Estimate
$5.00
Available
Perpetual Raises $8 Million in Seed Financing for AI Discovery of Novel Peptides
$5.00
Available
Coherus Sets US Price of Junshi-Developed PD-1 at 20% Discount to Merck’s Keytruda
$5.00
Available
GenFleet Reports KRAS G12C Inhibitor is Under Review in China for NSCLC Approval
$5.00
Available
Accutar to Apply its AI Platform to Discover Inflammatory Disease Therapies with Evommune
$5.00
Available
Everest Approved to Launch Nefecon in China for Rare Kidney Disease
$5.00
Available
Korea’s DxVx Plans Novel Cancer Vaccine In-licensing from its Partner Oxford Vacmedix
$5.00
Available
Gracell to Start US Phase I/II Trial of Lead CAR-T for Lupus
$5.00
Available
Zhifei Biological to Acquire Chongqing Chenan Bio, a Diabetes/Obesity Company
$5.00
Available
AstraZeneca to Build Hong Kong R&D Center for Cell and Gene Therapies
$5.00
Available
Usynova Out-Licenses KRASG12D Inhibitor to AstraZeneca in $419 Million Agreement
$5.00
Available
Myriex Bio Acquires Antibody for Novel ADCs Discovered by WuXi Biologics
$5.00
Available
BeiGene Acquires Global Rights to CDK2 Inhibitor from Ensem in $1.3 Billion Deal
$5.00
Available
Simcere Signs $141 Million Deal for Connect Bio’s Novel Atopic Dermatitis Therapy
$5.00
Available
Porton Advanced and Ascle Therapeutics Collaborate on CAR-NK Cell Therapy
$5.00
Available
Haisco Out-Licenses Global Ex-China Rights for Bronchiectasis Therapy to Italy’s Chiesi Farma
$5.00
Available
WuXi XDC Raises $520 Million in IPO; Climbs 39% in First Trading Session
$5.00
Available
Avistone Biotech Approved to Launch c-Met Inhibitor for NSCLC with Mutations
$5.00
Available
Gritgen’s Gene Therapy for Hemophilia 100% Effective in IIT Trial
$5.00
Available
ChromX Forms Diagnostic Collaboration with Boehringer Ingelheim for Lung Fibrosis
$5.00
Available
AriBio of South Korea Expands Phase III Trial of Alzheimer’s Therapy
$5.00
Available
Nona Collaborates with GeneQuantum to Offer Bioconjugate CMO Discovery Services
$5.00
Available
Viatris and Theravance Report COPD Therapy Effective in China Phase III Trial
$5.00
Available
Legend Signs $1.2 Billion Agreement Selling Global DLL3 CAR-T Rights to Novartis
$5.00
Available
AnchorDx and DiaCarta Team Up to Develop Early Cancer Screening Diagnostics
$5.00
Available
Sirius Files for Australian Trials of siRNA for Thromboembolic Disorders
$5.00
Available
Eccogene Signs $2 Billion Deal Selling Rights for GLP-1 Agonist to AstraZeneca
$5.00
Available
Porton Partners with BioMap for AI Based Gene Therapy Development
$5.00
Available
Lerna Biopharma to Present New siRNA Therapy for Liver Failure
$5.00
Available
WuXi XDC, an ADC/Bioconjugates CRDMO, Stages $500 Million IPO
$5.00
Available
Celest Therapeutics Acquires Novel CAR-NK Cell Therapy from Senti Bio in $156 Million Deal
$5.00
Available
Chipscreen Approved to Start China Trials for Novel Oral Psoriasis Therapy
$5.00
Available
Mellow Hope and Rational Vaccines Join to Develop Herpes Simplex Vaccines
$5.00
Available
Innovent Says GLP-1R/GCGR Dual Agonist Lowers Body Weight by 18.6%
$5.00
Available
CStone Out-Licenses China Rights for anti-PD-1 to 3SBio for $22 Million
$5.00
Available
HuidaGene Doses First Patient in Gene Therapy Trial for Inherited Blindness
$5.00
Available
BioLineRx in $270 Million Deal for China Rights for Stem Cell Mobilizer
$5.00
Available
AnHeart Sells Japanese Rights for ROS1 TKI to Nippon Kayaku for $40 Million Upfront
$5.00
Available
Hengrui Sells PARP1 Inhibitor to Germany’s Merck in $1.7 Billion Deal
$5.00
Available
Henlius Signs $200 Million Deal with Intas for EU/Indian Rights to its Anti-PD-1
$5.00
Available
Angita Closes $46 Million Series B Extension for Musculoskeletal Disease Therapies
$5.00
Available
Kelun-Biotech Releases Positive Data from TROP-2 ADC in Metastatic Breast Cancer
$5.00
Available
LianBio Sells China Rights to Cardiovascular Drug for $350 Million to BMS
$5.00
Available
OrbiMed Raises $751 Million for Asia Healthcare Fund; $3.6 Billion for Two Other Funds
$5.00
Available
Aiolos Raises $245 Million; Partners Hengrui’s Asthma Drug in $1 Billion Deal
$5.00
Available
Sirius Raises $60 Million for Cardiovascular siRNA Portfolio
$5.00
Available
Hansoh Out-Licenses ADC to GSK in $1.6 Billion Deal
$5.00
Available
AnHeart Says ROS1 Inhibitor Effective for NSCLC in Phase II Trial
$5.00
Available
BeiGene Reports anti-PD-1 Effective in Phase III Trial for Gastric Cancers
$5.00
Available
Ascentage Starts China Phase III trial of TKI for Leukemia
$5.00
Available
Skyline Approved to Start China Trials of Gene Therapy for Macular Degeneration
$5.00
Available
Belief BioMed Signs up Takeda to Commercialize Gene Therapy for Hemophilia in China
$5.00
Available
KBP Sells Hypertension Candidate for $1.3 Billion to Novo Nordisk
$5.00
Available
Hengrui Out-Licenses its PD-1 for Liver Cancer to Elevar in $1 Billion Deal
$5.00
Available
WuXi Biologics’ Novel Bioprocessing Platform Offers Higher Yields, Lower Costs
$5.00
Available
EpimAb Out-licenses Use of its Bispecific Platform to Almirall in $210 Million Agreement
$5.00
Available
SparX’s Lead Claudin 18.2 mAb Candidate Included in CAR-iNKT Cell Therapy
$5.00
Available
Ascentage Pharma to Start Phase III Trial of Bcl-2 Inhibitor for Leukemia
$5.00
Available
Akeso Reports Positive Data from PD-1/CTLA-4 Bispecific Published in Lancet
$5.00
Available
MediLink Out-Licenses Novel HER3 ADC to BioNTech in $1.1 Billion Agreement
$5.00
Available
Kintor Approved to Begin China Phase II Trial for Pulmonary Fibrosis Candidate
$5.00
Available
Gritgen Advances Hemophilia A Gene Therapy; Completes Manufacturing Plant
$5.00
Available
I-Mab and ABL Bio Report Preliminary Efficacy of Bispecific PD-L1/4-1BB
$5.00
Available
Beijing’s BioMap, an AI Drug Discovery Startup, Signs $1 Billion Deal with Sanofi
$5.00
Available
GenFleet Starts Phase Ib/II Trial of CDK9 Inhibitor for Peripheral T-Cell Lymphomas
$5.00
Available
Zeifei Biological Partners with GSK to Market Shingles Vaccine in China
$5.00
Available
Jiangsu Atom Bio Begins Global Phase IIb/III Trial of Gout Treatment
$5.00
Available
QYuns, an Autoimmune/Allergic Disease Biotech, Files for Hong Kong IPO
$5.00
Available
Everest Medicine Says Kidney Disease Therapy Effective in Asian Patients
$5.00
Available
Transcenta Cleared to Proceed in a US Phase III Trial of CLDN18.2 Antibody
$5.00
Available
Arctic Vision Completes China Phase III Enrollment for Macular Edema Candidate
$5.00
Available
PharmaEssentia Acquires Myeloid Immune Checkpoint Antibody from WuXi Biologics
$5.00
Available
Magpie Pharma Reports Results from Phase II Trial of ALS Therapy
$5.00
Available
Adlai Nortye Closes $97.5 Million Nasdaq IPO, Drops 27% Lower in Trading
$5.00
Available
BioCity Plans Trial of TIM-3 mAb with AstraZeneca’s PD-L1 for Liver Cancer
$5.00
Available
AffaMed Approved to Begin China Phase III Trial of Candidate for Dry AMD
$5.00
Available
RemeGen Says Dual Targeted B-Cell Drug Meets Endpoints for Rheumatoid Arthritis
$5.00
Available
Gracell Reports 100% Minimal Residual Disease Rate for CAR-T in Myeloma Trial
$5.00
Available
Ascletis Enrolls 120 Patients for Phase III Trial of Glioblastoma Candidate
$5.00
Available
Elpiscience Starts Australian Trial of Anti-Immunosuppressive Candidate
$5.00
Available
I-Mab Says AbbVie Returns Rights for CD47, Ending $2 Billion Partnership
$5.00
Available
Qihan Biotech Raises $16 Million for Gene-Edited Stem Cell Products
$5.00
Available
Chime Enters Cooperation with Panolos to Develop Multi-Specific Candidate
$5.00
Available
Tonghua Dongbao Out-Licenses US Rights for Three Insulin Biosimilars to Meitheal
$5.00
Available
Everest Acquires China Rights to Lupus Nephritis Candidate in $132 Million Agreement
$5.00
Available
Lynk Closes $16 Million C2 Round to Advance JAK Inhibitors for Autoimmune Diseases
$5.00
Available
AffaMed Begins China Phase III Trial of Therapy for Cataract Surgery Pain
$5.00
Available
Novartis Ends $2.2 Billion Global PD-1 Partnership with BeiGene
$5.00
Available
PackGene and Kudo Bio Partner to Provide End-to-End mRNA Services
$5.00
Available
Canton Biologics Raises $41 Million in C Round for Biologic CDMO Services
$5.00
Available
Clover Biopharma Starts China Distribution of Quadrivalent Seasonal Flu Vaccine
$5.00
Available
Cure Genetics to Develop AAV Vectors for Neuro Startup in $60 Million Deal
$5.00
Available
Dizal’s JAK1 Inhibitor NDA Accepted for China Review as PTCL Therapy
$5.00
Available
Shanghai Pharma Signs MOU to Run China Phase III Trial of Korean Alzheimer’s Drug
$5.00
Available
JW Therapeutics to Develop Two Additional 2seventy Cell Therapies in China
$5.00
Available
Insilico Out-Licenses Global Rights for USP1 Inhibitor to Exelixis for $80 Million Upfront
$5.00
Available
BioRay Approved to Launch Anruixi, a CD20 mAb, for B-Cell Lymphoma in China
$5.00
Available
Hasten Biopharma Enters $325 Million Deal for PCSK9 Cholesterol Drug
$5.00
Available
Sorrento Reports Positive Topline Results from China Trial of COVID Therapy
$5.00
Available
ImmuneOnco Stages $30 Million Hong Kong IPO for Innate/Adaptive Immunity Drugs
$5.00
Available
Biosyngen Approved for US Trials of TCR-T Candidate for Solid Tumor Cancers
$5.00
Available
Neurophth to Begin Australian Trial of Gene Therapy for Visual Impairment
$5.00
Available
Biocytogen Forms ADC Partnership with Myriex, a Cytotoxic Payload Company
$5.00
Available
AnHeart Starts Global Phase II Trial of mIDH1 Inhibitor for Brain Cancer
$5.00
Available
Gloria Bio Approved to Launch anti-PD-1 Drug for Metastatic Cervical Cancer
$5.00
Available
Brii Bio Announces Positive Interim Results for Hepatitis B Therapeutic Vaccine
$5.00
Available
Huadong Pharma Signs $52 Million China Deal for Topical Psoriasis Therapy
$5.00
Available
ABM Therapeutics Begins China Phase I Trial of BRAF Inhibitor for Brain Tumors
$5.00
Available
Kangpu Closes $13.8 Million B Round for Protein Ubiquitination Candidates
$5.00
Available
DualityBio and BioNTech to Begin Phase III US Trial of ADC for Breast Cancer
$5.00
Available
Biocytogen Re-organizes into Preclinical Service and Drug Discovery Divisions
$5.00
Available
Genexine/I-Mab Announce Positive Results from Phase III Growth Hormone Trial
$5.00
Available
InxMed Will Begin China Trial of FAPα Inhibitor to Lower Immunotherapy Resistance
$5.00
Available
Asieris Starts China Trials of Dopamine Beta-Hydroxylase Inhibitor for Ulcerative Colitis
$5.00
Available
Akeso Completes Phase III Trial Enrollment of PD-1/VEGF Bispecific for NSCLC
$5.00
Available
Harbour BioMed to Start US Trials of its First ADC Candidate
$5.00
Available
GenFleet Partners Three Pre-Clinical RAS Candidates with Verastem in $625.5 Million Deal
$5.00
Available
Henlius Collaborates with HanchorBio to Develop Novel Immuno-Biologics
$5.00
Available
China Consortium Aims to Acquire Drug Distributor in Poland
$5.00
Available
AusperBio Approved to Start US Trials of Antisense Oligonucleotide for Hepatitis B
$5.00
Available
Simcere Acquires Commercialization Rights to Mabpharm’s Colorectal Cancer Therapy
$5.00
Available
Lynk Pharma Says JAK1 Inhibitor Effective for Ankylosing Spondylitis
$5.00
Available
CirCode Raises “Millions of Dollars” in A Round for Circular RNA Drugs
$5.00
Available
Dizal Approved to Launch EGFR Inhibitor for NSCLC with Exon 20 Mutations
$5.00
Available
Hengrui Approved to Launch Antifungal for Vulvovaginal Candidiasis
$5.00
Available
HutchMed’s Syk Inhibitor Meets Phase III Endpoints for Immune Thrombocytopenia
$5.00
Available
Innovent Approved to Launch PCSK9 Inhibitor in China for High-Cholesterol
$5.00
Available
CARsgen and Moderna to Test Dual Claudin18.2 Cancer Therapy Combo
$5.00
Available
Sangon Raises $290 Million for Life Science Tools and Services Business
$5.00
Available
Akeso Starts Phase III Trial of PD-1/VEGF Bispecific for NSCLC
$5.00
Available
CytoMed Signs MOU with CNK Therapeutics for Gene Grafting Technology in CAR Therapies
$5.00
Available
China Announces Plans to Facilitate Foreign Investments in its Biopharma Industry
$5.00
Available
OnCusp to Start US Trials of CDH6 ADC In-licensed from China’s Multitude
$5.00
Available
Zhongmei Huadong In-licenses Skin Disease Therapy in $94 Million Agreement
$5.00
Available
Kelun-Biotech’s Lead ADC Meets Endpoint in Phase III Triple Negative Breast Cancer Trial
$5.00
Available
Antengene Signs up Hansoh in $101 Million Deal for Commercialization Rights to XPO1 Inhibitor
$5.00
Available
Neurophth Closes $95 Million Series C+ Round for Gene Therapy Ophthalmology Therapies
$5.00
Available
Jacobio Awarded China Breakthrough Status for KRAS Inhibitor in Pancreatic Cancer
$5.00
Available
AceLink Starts China Phase II Trial of Novel GCS Inhibitor for Fabry Disease
$5.00
Available
CanSinoBIO and AstraZeneca Form mRNA Vaccine Collaboration
$5.00
Available
BioCity Approved to Start US Trial of Bispecific Antibody for Solid Tumors
$5.00
Available
Investisbio Out-Licenses KRAS G12C Inhibitor to Sino Biopharm Subsidiary
$5.00
Available
BeiGene’s Breakup with Celgene/BMS Now Complete with Return of BeiGene Shares
$5.00
Available
Gracell Raises $100 Million in Private Placement for Trials of CAR-T Candidates
$5.00
Available
Duality Biologics Adds Third ADC Candidate to BioNTech Partnership
$5.00
Available
Mundipharma May Propose Sale of China Operations for $1 Billion
$5.00
Available
Oramed and Hefei Tianhui to Form $60 Million JV for Oral Insulin Product
$5.00
Available
Doer Biologics Starts Trial of Tri-Specific Drug for Obesity
$5.00
Available
ABVC Out-licenses China Rights for Two Neurologic Therapies to Xinnovation
$5.00
Available
CASI Acquires China Rights to Lymphoma Chemotherapy from Mundipharma
$5.00
Available
CirCode Forms Partnership with Pfizer to Develop Circular RNA Therapeutics
$5.00
Available
Xinkanghe Biomedical Raises $14 Million for Immunology Drugs
$5.00
Available
Transcenta to Start Phase II Trial of Osteoporosis Therapy in China
$5.00
Available
Mirxes Closes $50 Million Round for miRNA Tests; Will IPO in Hong Kong
$5.00
Available
RemeGen Publishes Data Showing Telitacicept Effective for Sjögren's Syndrome
$5.00
Available
Pyrotech Closes $97 Million Round to Develop Novel Technology for Autoimmune and Cancer Drugs
$5.00
Available
Everest Launches Novel Antibiotic in China for Difficult/Drug Resistant Infections
$5.00
Available
Viage Says Zhongze-Partnered Gut-Based Therapy Effective for Cognitive Decline
$5.00
Available
SunHo Bio Starts China Trials of Immunocytokine for Solid Tumor Cancers
$5.00
Available
Pillar Bio Partners with Illumina to Offer Genomic Profiling Assays for Oncology
$5.00
Available
Ascletis Says PD-L1/Chidamide Combination May Offer Cure for HIV
$5.00
Available
MindRank Raises $20 Million in A+ Round to Support AI Drug Development Operations
$5.00
Available
Overland ADCT Says Zynolonta BLA Accepted for China Review as Lymphoma Therapy
$5.00
Available
CASI Pharma Acquires VCP/p97 Inhibitor for Myeloid Leukemia and MDS
$5.00
Available
Qihan Starts Trial of Gene-Edited iPSC-Derived NK Cell Therapy for Leukemia
$5.00
Available
Triastek 3D-Printed Candidate Delivers Active Ingredient to Ulcerative Colitis Target
$5.00
Available
Novartis in $1 Billion Deal for DTx Pharma, an siRNA Company Incubated by Viva BioInnovator
$5.00
Available
Fosun Kite Approved to Launch CAR-T as Second Line Therapy for B-Cell Lymphoma
$5.00
Available
Antengene Doses First Patient in Trial of ERK1/2 Inhibitor Combined with BMS’s PD-1
$5.00
Available
HighField Biopharma Starts China Trial of Immune Modulating Liposome for Glioma
$5.00
Available
Kelun-Biotech Raises $174 Million in Hong Kong IPO for ADC Portfolio
$5.00
Available
GeneQuantum Licenses Novel Bioconjugation Technology to InxMed
$5.00
Available
Beijing InnoCare Plans Combined Therapy with Arrivent for NSCLC
$5.00
Available
Connect Reports Progress in Next-gen IL-4Rα Antibody for Atopic Dermatitis
$5.00
Available
GeneQuantum Adds Five ADC Candidates to its Collaboration with Aimed, a Korean Biotech
$5.00
Available
Fosun Pharma Files China NDA for Hyperphosphatemia Therapy in Dialysis Patients
$5.00
Available
Biosyngen to Establish Guangzhou-Singapore Translational Center for Cancer Drugs
$5.00
Available
Sinotau Pharma Completes $152 Million E Round for Radiopharmaceutical Portfolio
$5.00
Available
280Bio, a Yingli Pharma Subsidiary, to Start US Trials of RAS Inhibitor
$5.00
Available
BeiGene Options ADC for Solid Tumor Cancer from Duality Bio in $1.3 Billion Deal
$5.00
Available
WuXi Biologics Plans Spin-off and $500 Million Hong Kong IPO of Conjugates Subsidiary
$5.00
Available
Sirnaomics Provides Capital and RNA Delivery Technology to EDIRNA, an RNA Editing Company
$5.00
Available
Shanghai’s Skyline Approved to Start US Trial of Gene Therapy for Macular Degeneration
$5.00
Available
Brii Bio Expands Rights for VBI’s HBV Therapy to Global in $437 Million Deal
$5.00
Available
Hansoh Pharma to Start China Trials of Novel Endometriosis Therapy
$5.00
Available
F-star Signs Third Collaboration with Takeda; This One is Worth up to $1 Billion
$5.00
Available
Shanghai Wong Pharma Raises $152 Million for Allergy and Autoimmune Candidates
$5.00
Available
Zai Lab Approved to Launch Fc Receptor Agonist for Myasthenia Gravis Patients
$5.00
Available
Kelun-Biotech to Raise up to $208 Million in Hong Kong IPO for ADC Portfolio
$5.00
Available
AusperBio to Start China Trials of Antisense Oligonucleotide for Chronic Hepatitis B Cure
$5.00
Available
Laekna Raises $100 Million in Hong Kong IPO for Cancer, Liver Fibrosis Inhibitors
$5.00
Available
BCHT Bio Pays $21 Million for 20% Stake in mRNA Vaccine Company; Will Acquire the Rest
$5.00
Available
CBMG Out-Licenses Top Two CAR-T Candidates to Janssen for $245 Million Upfront
$5.00
Available
CStone RET Inhibitor Approved in China for First-Line Treatment in NSCLC Patients
$5.00
Available
Lion TCR Raises $40 Million to Develop HBV-Specific T Cell Receptor Therapy for Liver Cancer
$5.00
Available
Insilico Starts China-US Phase II Trials of AI-Discovered Therapy for Lung Fibrosis
$5.00
Available
Brii Bio to Receive $24 Million from Sale of Qpex; Gains Global License to Anti-Infective
$5.00
Available
Innovent Collaborates with RemeGen to Test PD-1/ADC Combination for Solid Tumors
$5.00
Available
Edding Group Files for Hong Kong IPO to Support its China In-licensing Operations
$5.00
Available
Everest Medicines Reports In-licensed Candidate Effective for Rare Kidney Disease
$5.00
Available
BioCity Starts China Phase II Trial of ETA-Receptor Antagonist for Kidney Disease
$5.00
Available
WestGene Biopharma Raises $42 Million in a Series A Funding for its mRNA Portfolio
$5.00
Available
Minghui Starts Clinical Trials for Two Novel ADCs Aimed at Solid Tumor Cancers
$5.00
Available
AstraZeneca May Create New Company for China Ops and List in Hong Kong or Shanghai
$5.00
Available
Cutia Therapeutics Raises $65 Million in Hong Kong IPO for Dermatology Products
$5.00
Available
Cullgen Forms $1.9 Billion Collaboration with Astellas for Protein Degraders
$5.00
Available
Cholesgen Collaborates with AstraZeneca to Develop Hypercholesterolemia Candidates
$5.00
Available
HighField Bio to Start US Trial of Immunoliposome for Solid Tumor Cancers
$5.00
Available
Genor Biopharma’s PD-1 Drug Nixed by China Regulators for Rare Lymphoma
$5.00
Available
Simcere to Underwrite up to Eight Research Projects at Mass General Brigham
$5.00
Available
China Medical System’s Novel Nasal Spray Approved to Treat Seizures in China
$5.00
Available
Innovent’s anti-CD47/PD-L1 Bispecific Antibody Effective in Hodgkin Lymphoma
$5.00
Available
Ractigen Starts China Trials of siRNA Candidate for ALS Patients
$5.00
Available
HighTide Plans Hong Kong IPO to Support Metabolic and Digestive Portfolio
$5.00
Available
WestVac Biopharma Approved to Launch COVID-19 Vaccine for XBB Variants
$5.00
Available
Fosun Pharma Lands $107 Million to Build African Production and Distribution Facility
$5.00
Available
Innovent/IASO Release Strong Long-Term Data on CAR-T for Multiple Myeloma
$5.00
Available
iTabMed Approved to Start China Trials of CD3 Bi-specific for Solid Tumors
$5.00
Available
Dizal Updates Clinical News of its Two Global Trial Assets at ASCO
$5.00
Available
ASCO: BioNTech and Merck Present Positive Data on China-Sourced Oncology Drugs
$5.00
Available
Gracell Reports Positive Data from Trial of BCMA/CD19 FasTCAR-T in Multiple Myeloma
$5.00
Available
CANbridge Approved to Launch Pruritus Therapy for Alagille Syndrome in China
$5.00
Available
Connect Reports UC Therapy Offers Statistically Significant Improvement
$5.00
Available
invoX Makes 2nd Investment in pHion, a Belfast mRNA Vaccine Company
$5.00
Available
Lynk Pharma Closes C1 Round with $28 Million for Oncology and Autoimmune Drugs
$5.00
Available
HighField Biopharma Reports Progression-Free Survival in Glioma Patients
$5.00
Available
Betta Signs $392 Million Agreement for Lung Cancer Drug with C4 Therapeutics
$5.00
Available
Unicar-Therapy Publishes Positive Data for Dual-Target CAR T-cell Leukemia Therapy
$5.00
Available
ProfoundBio Provides Updates on Two ADC Candidates in US-China Trials
$5.00
Available
Ascentage Details ASCO Abstracts for Four Novel Cancer Drugs
$5.00
Available
Lynk Doses First Cohort of Psoriasis Patients with Topical Third-Gen JAK Inhibitor
$5.00
Available
Accropeutics to Start Phase I Trial of TYK2/JAK1 Inhibitor for Psoriasis
$5.00
Available
Allgenesis Reports Positive Data from US Trial of Diabetic Macular Edema Therapy
$5.00
Available
BioRay to Start Trials of LIV-1 Targeting ADC for Advanced Malignant Tumors
$5.00
Available
Antengene Awarded Orphan Status for Claudin 18.2 ADC in Two Cancer Indications
$5.00
Available
Minghui Pharma Doses First Subject in Phase I Trial of Autoimmune Candidate
$5.00
Available
Laekna to Start Phase I/II Trials of ATP Inhibitor in US for Lung Cancer
$5.00
Available
HanxBio Approved to Start US Trials of anti-CD47/PD-1 for Lymphoma
$5.00
Available
CARsgen Starts US Phase II Trial of CLDN18.2 CAR-T for Gastric Cancer
$5.00
Available
Boan Bio Approved to Start Trials of Bispecific Antibody for CEA Solid Tumor Cancers
$5.00
Available
Hengrui Affiliate Files for US Approval of PD-1 in Early Liver Cancer
$5.00
Available
CANbridge Reports Data From Preclinical Test of Gene Therapy for Spinal Muscular Atrophy
$5.00
Available
Coherent Bio Closes B Round with $100 Million for XDC Candidates
$5.00
Available
Coherent Bio Closes B Round with $100 Million for XDC Candidates
$5.00
Available
Keymed and Rona Partner to Discover siRNA Drugs for Severe Kidney Disease
$5.00
Available
Amoytop and Aligos Team Up in $109 Million Deal to Develop Novel Drugs for Liver Diseases
$5.00
Available
Drug Farm Raises $27 Million for AI-based Immune-modulating Therapies
$5.00
Available
LaNova of Shanghai Sells Myeloma ADC Rights to AstraZeneca for $600 Million
$5.00
Available
Gracell Announces Trial of FasTCAR Candidate in Autoimmune Diseases
$5.00
Available
Innovent Reports Positive Data from GLP-1R/GCGR Agonist in Weight Loss Trial
$5.00
Available
Chance Pharma Acquires China Rights for Inhaled Parkinson’s Therapy in $144 Million Deal
$5.00
Available
GenAssist Says US IND Accepted for Base Editing Product in Duchenne Muscular Dystrophy
$5.00
Available
Suzhou Zion Out-Licenses Brain-Penetrating HER2 Candidate to Roche in $680 Million Deal
$5.00
Available
EQRx Gives up on In-licensing Drugs from China for Lower Cost Therapies in the West
$5.00
Available
Bliss Biopharma Out-Licenses HER2 ADC to Eisai for up to $2 Billion
$5.00
Available
Junshi Signs $728 Million Deal Granting Rights for Anti-PD-1 in 21 Countries to Dr. Reddy’s
$5.00
Available
Janssen In-licenses CAR-Ts for $245 Million Upfront, its 2nd CAR-T Deal with a China Biotech
$5.00
Available
Zai Lab Acquires Global Rights to ADC for Small Cell Lung Cancer from MediLink
$5.00
Available
Adcentrx, a San Diego-Shanghai Company, Raises $38 Million for ADC Portfolio
$5.00
Available
Hasten Bio of Hefei Raises $315 Million for Product Acquisitions
$5.00
Available
CARsgen CAR-T Approved to Start China Trials for Pancreatic Cancer
$5.00
Available
Pfizer Partners with Sinopharm to Bring 12 Innovative Drugs to China
$5.00
Available
XtalPi/Merck Collaboration Uses AI + Wet Lab to Improve Crystal Morphology
$5.00
Available
Junshi Bio’s PARP Inhibitor Effective as Maintenance Therapy for Ovarian Cancer
$5.00
Available
Bridge Bio Doses First Patient in Phase II Trial of ATX Inhibitor for Fibrosis
$5.00
Available
VintaBio Opens Cell and Gene Therapy CDMO after $64 Million Round led by Decheng
$5.00
Available
Sirnaomics Starts US Phase I Trial of RNAi Anticoagulant
$5.00
Available
OnCusp to Post Data on Lead Candidate, an Anti-CDH6 ADC
$5.00
Available
Genor Reports CDK4/6 Inhibitor NDA Under Review in China for Breast Cancer
$5.00
Available
JW Therapeutics Starts China Trial of CAR-T for Systemic Lupus Erythematosus
$5.00
Available
Mabwell Says Nectin-4 ADC Posts Positive Results in Solid Tumor Cancers
$5.00
Available
Evopoint to Start China Trial of EZH2 Inhibitor Combined with Merck/MSD’s Keytruda
$5.00
Available
InnoCare Doses First Patient in Trial of Protein Degrader for Myeloma and Lymphoma
$5.00
Available
Pierre Fabre Enters $618 Million Deal with Boston’s Scorpion for Two Novel EGFR Candidates
$5.00
Available
Biosion USA to Start US Phase II Trials of Novel Candidate for Asthma
$5.00
Available
Lynk Pharma Reports Third-Gen JAK Inhibitor Meets Safety Goals in Phase I Trial
$5.00
Available
HutchMed Completes US Filing of Fruquintinib for Metastatic Colorectal Cancer
$5.00
Available
DualityBio Sells Two ADC Assets to BioNTech for $170 Million Upfront, $1.5 Billion in Milestones
$5.00
Available
Mabwell Approved to Launch Biosimilar to Amgen's Osteoporosis Therapy in China
$5.00
Available
Mabwell Approved to Launch Biosimilar to Amgen's Osteoporosis Therapy in China
$5.00
Available
Apollomics Merges with SPAC to List on NASDAQ; Climbs 121% Higher in Trading
$5.00
Available
Ablaze Pharma Acquires China Rights to Targeted Radiotherapy Drug for Liver Cancers
$5.00
Available
SciNeuro Signs Up Secarna to Discover Antisense Oligonucleotide Therapies for Neurology Targets
$5.00
Available
ImmVira Approved to Start Trials of Oncolytic Virus Candidate for Malignant Glioma
$5.00
Available
Pharmaron Receives $186 Million Grant to Expand UK Cell/Gene Therapy Manufacturing
$5.00
Available
Junshi Forms Commercialization JV with Rxilient to Market PD-1 in Southeast Asia
$5.00
Available
SalubrisBio Reports $35 Million Infusion from Parent for Novel Biologic Drugs
$5.00
Available
ArriVent Closes $155 Million Round to In-license US Rights for China Drugs
$5.00
Available
YS Biopharma Says PIKA COVID-19 Vaccine Offers Superior Immunogenicity
$5.00
Available
Everest Forms Renal Research Partnership with Guangdong Medical Academy
$5.00
Available
F-star Partners Second Early-Stage Tetravalent Bispecific Antibody with Takeda
$5.00
Available
Transcenta Starts US Trials of Gremlin1 mAb for Prostate and Colorectal Cancer
$5.00
Available
Highlightll Out-licenses Dual Inhibitor for Parkinson’s in $970 Million Deal
$5.00
Available
Joincare to Develop TaiGen’s Pan-Flu Therapy in Greater China
$5.00
Available
Boan Biotech Files China BLA for Bone Metastases Biosimilar
$5.00
Available
280Bio Showcases Preclinical Findings for Novel KRAS Inhibitor
$5.00
Available
Connect Biopharma’s IL-4Rα Antibody Effective in Atopic Dermatitis Patients
$5.00
Available
Gracell Closes Cell Therapy Deal with Seagen; No Details Released
$5.00
Available
ArkBio and Scripps Research Extend Partnership for Novel Respiratory Candidate
$5.00
Available
Base Biotech Raises “Tens of Millions of Dollars” in A1 Round for Base Editing
$500.00
Available
Everest Approved to Launch Antibiotic in China for Intra-Abdominal Infections
$5.00
Available
Mabwell Starts Trials of mAb to Regulate Iron Homeostasis In Vivo
$5.00
Available
Simcere to Test TNRF2 mAb in Combination with MSD’s Keytruda for Solid Tumors
$5.00
Available
Everest’s In-licensed Kidney Drug Meets Endpoints in Phase III Trial
$5.00
Available
Bio-Thera Starts Phase I Trial of Nectin-4 ADC for Solid Tumors
$5.00
Available
Livzon Acquires Rights to GERD Therapy from Onconic for $127.5 Million
$5.00
Available
Luye Enrolls Last Patient in Phase III Trial of Eylea Biosimilar
$5.00
Available
Allorion Raises $50 Million for Oncology/Autoimmune Precision Medicines
$5.00
Available
AusperBio Starts New Zealand Phase I Trial of Novel Therapy for CHB
$5.00
Available
Ambrx Partner Says HER2 ADC Ups Progression-Free Survival in Breast Cancer Trial
$5.00
Available
Ractigen Granted Orphan Drug Status for Use of Novel siRNA in ALS
$5.00
Available
CFIUS Approves Sino Biopharm’s Acquisition of F-Star after Nine Month Wait
$5.00
Available
Rinua Gene Raises $14.5 Million in Pre-A+ Round for mRNA Drugs
$5.00
Available
Harbour BioMed mAb Posts Positive Results in Phase III Myasthenia Gravis Trial
$5.00
Available
JW Therapeutics Starts China Trial of T-cell Immunotherapy for Liver Cancer
$5.00
Available
Transcenta Reports Immuno-PET Diagnoses CLDN18.2 Levels in Gastrointestinal Tumors
$5.00
Available
Abbisko Out-Licenses Precision EGFR-TKI Medicine to Allist in $188 Million Deal
$5.00
Available
TandemAI Raises $35 Million for AI/WetLab Drug Discovery Operations
$5.00
Available
Immorna Raises $100 Million for Clinical Trials of Novel RNA Candidates
$5.00
Available
Atom Bioscience Says Gout Treatment Meets Phase II Efficacy/Safety Endpoints
$5.00
Available
Shanghai Oricell Raises $45 Million to Take Cellular Immunotherapies to US
$5.00
Available
Junshi Reports anti-PCSK9 mAb Lowers Cholesterol in Phase III Trials
$5.00
Available
Kelun Biotech Plans Hong Kong IPO to Develop ADCs and Other Products
$5.00
Available
Chipscreen Signs $72 Million Deal for Eucure Bispecific Immunotherapy
$5.00
Available
BeiGene’s PD-1 Approved in China for Tenth Indication, Gastric Cancer
$5.00
Available
InnoCare-Keymed JV Starts China Trial of Novel CCR8 Immunotherapy
$5.00
Available
Keymed-Lepu JV Out-Licenses Claudin 18.2 ADC to AstraZeneca in $1.2 Billion Agreement
$5.00
Available
Kinnate, a Precision Oncology Company, Pays $24 Million to Buy Out JV Partners
$5.00
Available
Shenzhen Fapon Bio Starts US Trial of CD47 mAb for Advanced Malignancies
$5.00
Available
InnoCare’s $937 Million MS Deal Falls Apart as Biogen Returns Rights
$5.00
Available
Neurophth Completes Dosing in Phase III Trial of Gene Therapy for Hereditary Blindness
$5.00
Available
Frontera Therapeutics Begins Trials for Three Leading Gene Therapy Candidates
$5.00
Available
Innovent Starts China Trial of Novel mAb as Extended-Dose Psoriasis Therapy
$5.00
Available
Junshi/Coherus Report PD-1 Effective in US Trial for Nasopharyngeal Carcinoma
$5.00
Available
Henlius Biotech Reports US Accepts Herceptin Biosimilar BLA for Review
$5.00
Available
Harbour BioMed Out-Licenses US Rights for Bispecific in $588 Million Deal
$5.00
Available
Clover Launches COVID-19 Vaccine in China as Second Booster Dose
$5.00
Available
CSPC Pharma Out-Licenses Nectin-4 ADC to Corbus in $692 Million Deal
$5.00
Available
Wondercell Closes $14 Million in Angel Funding for Immune Cell Therapies
$5.00
Available
Boan Biotech Starts China Trial of Anti-CD25 Antibody for Solid Tumor Cancers
$5.00
Available
CANbridge Acquires Global Rights to Rare Disease Therapy from UMass
$5.00
Available
ImmVira Posts Positive Data from Trial of Oncolytic Virus Injection for Melanoma
$5.00
Available
Technoderma Starts US Trial of JAK1/Tyk2 Inhibitor for Atopic Dermatitis
$5.00
Available
Asieris Collaborates with ReviR to Discover RNA Candidates for Genitourinary Tumors
$5.00
Available
China to Ban Export of Cutting-Edge Cell Therapy Technologies
$5.00
Available
Results from InnoCare’s BTK Lymphoma Trial Published in Hematology Journal
$5.00
Available
JiXing Buys Global Rights for Hypertension Candidate from PhaseBio
$5.00
Available
Structure Stages Expanded $161 Million IPO for Novel Small Molecules
$5.00
Available
Gracell Biotech to Start US Trial of Dual-Targeting CAR-T Therapy for Myeloma
$5.00
Available
AnHeart to Use Guardant’s Assays for NSCLC Trials of ROS1 Inhibitor
$5.00
Available
NeuShen and UMass Partner To Develop Gene Therapy for ALS
$5.00
Available
Nervtex AI Device Approved in China to Diagnose Parkinson’s
$5.00
Available
CS Pharma Acquires China Rights to Fibrosis Drug in $336 Million Agreement
$5.00
Available
CARsgen to Test Claudin18.2 mAb with Roche’s PD-L1 for Gastric Cancer
$5.00
Available
Help Therapeutics to Start Trial of Universal Cell Therapy for Heart Failure
$5.00
Available
HuidaGene’s CRISPR Therapy Approved to Start US Trial for Inherited Retinal Disease
$5.00
Available
Legend Reports CAR-T Meets PFS Endpoint as Second-line Therapy for MM
$5.00
Available
HBMAT, a Harbour Biomed JV, Closes Seed Round for Novel Endocrine Therapies
$5.00
Available
Akeso Approved to Market PD-1 in China as First-Line NSCLC Therapy
$5.00
Available
Junshi Bio’s NDA for COVID-19 Therapy Accepted for Review in China
$5.00
Available
HutchMed Out-licenses Rights for VEGFR Drug to Takeda in $1.1 Billion Deal
$5.00
Available
Mabwell Out-licenses Rare Disease Drug to Disc Medicine for $412.5 Million
$5.00
Available
Tigermed Expands Footprint and Services by Acquiring Marti Farm, a Croatian CRO
$5.00
Available
Aprinoia, a Neurodegenerative Company, to be Acquired by $280 Million SPAC
$5.00
Available
Nanjing IASO Bio Raises $75 Million to Develop/Commercialize CAR-T Assets
$5.00
Available
GenScript ProBio -- a mAb, Cell & Gene Therapy CDMO -- Raises $224 Million
$5.00
Available
Henlius anti-PD-1 Approved to Launch in China for Small Cell Lung Cancer
$5.00
Available
CARsgen Signs $181 Million Deal to Commercialize CAR-T in China with Huadong
$5.00
Available
Harbour Biomed to Start US Trials of Novel B7H7 Immunoncology Asset
$5.00
Available
Bio4t2 Starts China Trial of BT-001 Antigen CAR-T for Solid Tumor Cancers
$5.00
Available
Visen Pharma Completes Phase III Trial of Therapy for Rare Thyroid Disease
$5.00
Available
Evopoint Options-Out Rights for Pre-clinical Solid Tumor ADC to AmMax
$5.00
Available
Takeda Approved to Launch Targeted Drug for NSCLC with Mutations in China
$5.00
Available
Chengdu Qitan Raises $101 Million for Nanopore Sequencing Devices
$5.00
Available
Dizal’s NDA Filing for NSCLC Therapy Accepted for Review in China
$5.00
Available
Innovent Starts China Phase III Trial for Dual Agonist Diabetes Therapy
$5.00
Available
Immune-Onc Adds $25 Million to B Round for Novel Myeloid Checkpoint Inhibitors
$5.00
Available
Duality Licenses ADC Platform to Adcendo for Mesenchymal Cancer Program
$5.00
Available
WuXi Biologics Signs $1.5 Billion Pact with GSK for Four Novel TCE Antibodies
$5.00
Available
HighTide Closes $107 Million Round for Metabolic/Digestive Disease Candidates
$5.00
Available
ArriVent in Hunt for $145 Million to Finance US In-licensing Operations
$5.00
Available
Transcenta Approved to Start China Trials of Gremlin1 mAb for Prostate Cancer
$5.00
Available
Biocytogen Out-Licenses Global Rights for mAb Candidates to Hansoh
$5.00
Available
ProfoundBio Starts US Trial of ADC in Solid Tumor Cancers
$5.00
Available
Boan Stages $20 Million Hong Kong IPO for Biosimilar/Novel mAb Drugs
$5.00
Available
InnoCare Approved to Launch Cytolytic CD-19 Immunotherapy in Hong Kong
$5.00
Available
Ablaze Pharma Forms CDMO Partnership with Yonghe for Radiopharmaceuticals
$5.00
Available
Junshi Out-licenses Middle East/North African Rights for PD-1 to Hikma Pharma
$5.00
Available
WuXi XDC to Offer GeneQuantum’s Platforms for Bioconjugate Development
$5.00
Available
MindRank OK’d to Start US Trials of GLP-1 Candidate for Obesity and Diabetes
$5.00
Available
TenNor Raises $10 Million for Conjugate Infectious Disease Products
$5.00
Available
IASO Approved to Start US Trials of Lead Drug, a BCMA CAR-T
$5.00
Available
Kelun-Biotech Signs $9.5 Billion Deal with Merck for Seven ADC Candidates
$5.00
Available
XtalPi Collaborates with Singapore’s EDDC to Discover NSCLC Candidates
$5.00
Available
Shanghai Group Leads $20 Million Round for Israel’s Biomica, a Microbiome Company
$5.00
Available
Staidson Bio In-Licenses mAb Complement Therapy for COVID in $10 Million Deal
$5.00
Available
LianBio Sells Rights for RSV Therapy to Pfizer in $155 Million Deal
$5.00
Available
Kira Pharma Starts China-Australia Trials of Dual Complement Pathway Candidate
$5.00
Available
Innovent Enters $95 Million Agreement to In-License Gout Treatment
$5.00
Available
Alternative Bio Lands $15 Million to Develop Oncology Drugs based on Novel Enzymes
$5.00
Available
Suzhou 4B Technologies Closes $14 Million Pre-B Financing for Neuro Drugs
$5.00
Available
BeiGene Says its BTK Inhibitor Out-Performs Janssen’s Imbruvica
$5.00
Available
Boston Scientific Pays $523 Million for Control of Acotec, a Beijing Device Company
$5.00
Available
Nanjing Biosion Forms ADC Discovery Collaboration with Boston’s ImmunoGen
$5.00
Available
HitGen Forms Partnership with Nitrase to Develop Novel Enzyme Inhibitors
$5.00
Available
CARsgen Files NDA for China Approval of CAR-T Based on Phase II Data
$5.00
Available
GenScript to Build Synthetic Biology Library with Singapore’s Allozymes
$5.00
Available
Ascletis Pharma to Start China Trials of Protease Inhibitor to Treat COVID-19
$5.00
Available
Hexaell to Start China Trial of Novel Drug-Device for Chronic Liver Failure
$5.00
Available
China Approves Covid Vaccines from Two Companies, Sinocelltech and Clover
$5.00
Available
Innovent Starts China Trials of In-licensed Oral Therapy for Skin Diseases
$5.00
Available
Henlius and Innovent/Lilly: A Tale of Two PD-1 Candidates
$5.00
Available
Boan Biotech’s IPO Application Accepted by Hong Kong Exchange
$5.00
Available
Boston’s Regenta Raises $52 Million for RNA Drugs from China Investors
$5.00
Available
Gland Pharma, a Fosun Subsidiary, to Buy French CDMO for $124 Million
$5.00
Available
Pediatrix Acquires Atopic Dermatitis Therapy in $96 Million Agreement
$5.00
Available
Full-Life Enters $245 Million Deal to Acquire Focus-X, a Radiopharma Company
$5.00
Available
Biocytogen Signs Option to Out-License Three Antibodies to ADC Therapeutics
$5.00
Available
XtalPi and CK Life Sciences Partner to Discover Therapeutic Tumor Vaccines
$5.00
Available
Lyvgen to Start Phase II Trial of mAb with BMS’s PD-1 Keytruda
$5.00
Available
Wanbang Biopharma Adds Animal Rights to Agreement for Diabetes Therapy
$5.00
Available
AnchorDx Starts US Trial of Non-Invasive Test for Bladder Cancer
$5.00
Available
Nona, a Harbour BioMed Subsidiary, to Discovery Immunotherapies for Dragonfly
$5.00
Available
Luye Pharma’s Long-Acting Schizophrenia Drug Meets Endpoints in US Trial
$5.00
Available
IASO Forms Collaboration with Umoja for Allogenic CAR-T Therapies
$5.00
Available
Triastek to Start US Trials of Third 3D Printed Therapy
$5.00
Available
Everest’s NDA for Renal Disease Therapy Accepted in China
$5.00
Available
Tenacia Signs $266 Million Agreement with Marinus for Seizure Drug
$5.00
Available
SynRx Raises $14 Million to Develop Drugs for Solid Tumor Cancers with DNA Damage
$5.00
Available
Evive Sells US Rights for Neutropenia Therapy to Aerotech in $236.5 Million Deal
$5.00
Available
Simcere Enters $50 Million Deal for China Rights to Novel Insomnia Therapy
$5.00
Available
Hansoh Enters $207 Million Agreement for Biotheus EGFR/MET Bispecific
$5.00
Available
WuXi Vaccines Acquires Suzhou Manufacturing Facility from Harbour BioMed
$5.00
Available
Lupeng Pharma Closes 2nd $35 Million Pre-B Tranche for Small Molecule Drugs
$5.00
Available
Nuance Pharma to Start China Phase III Trial of RSV Vaccine in Adults
$5.00
Available
EQRx Retracts Promise to Bring Low-Cost China Drugs to US
$5.00
Available
Harbour BioMed Forms Immunotherapy Discovery Collaboration with Moderna
$5.00
Available
Zenas BioPharma Raises $118 Million for Global Autoimmune Portfolio
$5.00
Available
YS Biopharma to Start Trials for PIKA COVID-19 Vaccine in US
$5.00
Available
NovoCodex Starts China Trial of anti-CD70 ADC in Solid Tumors
$5.00
Available
Sirnaomics Starts Trial of Lead siRNA Therapy for Fat Reduction
$5.00
Available
Insilico Announces Six-Drug, $1.2 Billion AI Drug Discovery Deal with Sanofi
$5.00
Available
XellSmart Raises $27.6 Million for Low-Cost Stem Cell Therapies
$5.00
Available
Neurophth Enters $140 Million Gene Therapy Collaboration with Cyagen
$5.00
Available
Asieris Starts China Phase III Trial of Bladder Cancer Diagnostic
$5.00
Available
China Allows BioNTech to Import mRNA COVID Vaccine – for Expats Only
$5.00
Available
Akeso Completes Enrollment in Phase III Trial of PD-1/VEGF Bi-specific
$5.00
Available
CBC Group Plans $137 Million Shanghai Biopharma Center
$5.00
Available
Kira Says First-in-Human Trial Shows Complement Candidate Effective
$5.00
Available
Beijing Immunochina Closes Series D+ with at least $28 Million for CAR-T Drugs
$5.00
Available
Eucure Partners CD40 Antibody for Tri-Specific Drug with Korea’s ISU ABXIS
$5.00
Available
China Blocks GSK Generic BPH Drug Due to Safety Concerns
$5.00
Available
Beihai Raises $27 Million to Support Increased Solubility Oncology Drugs
$5.00
Available
CorreGene Closes $14 Million Pre-A+ round for Novel TCR Drugs
$5.00
Available
JHM Bio Closes $28 Million Round for Biologic Product Portfolio
$5.00
Available
Fosun Kite’s NDA Accepted for Second Indication of CAR-T in China
$5.00
Available
JW Therapeutics Partners with 2seventy bio to Develop T Cell Immunotherapies
$5.00
Available
Salubris and Anlong to Co-develop Nucleic Acid Hypertension Drug
$5.00
Available
ImmVira Closes C+ Tranche, Will Keep Round Open for Two Months
$5.00
Available
Ascletis Files US IND to Test COVID Antiviral for Monkeypox
$5.00
Available
Celgenyx Closes $14 Million A Round for Off-the-Shelf Cell Therapies
$5.00
Available
Akeso Receives Breakthrough Designation for PD-1/VEGF Bispecific
$5.00
Available
Maxinovel Raises $14 Million for Novel Small Molecule Portfolio
$5.00
Available
Hrain Biotech Plans $352 Million Shanghai STAR IPO for Novel CAR Candidates
$5.00
Available
Hrain Biotech Plans $352 Million Shanghai STAR IPO for Novel CAR Candidates
$5.00
Available
Everest's Partner, Providence Therapeutics, Reports mRNA Vaccine Matches Pfizer’s
$5.00
Available
Everest's Partner, Providence Therapeutics, Reports mRNA Vaccine Matches Pfizer’s
$5.00
Available
Eucure Biopharma Licenses Antibody to Syncromune for Personalized Cancer Therapy
$5.00
Available
Zhiyi Bio to Start US Trial of Live Biotherapy for Chemotherapy-Induced Diarrhea
$5.00
Available
Gracell Starts China Trial of Donor-Derived CD-19 CAR-T for Leukemia
$5.00
Available
Innovent Publishes Positive Weight Loss Data from Trial of GLP-1/Glucagon Agonist
$5.00
Available
Bio-Thera Starts China Trial of mAb Biosimilar for Asthma
$5.00
Available
LianBio Stops China Trial of Liver Cancer Drug After Helsinn Asks FDA to Withdraw Approval
$5.00
Available
Accutar Starts China Phase I Trial of AI-developed Protein Degrader for Breast Cancer
$5.00
Available
Harbour BioMed Announces $140 Million Deal to Out-license Autoimmune Therapy to CSPC
$5.00
Available
WuXi Biologics to Partner with Toregem to Develop mAb for Tooth Regeneration
$5.00
Available
Jemincare Out-licenses Prostate Cancer Drug to Roche in $650 Million Deal
$5.00
Available
IASO Signs $162 Million Agreement to Out-License CD19 Binder to Cabaletta For CAR-T
$5.00
Available
JW Therapeutics Approved to Launch CAR-T for Second Lymphoma Indication
$5.00
Available
Innovent Approved to Launch Oncology Drug for Cancers with RET Gene Fusions
$5.00
Available
Tracon Pharma Says PD-L1 Passes Interim Safety Test in Sarcoma Trial
$5.00
Available
Ascletis Doses First Patient in China Trial of THRβ Agonist for NASH
$5.00
Available
Transcenta OK’d to Start US Trials of MASP2 mAb for Kidney Disease
$5.00
Available
Connect Reports Positive Results from Pivotal Trial of its Atopic Dermatitis Therapy
$5.00
Available
Moderna and China at Impasse over Selling mRNA COVID Vaccine in China
$5.00
Available
Kira Pharma to Start Phase II Trials of Biologic Targeting Two Complement Pathways for Severe Lupus
$5.00
Available
Biosyngen’s IND Accepted in China for T Cell Treatment of Nasopharyngeal Cancer
$5.00
Available
YishengBio Announces Merger with NASDAQ SPAC Company at $834 Million Value
$5.00
Available
Harbour BioMed Starts Phase I Trial of Biologic Therapy for Asthma
$5.00
Available
Simcere Out-Licenses Autoimmune Candidate to Almirall in $507 Million Deal
$5.00
Available
NeuShen Raises $20 Million in Pre-A Round for CNS Gene Therapy/Small Molecule Drugs
$5.00
Available
Xuanzhu Biopharm, a Sihuan Subsidiary, Files to Raise $345 Million in Shanghai STAR IPO
$5.00
Available
SynerK Partners with SciWind to Develop siRNA Drugs for Liver and Metabolic Diseases
$5.00
Available
Hansoh Acquires China Rights to Osteoarthritis Therapy in Deal Worth $63 Million-Plus
$5.00
Available
Zai Lab In-Licenses Cervical Cancer ADC from Seagen for $30 Million Upfront
$5.00
Available
Huisheng Biopharma Closes $70 Million Round for Diabetes Drug Portfolio
$5.00
Available
CASI Divests 12% Stake in Juventas, its CAR-T Partner, for $34 Million
$5.00
Available
MilliporeSigma Opens Viral Clearance Lab in Shanghai, Part of a $29 Million Project
$5.00
Available
Sino Biopharm Signs $307 Million Deal with Inventiva for NASH Therapy
$5.00
Available
Keymed’s Claudin 18.2 ADC Granted China Breakthrough Status for Gastric Cancer
$5.00
Available
RemeGen Reports Positive Results from Confirmatory Trial of Lupus Therapy
$5.00
Available
Frontera Approved to Start China Trial of Gene Therapy for Inherited Retinal Degeneration
$5.00
Available
Immuno Cure Acquires Partner Teresa Healthcare, an Electroporation Company
$5.00
Available
Biocytogen and FineImmune Partner on Cell Therapies Targeting Intracellular Antigens
$5.00
Available
Arnatar Biomedical Raises $15 Million in Seed Round for RNAi Therapies
$5.00
Available
Belite Bio Starts China Trial of Therapy for Stargardt, an Inherited Renal Disease
$5.00
Available
Apollomics, a US-China Biopharma, will Merge with SPAC to List on NASDAQ Exchange
$5.00
Available
Lepu Medical, a Medical Device Company, Raises $224 Million by Listing on Swiss Exchange
$5.00
Available
METiS Acquires Rights to Pan-RAF Inhibitor in $482 Million Agreement
$5.00
Available
Great Bay Bio, a Hong Kong CRO, Closes $15 Million Round for AI-based Bioprocessing
$5.00
Available
Great Bay Bio, a Hong Kong CRO, Closes $15 Million Round for AI-based Bioprocessing
$5.00
Available
Celregen Therapeutics In-Licenses iPS Therapy for Cornea Transplants in $100 Million Deal
$5.00
Available
Worg Pharma Completes $57 Million Series B for Novel Allergy and Autoimmune Therapies
$5.00
Available
Advanced MedTech Acquires WIKKON, a Shenzhen Urology Device Maker
$5.00
Available
US Blocks Asymchem’s $58 Million Acquisition of Boston’s Snapdragon
$5.00
Available
Redbud Closes $10 Million Round for China-US Clinical CRO Services
$5.00
Available
I-Mab Says CD47 Inhibitor Effective in Myelodysplastic Syndrome
$5.00
Available
Frontier Biotech Raises $29 Million for Novel COVID-19 Therapy
$5.00
Available
CanSino Inhaled COVID-19 Vaccine Approved in China as Booster
$5.00
Available
CanSino Inhaled COVID-19 Vaccine Approved in China as Booster
$5.00
Available
CellOrigin and Qilu to Develop Off-the-Shelf CAR-Macrophage Immunotherapies
$5.00
Available
CASI and BioInvent Start China Trial of FcγRIIB Inhibitor for NHL
$5.00
Available
BoomRay Raises $43 Million for Novel Diagnostic/Therapeutic Radionuclide Medicines
$5.00
Available
Vernalis Collaborates with Unison to Discover Drugs for “Undruggable” Bacterial Target
$5.00
Available
Neukio Bio Completes $50 Million Round for Allogenic CAR-T Therapies
$5.00
Available
DAC Biotech to Discover Five ADCs in Partnership with Janssen Biotech
$5.00
Available
Hangzhou Innoforce and Hibiscus Join to Advance Mayo Clinic’s Cell and Gene Therapies
$5.00
Available
E-nitiateBio Closes $15 Million Round to Support Autoimmune Portfolio
$5.00
Available
Asieris Acquires Rights to Heart Failure Therapy from Acorda
$5.00
Available
I-Mab to Concentrate on Five Clinical-Stage Candidates, Out-licensing International Rights
$5.00
Available
Sirnaomics Reports 100% Complete Response for Lead siRNA Candidate
$5.00
Available
UniCar Closes C Funding for “Safe” CAR-T Dual Target Candidate
$5.00
Available
RedCloud Doses NSCLC Patient in China Trial of Next-Gen EGFR TK
$5.00
Available
Bao Pharma Raises $100 Million in Series B Round for Protein/Antibody Drugs
$5.00
Available
Bao Pharma Raises $100 Million in Series B Round for Protein/Antibody Drugs
$5.00
Available
AlphaBio Completes Trials of Therapy for NSCLC with CNS Metastases
$5.00
Available
Clover Plans to Add Adolescents to List of Groups Approved for COVID-19 Vaccine
$5.00
Available
Lee’s Pharm Signs $78.9 Million Deal for RDS Drug/Device for Pre-Term Infants
$5.00
Available
Ranok Starts Trials of BRD4 Protein Degradation Therapy for Solid Tumors
$5.00
Available
Hansoh Forms $270 Million Partnership with GHDDI for COVID-19 Therapy
$5.00
Available
I-Mab to Start $40 Million Company/Management Share Repurchase Program
$5.00
Available
Porton Advanced Raises $80 Million for Gene and Cell Therapy CDMO Operations
$5.00
Available
Sirnaomics Starts US Trial of siRNA Therapy for Squamous Cell Skin Cancer
$5.00
Available
IASO to Start China Trial of Injected CAR-T Therapy for Autoimmune Disease
$5.00
Available
Accutar’s Chimeric Degrader OK’d for Prostate Cancer Trials in China
$5.00
Available
Jemincare Out-Licenses Prostate Cancer Candidate to Genentech for $650 Million
$5.00
Available
Wyze Biotech Closes A Rounds with $30 Million for Universal Immune Cell Products
$5.00
Available
Everest Returns Greater China Rights for Trodelvy to Gilead for $455 Million
$5.00
Available
SinocellTech Says Anti-CD20 mAb Shows Non-Inferiority to Genetech’s Rituxan
$5.00
Available
Bennu Bio Closes $15 Million Funding for T-Cell Therapies
$5.00
Available
Frontier Reports Positive Results from Early Trial of COVID-19 Therapy
$5.00
Available
Insilico Closes $35 Million D2 Round; Will Expand AI Beyond Drug Discovery
$5.00
Available
Axcynsis Opens Shanghai R&D Center; Raises $15 Million
$5.00
Available
LianBio Completes Enrollment of Phase III Trial for Cardiomyopathy Therapy
$5.00
Available
Arbele Starts Australian Trial of CDH17xCD3 Bispecific for GI Cancers
$5.00
Available
Hansoh Enters $170 Million Agreement for Endometriosis/Uterine Fibroid Therapy
$5.00
Available
Inmagene and HutchMed Start Global Trial of BTK Inhibitor
$5.00
Available
Epigenic Therapeutics Raises $20 Million in Angel and Pre-A Rounds for Epigenetic Drugs
$5.00
Available
ImmVira Granted US Orphan Drug Status for Oncolytic Virus Candidate in Glioma
$5.00
Available
Innovent to Partner two Sanofi Cancer Assets in China; Sanofi Invests $305 Million in Innovent
$5.00
Available
Genuine Biotech Files for Hong Kong IPO to Support Novel Drugs Portfolio
$5.00
Available
Radiopharm Forms Collaboration to Develop PD-L1 Diagnostic/Therapeutic Antibody
$5.00
Available
ProfoundBio Cleared to Start US Trials of ADC for Solid Tumor Cancers
$5.00
Available
Ablaze Plans $100 Million Facility in Chengdu Medical City for Targeted Radiation Therapies
$5.00
Available
Zenas to Start China Trials of Thyroid Eye Disease Therapy
$5.00
Available
Sironax Closes $200 Million Round for Novel Degenerative Disease Therapies
$5.00
Available
Structure Therapeutics Closes $33 Million for Novel Small Molecule Drugs
$5.00
Available
OriCell Closes $120 Million Round for Cell Therapies and Bispecific Candidates
$5.00
Available
GluBio Completes $22 Million Funding for Protein Degradation Candidates
$5.00
Available
CSPC Pharma Out-Licenses Claudin18.2 ADC in Deal with $1 Billion in Commercial Milestones
$5.00
Available
Maxvax Completes $74 Million Series B for China Vaccine Development
$5.00
Available
BridGene Closes $38.5 Million Funding from China Investors for Novel Small Molecule Targets
$5.00
Available
Legend Bio Plans to Raise $250 Million in Public Offering of Shares
$5.00
Available
HanX and Lepu Approved to Launch PD-1 mAb for Colorectal Cancer
$5.00
Available
InvestisBio Completes $296 Million IPO on the Shanghai STAR Board
$5.00
Available
Rona Therapeutics In-licenses Exclusive Global Rights to Sanofi’s siRNA Platform
$5.00
Available
WuXi Biologics and WuXi AppTec to Spend $2.8 Billion to Build Separate Singapore Facilities
$5.00
Available
Luzhu Biotech Files for HK IPO to Support Shingles Vaccine and Adalimumab Biosimilar
$5.00
Available
NeuroFront Acquires Non-Opioid Neuropathic Pain Killer for $130 Million
$5.00
Available
ImmVira Says IV Administration of Oncolytic Herpes Simplex Virus Shows Promise
$5.00
Available
Frontera Closes $160 Million B Round for US-China Gene Therapy Development
$5.00
Available
Ascentage-Innovent NDA Accepted for Priority Review as Chronic Myeloid Leukemia Therapy
$5.00
Available
Innovent Says Type 2 Diabetes Therapy Meets Glycemic/Weight Loss Endpoints
$5.00
Available
Antengene to Test its Bispecific with Celularity’s Stem Cell Natural Killer Cell Therapy
$5.00
Available
Merck’s Uptune Program to Back Asia Health/Technology Startups with €100,000
$5.00
Available
Simcere Approved to Launch Myelosuppression-Prevention Drug in China
$5.00
Available
Suzhou CStone Pharma Engages Goldman Sachs to Explore Sale of Company
$5.00
Available
CStone Approved to Launch RET Inhibitor in Hong Kong for NSCLC
$5.00
Available
Epic Bio Completes $55 Million Funding Led by HK’s Horizon to Modify Gene Expression
$5.00
Available
Triastek and Lilly Collaborate on Using 3D Printing for Programed Release of GI Drugs
$5.00
Available
Bio-Thera Starts China Trials of ADC for Solid Tumors
$5.00
Available
Connect to Use Early Results from China Phase III Trial of Atopic Dermatitis Therapy
$5.00
Available
Tasly Forms JV to Commercialize Confocal Laser Endomicroscopy Device
$5.00
Available
Sinopharm May Bid $1 Billion for Shanghai’s BBI, a Research Products Company
$5.00
Available
Overland ADCT Starts China Trial of ADC for B-cell Lymphoma
$5.00
Available
Precision Autoimmune Therapies Raises $21 Million to Develop Anti-CD38 Program
$5.00
Available
BeiGene Collaborates with InnoRNA to Develop mRNA Therapeutics
$5.00
Available
Zhiyi Bio Raises $45 Million for Live Biotherapeutic Products Aimed at IBS and Cancer
$5.00
Available
SunHo Starts Trial of Dual Immunocytokine Therapy for Solid Tumor Cancers
$5.00
Available
Sequoia Raises $9 Billion for Healthcare/Tech Investments in China
$5.00
Available
Arctic Vision Starts China Phase III Trial of Farsightedness Therapy
$5.00
Available
ClinChoice, a Global Clinical CRO, Raises $150 Million from China Investors
$5.00
Available
Brii Bio In-licenses China Rights to Second HBV mAb from Vir
$5.00
Available
Ascletis Says PD-L1 Induces “Functional Cure” in CHB Patients
$5.00
Available
Clover Bio’s COVID Vaccine Effective as Booster Against Omicron Variants
$5.00
Available
BeiGene’s Phase III Data Shows PD-1 Effective as First Line Therapy for Esophageal Carcinoma
$5.00
Available
Suzhou Ascentage to Start US Trial of Novel EED Protein Inhibitor
$5.00
Available
Akeso Approved to Launch Dual Checkpoint Inhibitor for Cervical Cancer
$5.00
Available
GenFleet to Receive Royalty Rights for Conducting China Trial of BioLineRx Cancer Drug
$5.00
Available
Henlius Acquires Two Novel Immunotherapy Candidates in $196.5 Million Deal
$5.00
Available
Shanghai Zai Lab Raises Hong Kong Listing to Primary Status
$5.00
Available
Innovent/Lilly Announce China Approval for Sixth Indication of PD-1 Drug
$5.00
Available
Harbour BioMed to Start US Trials of Novel Bispecific for Solid Tumor Cancers
$5.00
Available
Reistone Completes $100 Million A Round for Inflammatory Disease Drugs
$5.00
Available
Sino Biopharm’s invoX Acquires F-Star, a UK Bispecific Company, for $161 Million
$5.00
Available
Xuanzhu Out-Licenses China Rights for Two Antibiotics in $66 Million Deal
$5.00
Available
InnoCare Starts China Trial of SHP2 Inhibitor for Solid Tumors
$5.00
Available
OcuMension Approved to Launch Novel Uveitis Therapy in China
$5.00
Available
Shenzhen's AxBio Raises $100 Million for Low-Cost, High Precision Sequencing Machines
$5.00
Available
MegaRobo Raises $300 Million for Automated Drug Lab Systems and Robots
$5.00
Available
CANbridge Says Anti-C5 mAb Shuts Down Complement Activity
$5.00
Available
Joincare Plans IPO on the SIX Swiss Stock Exchange
$5.00
Available
Clover Starts Phase III Trial of COVID Vaccine as a Booster to Other Vaccines
$5.00
Available
I-Mab’s Partner MorphoSys Out-Licenses Ex-China Rights for Two Oncology Candidates to HIBio
$5.00
Available
WinHealth Acquires Two Rare Disease Therapies from Quoin Pharma
$5.00
Available
Kangpu Doses First Patient in Phase IIa Trial for Protein Degradation Therapy
$5.00
Available
Alphamab Starts China Trial of PD-L1/OX40 Bispecific for Solid Tumors
$0.00
Available
Organon Pays $103 Million to Acquire Global Rights for Two Henlius Biosimilars
$5.00
Available
META Raises $15 Million to Develop Small Molecule Immunometabolism Drugs
$5.00
Available
Everest Approved to Launch ADC for Triple-Negative Breast Cancer in China
$5.00
Available
Chengdu Keymed Starts China Trial of Bispecific for Solid Tumor Cancers
$5.00
Available
Chengdu Keymed Starts China Trial of Bispecific for Solid Tumor Cancers
$5.00
Available
Shanghai Degron Raises $22 Million for Protein Degradation Drugs
$5.00
Available
I-Mab Alters Collaboration with Ferring Pharma for Developing IBD Candidate
$5.00
Available
OnCusp Acquires Global Rights (ex-China) to CDH6 ADC from Multitude Therapeutics
$5.00
Available
Insilico Medicine Completes $60 Million Funding; Will Build Robotic Drug Discovery Lab
$5.00
Available
Henlius Releases Positive Results for PD-1 as First-Line Therapy for SCLC
$5.00
Available
NuProbe Raises $50 Million for Genomics and Molecular Diagnostics
$5.00
Available
Insilico Starts China Trial of AI-Discovered Novel Fibrosis Therapy
$5.00
Available
ProfoundBio Closes $70 Million Series A+ Funding for ADC and Immunotherapy Drugs
$5.00
Available
Sihuan and CTTQ-Akeso Team up to Test AXL Inhibitor and PD-1 in Solid Tumors
$5.00
Available
Vivo Capital Closes First Tranche of China Fund at $600 Million; Aiming for $1.5 Billion
$5.00
Available
SciNeuro Acquires Rights to Lp-PLA2 Inhibitor from GSK for Alzheimer’s
$5.00
Available
Hansoh Publishes Positive Results in ASCO Journal for Third-Gen EGFR-TKI Inhibitor
$5.00
Available
IASO IND for CAR-T to Treat Autoimmune Disease Accepted in China
$5.00
Available
Oncotelic Forms $50 Million Hong Kong JV to Develop Antisense Candidate
$5.00
Available
Legend Bio to Launch CAR-T in Europe for Multiple Myeloma
$5.00
Available
Full-Life Closes $37 Million Series A for Radiopharmaceutical Oncology Products
$5.00
Available
Laekna Starts China-US Trials of AKT Kinase Inhibitor for Breast Cancer
$5.00
Available
Junshi’s Novel SARS-CoV-2 Therapy Out-Performs Pfizer’s Paxlovid
$5.00
Available
DongCheng Acquires Imaging Tracer to Predict Immunotherapy Efficacy
$5.00
Available
CASI Signs $10 Million Out-licensing of CD38 for Autoimmune Indications to Tianshi
$5.00
Available
CanSino One-Shot COVID Vaccine Accepted by WHO
$5.00
Available
Fosun Acquires Novel Cancer Immunotherapy in $125 Million Deal
$5.00
Available
CTTQ Acquires Global Rights to Clinical Stage Symphogen Immunotherapy
$5.00
Available
Belief BioMed Reports Positive Data for Hemophilia Gene Therapy
$5.00
Available
Inmagene Approved to Start Phase I Trial of Novel BTK Inhibitor
$5.00
Available
Bayer/Merck Cardiovascular Drug Approved for China Use
$5.00
Available
Ascentage Oncology Drug Effective in Preclinical Tests for COVID Cytokine Storm
$5.00
Available
Hengrui Launches Luzsana to Bring its Novel Medications to Global Markets
$5.00
Available
Laekna Raises $61 Million for its 14-Drug Cancer/Liver Disease Portfolio
$5.00
Available
Kelun Out-Licenses Global Rights for Candidate to Merck/MSD in $1.4 Billion Deal
$5.00
Available
Henlius Out-licenses Latin American Rights for Three Biosimilars in $55 Million Deal
$5.00
Available
Green Valley Stops Global Phase III Trial of its Novel China-Approved Alzheimer’s Drug
$5.00
Available
Zenas Files China IND for mAb to Treat Thyroid Eye Disease
$5.00
Available
Hengrui Reports PD-1 Combo Therapy Effective in Global Trial for Liver Cancer
$5.00
Available
CARsgen Reports Positive Results for CAR T Therapy in Solid Tumor Cancers
$5.00
Available
Coherus Returns Rights for Avastin Biosimilar to Innovent
$5.00
Available
Zhimeng Bio Starts US Trials for Novel Epilepsy Therapy
$5.00
Available
Zhaoke Signs $130 Million Deal for Two Eyedrop Near-Vision Treatments
$5.00
Available
Ascletis Starts US Trial of PD-L1 as AIDS/HIV-1 Cure
$5.00
Available
SCG to Start China/Singapore Trials of Cell Therapy for Hepatocellular Carcinoma
$5.00
Available
Tonghua Dongbao Doses First Patient in China Phase III Trial of Ultra-Rapid Insulin
$5.00
Available
InxMed Adds $15 Million B+ Funding for China/US Pivotal Trials of FAK Inhibitor
$5.00
Available
Elpiscience Cleared for US Trials of Bispecific Immunotherapy in Solid Tumors
$5.00
Available
Jemincare Out-Licenses Global Rights (ex-China) for Novel Pain Drug to Finland’s Orion
$5.00
Available
Newsoara Ok’d to Start China Phase III Trial of Bowel Function Drug
$5.00
Available
Zhifei Lvzhu In-Licenses Whooping Cough Vaccine from Intravacc
$5.00
Available
Connect Plans to Partner Ulcerative Colitis Candidate After Disappointing Trial
$5.00
Available
BeiGene Approved to Launch Bi-Specific in China for Pediatric Leukemia Patients
$5.00
Available
Suzhou Kintor Starts US Trial of ALK-1 mAb for Hepatocellular Carcinoma
$5.00
Available
What Biopharma Slowdown? OrbiMed Raising $1.1 Billion for Asia Companies; $4.75 Billion for Three Funds
$5.00
Available
Hansoh Signs $218 Million Agreement with NiKang for Oncology Asset
$5.00
Available
Inmagene Approved to Start US Trials of HutchMed Immune Disease Therapy
$5.00
Available
Junshi and Coherus Undaunted by US Rejection of Partnered PD-1
$5.00
Available
LianBio’s Partner BMS OK’d to Launch Cardiomyopathy Drug in US
$5.00
Available
Xbiome Acquires Global Rights to Microbiome Product for Ulcerative Colitis
$5.00
Available
Xbiome Acquires Global Rights to Microbiome Product for Ulcerative Colitis
$5.00
Available
Chimera Bio Wins $7.5 Million Asia Award for Novel CAR-T Technology
$5.00
Available
RVAC Completes B Round for mRNA Drugs, Bringing Total Raised to $140 Million
$5.00
Available
Huadong Medicine Acquires Rights to Four Ashvattha Candidates for $45 Million
$5.00
Available
I-Mab and VMS Partner to IPO a SPAC in HK for a China Life Science Company
$5.00
Available
Viva Invests $60 Million in China RNAi JV it Formed with Arrowhead
$5.00
Available
Sinorda and Porton Partner to Advance Cell and Gene Therapy Products
$5.00
Available
Shanghai STAR Exchange Biologic and Medicine Index Launches May 9
$5.00
Available
Lynk to Start China Trials of Novel Kinase Inhibitor for Psoriasis
$5.00
Available
Binhui Raises $47 Million for Oncolytic Virus Products
$5.00
Available
I-Mab Seeks Deal – Maybe Partnering a Drug, Maybe Selling the Company
$5.00
Available
ImmVira to Test its 3-in-1 Virus Delivery Product with Roche’s MEK Inhibitor
$5.00
Available
JW to Start China Trials of CAR-T for Pediatric/Young Adult Leukemia
$5.00
Available
GeneQuantum Partners with Aimed Bio to Develop ADC for Brain Cancer
$5.00
Available
Ascletis Reports Positive Preclinical Data from 3CLpro COVID Therapy
$5.00
Available
Trevena Closes $40 Million Revenue-based Financing with CBC Affiliate
$5.00
Available
Amoy to Develop Companion Diagnostics for AstraZeneca Drugs
$5.00
Available
Bayer Precision Medicine Approved in China for NTRK Gene Fusion Cancers
$5.00
Available
BeiGene Snags 8th China Approval for Tislelizumab, a PD-1 mAb
$5.00
Available
Junshi PD-1 Granted US Orphan Designation for Small Cell Lung Cancer
$5.00
Available
CStone Presents Preclinical Data on Tri-specific (PD-L1, 4-1BB, HSA) mAb
$5.00
Available
AnPac Bio-Medical Raises $15 Million to Develop Early Cancer Detection Tests
$5.00
Available
AffaMed and VistaGen Start China Phase III Trial of Social Anxiety Therapy
$5.00
Available
InventisBio Reports Promising Data from KRAS G12C Trials
$5.00
Available
LTZ Completes $17 Million Pre-A Raise for Immunotherapies
$5.00
Available
Everest Medicines Signs MOU with CR Pharma to Form mRNA Company
$5.00
Available
Harbour BioMed Out-licenses Bispecific to AstraZeneca in $350 Million Agreement
$5.00
Available
ENSEM Raises $67 Million in A Round for Structure-Based Oncology Drugs
$5.00
Available
GenFleet Out-Licenses CDK9 Inhibitor to Sellas in $150 Million Deal
$5.00
Available
Pregene Out-licenses CAR-T to CellPoint for $22 Million in Near-Term Payments
$5.00
Available
Innovent Reports Positive Data from Phase III Trial of PCSK-9 Cholesterol Drug
$5.00
Available
Sirnaomics Starts US Trial of siRNA Therapy for Liver Fibrosis
$5.00
Available
China Changes Policy: US Auditors Can Examine US-Listed China Companies
$5.00
Available
CanSinoBIO Approved to Start China Trials of mRNA COVID Vaccine
$5.00
Available
RemeGen Stages $410 Million Shanghai IPO; Trades Lower
$5.00
Available
Zhongze Completes China Dose Escalation Trial for Schizophrenia Therapy
$5.00
Available
CStone Starts US Trial of ROR1 Conjugate Drug for Lymphoma and Solid Tumors
$5.00
Available
Hasten Closes $353 Million Deal to Distribute Five Takeda Drugs in China
$5.00
Available
InnoRNA Raises $120 Million in B Round for mRNA Candidates
$5.00
Available
Brii Bio Partners with Sinopharm to Distribute COVID mAb Therapy in China
$5.00
Available
Biosion Out-Licenses Siglec-15 mAb for Solid Tumors in $226 Million Pact
$5.00
Available
CANbridge NDA for Rare Disease Therapy Accepted in Taiwan
$5.00
Available
Innovent Signs $45 Million Deal to Commercialize Two Lilly Oncology Drugs in China
$5.00
Available
InnoCare Approved to Start Trials of JH2 Inhibitor for Autoimmune Diseases
$5.00
Available
OBiO Completes Shanghai IPO for Gene-Cell CDMO Services; Trades 67% Higher
$5.00
Available
Ascentage Granted US Rare Pediatric Disease Status for Neuroblastoma Therapy
$5.00
Available
Recbio Plans to Raise $98 Million in a Hong Kong IPO for Vaccines
$5.00
Available
Nuance In-licenses Adult RSV Vaccine in $225 Million Deal
$5.00
Available
Simcere to Commercialize Lynk's JAK1 Inhibitor in China
$5.00
Available
China and US May Solve De-Listing Problem
$5.00
Available
Bioheng Approved to Start First China Trial of Universal CAR-T Therapy
$5.00
Available
EdiGene Licenses IP to Treat Genetically Caused Hemoglobin Diseases
$5.00
Available
Junshi Starts Global Phase III Trial of COVID-19 Therapy
$5.00
Available
Junshi/Coherus Says PD-1 Meets Endpoints in US Phase III NSCLC Trial
$5.00
Available
I-Mab Expects Resolution of China-US Auditor Conflict without De-Listings
$5.00
Available
MediLink Raises $70 Million in B Round for ADC Portfolio
$5.00
Available
Shanghai Impact Closes D1 Round for Synthetic Lethality Drugs
$5.00
Available
Three China-Based Biopharmas Receive US De-listing Notices
$5.00
Available
Gan & Lee Starts US Trial of GLP Therapy for Type 2 Diabetes
$5.00
Available
WuXi AppTec Partners to Offer Services with UK's Orbit Discovery
$5.00
Available
Eucure-Biocytogen Start Trial of Dual Drug Combo for Solid Tumors
$5.00
Available
China Approves VR Therapy as Medical Device for Acrophobia
$5.00
Available
J&J in Partnership Talks with Two China Biopharmas
$5.00
Available
Tencent Co-Leads $67 Million Financing for UK's Microbiotica
$5.00
Available
SalubrisBio Raises $32 Million from China Parent for Novel Biologics
$5.00
Available
Nuance Pharma Acquires Rights to Nasal Spray in $23.5 Million Deal
$5.00
Available
InxMed Raises $50 Million for Resistance-Fighting Cancer Therapies
$5.00
Available
OBiO Signs MOU to Manufacture Cell Therapy for Korea's Eutilex
$5.00
Available
Haisco In-Licenses Oral Film Version of Riluzole for ALS
$5.00
Available
Adagene to Add Masking Technology to 4 Sanofi Candidates in $2.5 Billion Deal
$5.00
Available
Zhongze In-licenses CNS Candidate for Schizophrenia and Parkinson's
$5.00
Available
Legend-Janssen CAR-T Therapy Approved in US for Multiple Myeloma
$5.00
Available
AnHeart-Innovent Granted China Breakthrough Status for NSCLC Drug
$5.00
Available
Huadong Strikes $1 Billion Deal for Asia Rights to Four ADC Candidates
$5.00
Available
Transcenta Starts Phase II Trial of Claudin18.2 Therapy for Biliary Tract Cancer
$5.00
Available
CANbridge to Launch Rare Disease Therapy in China's Medical Tourism Zone
$5.00
Available
Simcere Reports Anti-Neutropenia Oncology Drug Meets Phase III Endpoint
$5.00
Available
Huadong Pharma Forms $662 Million Collaboration for Anti-Inflammatory Drugs
$5.00
Available
Lepu Completes $116 Million HK IPO; Trades Flat in Opening Sessions
$5.00
Available
Sirnaomics Says siRNA Effective in Phase II Basal Cell Carcinoma Trial
$5.00
Available
SyMap Starts China Trial of Renal Denervation Device for Hypertension
$5.00
Available
Odeon Acquires China Rights for Two Cancer Therapies in $200 Million Deal
$5.00
Available
Stemirna Planning Phase III Trial of COVID mRNA Vaccine in Brazil
$5.00
Available
Innovent Says China Trial Started for Claudin 18.2 CAR-T Cell Therapy
$5.00
Available
Revotek Starts Trial of Stem Cell 3D Printing Product for Arterial Disease
$5.00
Available
TransThera to Start US Trials of Novel BTK Inhibitor
$5.00
Available
Legend Halts US Trial of CD4+ CAR-T after First Patient Dosed
$5.00
Available
Innovent Reports PCSK-9 mAb Meets Endpoint in Hypercholesterolemia Trials
$5.00
Available
Gracell's BCMA/CD19 CAR-T Starts China Trial for Non-Hodgkin's Lymphoma
$5.00
Available
Sirnaomics Ok'd to Start US Trials of siRNA Therapy for Rare Disease
$5.00
Available
SciNeuro Teams Up with Alamar to Discover Novel CNS Drugs
$5.00
Available
AffaMed In-licenses Rights to AMD Therapy, Approved to Start US Trials
$5.00
Available
IASO/Innovent BCMA CAR-T Granted US Orphan Status for Myeloma
$5.00
Available
CStone Approved to Market Precision Medicine Drug for AML Patients
$5.00
Available
Everest Approved to Launch Triple-Negative Breast Cancer ADC in Singapore
$5.00
Available
Innovent/Lilly PD-1 Rejected by US FDA Panel; Lilly Says Price 40% Below Competition
$5.00
Available
Zerun Bio Lands CEPI Grant to Start Trials of Multi-Variant COVID Vaccine
$5.00
Available
Innovent/Lilly Face US FDA Setback Due to China-Only PD-1 Trials
$5.00
Available
Huadong Med Acquires Rights To Bi-functional Immunotherapy in $75 Million Deal
$5.00
Available
EdiGene to Discover Stem Cell/Natural Killer CAR Therapy for Neukio
$5.00
Available
Ascletis Approved to Start US Trials of an Oral PD-L1 for Solid Tumors
$5.00
Available
CANbridge Says C5 mAb Effective in Early Trial for Complement Diseases
$5.00
Available
Antengene Approved to Start Trial of Oral CD73 Inhibitor for Solid Tumors
$5.00
Available
Xvivo Perfusion Approved to Launch Lung Transplant Product in China
$5.00
Available
Hutchmed Starts China Trial of Novel FGFR Inhibitor in Solid Tumor Cancers
$5.00
Available
Kintor Starts US Trial of Topical Androgen Inhibitor for Alopecia
$5.00
Available
Beroni Group to Build Biopharma R&D Facility in Zhuhai Park
$5.00
Available
Dizal Pharma Awarded US Breakthrough Status for NSCLC Therapy
$5.00
Available
HanBio Raises $40 Million for BiSpecific Antibody Portfolio
$5.00
Available
Akeso Starts Phase III Trial of Bispecific Immunotherapy for NSCLC
$5.00
Available
Xbiome Signs $139 Million China Deal for Probiotic Diabetic Foot Ulcer Therapy
$5.00
Available
I-Mab Partners with Hangzhou Qiantang Park to Build Manufacturing Plant
$5.00
Available
Ractigen Closes $30 Million Financing for RNAa Candidates
$5.00
Available
Grand Pharma Acquires Rights to Mitral Valve Replacement Device
$5.00
Available
Biotime In-licenses Five Adlai Nortye Candidates in $32 Million Deal
$5.00
Available
Ignis Acquires China Rights for ADHD Therapy Device from NeuroSigma
$5.00
Available
Cure Genetics Raises $60 Million to Advance Universal CAR-T Products
$5.00
Available
ImmVira Manufacturing Virus Vectors to Enable Solid Tumor CAR-T Products
$5.00
Available
EdiGene Forms Translational Stem Cell Collaboration with Haihe Lab
$5.00
Available
Applied Pharmaceutical Science to Start US Trial of 2nd Gen RET Inhibitor
$5.00
Available
Eluminex Acquires Global Rights to Therapy for Rare Genetic Blindness
$5.00
Available
Elpiscience Starts US Trial of Novel CD39 Immunotherapy
$5.00
Available
Neurophth Approved to Start Gene Therapy for Hereditary Neuropathy
$5.00
Available
Novotech Raises $255 Million to Expand Asia-China Clinical CRO Operations
$5.00
Available
CStone Says PD-L1 Meets Overall Survival Endpoint for NSCLC
$5.00
Available
Abbisko Forms $258 Million Collaboration with Lilly for Cardiometabolic Candidates
$5.00
Available
Innovent Options China Rights to Amagma's Inflammatory Disease Inhibitors
$5.00
Available
JYSSBio Closes B+ Round for Single-Use Bioreactor Manufacturing
$5.00
Available
Thousand Oaks Bio Completes $235 Million Round for CDMO Ops
$5.00
Available
CARsgen's Claudin18.2 CAR T-Cell Candidate Granted US RMAT Designation
$5.00
Available
Fosun and Insilico Collaborate to Develop Five Candidates
$5.00
Available
Accuredit and N1 Life Form JV to Develop Gene Editing Delivery Technologies
$5.00
Available
Shanghai ZhenGe Completes $100 Million Round for Biologic CDMO Services
$5.00
Available
Sana In-Licenses BCMA CAR Construct from IASO/Innovent in $204 Million Deal
$5.00
Available
Junshi and Coherus Enter $290 Million Agreement for Junshi's TIGIT Antibody
$5.00
Available
Junshi Collaborates With DotBio to Discover Multi-Specific Antibodies
$5.00
Available
Akeso Approved for China Trial of Dual PD-1 Bi-Specifics Therapy
$5.00
Available
Nuance Acquires Sino Health in a Deal Worth at Least $32 Million
$5.00
Available
Clover Bio Starts Construction of R&D Center in Zhangjiang Hi-Tech Park
$5.00
Available
Accro Raises $50 Million for Regulated Cell Death Drug Candidates
$5.00
Available
Jiangsu Atom Closes $45 Million Round for Global Phase III Gout Trial
$5.00
Available
AffaMed Signs $145 Million Agreement for China Rights to Ophthalmic Drug
$5.00
Available
Sperogenix In-licenses Rare Disease Treatment in $124 Million Deal
$5.00
Available
Xuanzhu, a Novel Drug Subsidiary of Sihuan Pharm, Completes $96 Million Round
$5.00
Available
CStone Approved for US Trial of ROR1 ADC
$5.00
Available
Amador Bio Raises $60 Million for Translational/Pharmacology CRO Services
$5.00
Available
Great Bay Bio Raises $10 Million for AI CMC Biologic Services
$5.00
Available
Sirnaomics Raises for RNA Therapy in $64 Million in Hong Kong IPO
$5.00
Available
ArkBio In-licenses Novel ADHD Drug in $105 Million Agreement
$5.00
Available
SyMap Closes $100 Million Round for Renal Denervation Devices
$5.00
Available
Biosyngen Opens Cell Therapy Production Facility in Guangzhou
$5.00
Available
Innogen Pharma Closes $120 Million Financing for GLP-1 Diabetes Treatment
$5.00
Available
CStone Announces Hong Kong Approval of Precision Medicine for GIST
$5.00
Available
Kintor COVID-19 Candidate to Target Higher Risk Patients
$5.00
Available
BeiGene Launches Guangzhou Innovation Center for Drug/Device Startups
$5.00
Available
GeneSci In-licenses Alzheimer's Patch Therapy from Luye Pharma
$5.00
Available
Nuance Announces $213 Million Deal for China Rights to Inhaled RDS Therapy
$5.00
Available
ArriVent and Aarvik Form $100 Million Partnership to Develop Oncology Drug
$5.00
Available
Suzhou's TandemAI Raises $25 Million for AI-Wet Lab Discovery Operations
$5.00
Available
Zai Lab's Partner Approved for US Launch of Myasthenia Gravis Therapy
$5.00
Available
BeiGene Out-Licenses TIGIT Inhibitor to Novartis in $2.8 Billion Agreement
$5.00
Available
Antengene Approved to Launch XPO1 Inhibitor for Multiple Myeloma
$5.00
Available
3SBio Acquires China Rights to Numab Immunotherapy
$5.00
Available
Nanjing Biosion Out-licenses Global Rights for Trop2 mAb to OBI Pharma
$5.00
Available
Denovo Discovers Biomarker for Gene Therapy
$5.00
Available
BeiGene Begins Trading on STAR Board; Slides 17% Lower
$5.00
Available
LisenID Says Novel Epigenetics Diagnostic Effective in Early Lung Cancer
$5.00
Available
BeiGene In-licenses Rights To LAG-3 mAb from Leads Bio in $772 Million Deal
$5.00
Available
AnHeart Closes $61 Million Round for Precision Oncology Therapies
$5.00
Available
Qilu Enters $300 Million Deal for Novel RNAi Hepatitis B Therapy
$5.00
Available
Hansoh Acquires Cytopenia Therapy in Agreement Worth up to $190 Million
$5.00
Available
Shanghai Regor Enters $1.5 Billion Deal with Lilly for Metabolic Therapies
$5.00
Available
CANbridge Raises $77 Million in Hong Kong IPO; Shares Trade Lower
$5.00
Available
Avistone of Beijing Raises $200 Million; Will Combine with Pearl Biotech
$5.00
Available
I-Mab and Nhwa Announce Novel Alzheimer's Drug Starts US Trials
$5.00
Available
METiS, a US-China AI Company, Raises $86 Million in Series A
$5.00
Available
Xcovery, a US Affiliate of China's Betta, Acquires Majority Stake in Meryx
$5.00
Available
Innoforce Raises $157 Million for Cell/Gene Therapy and RNA CDMO
$5.00
Available
RareStone In-Licenses China Rights to Obesity Therapy in $75 Million Deal
$5.00
Available
Sciwind In-licenses Sanofi's Portfolio of GIP Agonists for Obesity and Diabetes
$5.00
Available
Lynk Pharma Starts China Trial of RA Treatment
$5.00
Available
Tot Biopharma Approved to Launch Avastin Biosimilar in China
$5.00
Available
MingMed Approved to Start US Trial of Immunotherapy
$5.00
Available
SanReno, a China JV, Formed with $40 Million and Two Kidney Disease Drugs
$5.00
Available
ITabMed Formed as JV to Develop T Cell Engagers; Raises $20 Million
$5.00
Available
Ascentage and Innovent Approved to Launch Leukemia Drug in China
$5.00
Available
BeiGene Raises $3.5 Billion in Shanghai STAR Board IPO
$5.00
Available
Suzhou Abogen Raises $300 Million to Support mRNA COVID Vaccine
$5.00
Available
Ablaze Closes $75 Million Series for Targeted Radiopharmaceutical Therapies
$5.00
Available
Help Therapeutics Raises $25 Million for iPSC Heart Failure/Oncology Therapies
$5.00
Available
3D Medicines Approved to Launch Anti-PD-L1 in China
$5.00
Available
Tongshu Biotechnology Raises $78 Million for Early Cancer Screening Tests
$5.00
Available
Neurophth Closes $60 Million C Round for Ophthalmic Gene Therapies
$5.00
Available
BeiGene to Invest Hundreds of Millions of Dollars in US Manufacturing Site
$5.00
Available
Zenas, a US-China Biopharma, Announces $480 Million Deal for Autoimmune Therapy
$5.00
Available
CStone Out-Licenses China CTLA-4 Rights to Hengrui in $200 Million Deal
$5.00
Available
Apollomics Starts China Phase III Trial of Leukemia Drug
$5.00
Available
Livzon Out-licenses PD-1 to Bright Peak for PD-1 Targeted Immunocytokines
$5.00
Available
Connect Bio Reports Positive Data from Phase II Trial of Dermatitis Therapy
$5.00
Available
Clover Receives $38.9 Million CEPI Grant to Finish Development of COVID Vaccine
$5.00
Available
EdiGene Forms University Collaboration for RNA Edited Genetic Therapies
$5.00
Available
HebaBiz Approved to Start China Trial of Novel Hepatitis B Therapy
$5.00
Available
Shanghai AoHua Endoscope Raises $117 Million in IPO; Trades 71% Higher
$5.00
Available
Newsoara Expands In-Licensed Territory for BET Inhibitor to Asia
$5.00
Available
Ascletis Approved to Start China Trial of PD-L1 to Cure HIV-1
$5.00
Available
Everest Reports ADC Meets Endpoint for Triple-Negative Breast Cancer
$5.00
Available
Ignis Formed with $180 Million to Develop SK Bio's CNS Candidates in China
$5.00
Available
Gmax Starts China Phase I Trial of 2nd Gen Obesity Therapy
$5.00
Available
I-Mab Announces $315 Million Commercialization Deal for Growth Hormone
$5.00
Available
IASO Starts China Phase I/II Trial of CD19/CD22 CAR-T for Lymphoma
$5.00
Available
Zai Lab Signs Two In-Licensing Deals with $800 Million Total Value
$5.00
Available
Arbor, a US Gene Editing Company, Raises $215 Million Led by Singapore, Hong Kong, US Investors
$5.00
Available
Hopstem Bio Completes $40 Million B Round for Neural Stem Cell Therapy
$5.00
Available
HitGen and Cambridge Molecular Form Alliance to Source Ligands for Targets
$5.00
Available
CANbridge Sponsors Gene Therapy Research for Duchenne Muscular Dystrophy
$5.00
Available
Nanjing's TransThera Granted US Fast Track for Cholangiocarcinoma Therapy
$5.00
Available
Antengene to Start US Trials of PD-L1 Bispecific for B-NHL
$5.00
Available
Kintor Starts Taiwan Trial of ALK-1 Antibody in HCC Patients
$5.00
Available
LianBio Completes $325 Million US IPO to Support China In-Licensing Program
$5.00
Available
BeiGene Pays $45 Million Upfront for Global Rights to Shoreline Cell Therapies
$5.00
Available
HitGen Subsidiary Forms Partnership to Develop Novel Cancer Drug
$5.00
Available
Junshi and Coherus File for US Approval of Partnered PD-1
$5.00
Available
Shanghai Pharma Unit Acquires Microbiome Therapies in $110 Million Deal
$5.00
Available
Alphamab Starts China Phase II/III Trial of PD-L1/CTLA-4 Bispecific
$5.00
Available
Novadip's $22 Million B Round for Skeletal Tissue Therapies Includes HK Investor
$5.00
Available
Innovent and NeoCura to Test PD-1/mRNA Vaccine Combination for Cancer
$5.00
Available
Fosun Announces $628 Million Deal for Majority Stake in Chengdu Antejin
$5.00
Available
CANbridge Doses First Patient in Phase II GBM Trial
$5.00
Available
SciNeuro Partners with Mabylon to Discover Antibodies for Neurological Diseases
$5.00
Available
Angel to Start China Trial of ITK Inhibitor for Lymphoma
$5.00
Available
Silenseed Raises $7.8 Million for China RNAi Joint Venture
$5.00
Available
CANbridge to Acquire Gene Therapy for Rare Diseases from Scriptr
$5.00
Available
Kintor Approved to Start Phase I Trial of Dual-Targeting Antibody
$5.00
Available
Shanghai I-Mab to Open San Diego R&D Lab
$5.00
Available
Antengene and LegoChem to Create ADCs Using Antengene's Antibodies
$5.00
Available
ShouTi Closes $100 Million Round for Structure-Based Drug Discovery
$5.00
Available
Chase Raises $20 Million from Hong Kong Investor for Novel Neuro Drugs
$5.00
Available
Zai Lab Says Novel Antibacterial Effective Against a Drug Resistant Pathogen
$5.00
Available
Microtech Medical Stages $233 Million Hong Kong IPO for Diabetes Devices
$5.00
Available
United BioPharma Starts Taiwan-China Trial of Herpes Treatment
$5.00
Available
Hansoh Signs $1.3 Billion siRNA Deal; Its Second siRNA Deal in a Week
$5.00
Available
Innovent Says PD-1 Meets Survival Endpoint in Phase III NSCLC Trial
$5.00
Available
Abbisko Raises $226 Million in Hong Kong IPO for Cancer Therapies
$5.00
Available
GV20 Oncotherapy Closes Series B for Genomics/AI-based mAb Portfolio
$5.00
Available
BeiGene and Bristol-Myers in Fight over China Abraxane Distribution Deal
$5.00
Available
Zai Collaborates with Geneseeq to Implement Personalized Cancer Care
$5.00
Available
Sirtex Doses First Patient in China Trial of Microsphere Radiation Therapy
$5.00
Available
Kintor Starts China Trial of Combination Therapy for Liver Cancer
$5.00
Available
Hansoh Signs $456 Million Agreement for siRNA Products from OliX Pharma
$5.00
Available
BioNova Acquires Rights to CD74 Candidate from Sutro in $204 Million Deal
$5.00
Available
Hangzhou's Sciwind Closes $70 Million Series C for Metabolic Therapies
$5.00
Available
Chance Pharma Completes $30 Million Round for Inhalation Therapies
$5.00
Available
Biocytogen Subsidiary Out-Licenses US Rights for CTLA-4 to Tracor
$5.00
Available
AnchorDx and Twist Launch Pan-Cancer Screening Product Globally
$5.00
Available
MicroTech to Raise up to $254 Million in Hong Kong IPO for Diabetes Products
$5.00
Available
AffyImmune Raises $30 Million for CAR-T Therapies from HK Investor
$5.00
Available
Zai Lab Says HER2 Drug Meets Endpoints in Bridging Trial
$5.00
Available
I-Mab in Discussions with Global BioPharmas for a Deal
$5.00
Available
I-Mab in Discussions with Global BioPharmas for a Deal
$5.00
Available
Himalaya Files Four INDs in China for Conditionally Active Biologics
$5.00
Available
NovoCodex Reports Positive Data from ADC for Gastric Cancer
$5.00
Available
CBMG Raises $120 Million for Clinical Trials of Cellular Immunotherapies
$5.00
Available
iX Signs Up CRPCC to Distribute Sublingual ED Therapy in China
$5.00
Available
Bio-Thera Partners with Intract to Develop Oral mAb for GI Disease
$5.00
Available
Newsoara Bio Enters $171 Million Agreement for Oncolytic Viruses
$5.00
Available
Worg Pharma Acquires Apitope's Autoimmune Platform and Pipeline
$5.00
Available
Innovent Signs $267 Million Deal for Novel Anti-Inflammatory Candidate
$5.00
Available
Anji Pharma Closes $70 Million Series B for US-China Drug In-licensing
$5.00
Available
Salubris Acquires China Rights to Therapy for Obesity, NASH and Diabetes
$5.00
Available
Harbour BioMed Starts Phase III Trial of mAb for Myasthenia Gravis
$5.00
Available
Broncus Completes $200 Million Hong Kong IPO for Pulmonary Devices
$5.00
Available
Akeso Files for China Approval of PD-1/CTLA-4 for Cervical Cancer
$5.00
Available
Impact Uses Cyclia Platform to Validate Targetivity of Oncology Candidates
$5.00
Available
HighTide Says Lead Drug Effective for NASH and Type2 Diabetes
$5.00
Available
Hutchmed and Junshi Start Phase III trial of Sulanda/Tuoyi Combination
$5.00
Available
InnoCare and Keymed Approved to Start Trials of CD20xCD3 Bispecific
$5.00
Available
CStone and EQRx Report Positive Phase III PD-(L)1 Results in NSCLC
$5.00
Available
CARsgen Reports Positive Data from China Trial of Claudin18.2 CAR-T
$5.00
Available
Everest Medicines In-licenses BTK for Renal Diseases in $561 Million Deal
$5.00
Available
IASO Completes $108 Million C Round for Novel Cell Therapies
$5.00
Available
Cytovia Raises $45 Million for JV to Develop NK Products in China
$5.00
Available
Haisco Enters $140 Million Deal for Osteoarthritis Therapy
$5.00
Available
CStone to Start China Trials of Tri-Specific Immunotherapy in Solid Tumor Cancers
$5.00
Available
Alebund Pharma Raises $54.5 Million for Renal Disease Therapies
$5.00
Available
Harbour Bio to Start China Trials of CLTA-4/PD-1 Combo in Two Additional Cancers
$5.00
Available
Legend Bio Starts US Trial of CD4 CAR-T Therapy for Lymphoma
$5.00
Available
Huadong and Insilico Partner to Discover Novel Oncology Candidates
$5.00
Available
Frontage Acquires Majority Stake in Wuhan Heyan Biomedical, a CRO
$5.00
Available
Sanofi Acquires Kadmo, its Novel GVHD Therapy and China JV
$5.00
Available
Bio-Thera Out-Licenses Ex-China Rights for Avastin Biosimilar to Sandoz
$5.00
Available
Brii Bio Allocates $100 Million to Bring Dual SARS-CoV-2 mAb Therapy to Market
$5.00
Available
JW Therapeutics to Launch CD-19 CAR-T in China for Lymphoma
$5.00
Available
Arctic Vision Will Start Phase III Trial of Nearsightedness Therapy in China
$5.00
Available
Harbour BioMed to Start China Phase III Trial of Autoimmune Therapy
$5.00
Available
Innovent Acquires Rights to KRAS G12C Candidate in $312 Million Pact
$5.00
Available
NeuExcell Raises $10 Million For Gene Therapies Aimed at Neurodegenerative Repair
$5.00
Available
Jacobio Invests $53 Million into Hebecell and its Stem Cell Based CAR-T Therapies
$5.00
Available
ETERN Closes Funding to Advance Novel Technology for Undruggable Targets
$5.00
Available
GloriaBio Approved to Launch PD-1 in China for Hodgkin's Lymphoma
$5.00
Available
4B to Partner with Insilico to Develop Small Molecule ALS Treatments
$5.00
Available
Ionova Completes $100 Million Round for Targeted and Immuno Therapies
$5.00
Available
Microport EP and Stereotaxis Form Robotic Ablation Device Collaboration
$5.00
Available
Bio-Thera Sells US Rights to Autoimmune Biosimilar in $150 Million Deal
$5.00
Available
Lynk Raises $50 Million to Develop Small Molecule Drug Portfolio
$5.00
Available
Ocumension Acquires Two Novartis Products in $35 Million Agreement
$5.00
Available
BeyondSpring Signs $200 Million Commercialization Deal with Hengrui
$5.00
Available
Everest Starts China Phase III Trial of ADC for Urothelial Cancer
$5.00
Available
LianBio Starts China Trials of Gastric Cancer Therapy
$5.00
Available
Alphamab Out-Licenses HER-2 Bispecific to CSPC in $150 Million Agreement
$5.00
Available
Reistone Reports Positive Results from Trial of JAK1 Inhibitor for Alopecia Areata
$5.00
Available
Kangle Weishi Completes $157 Million Pre-IPO Round for Recombinant Vaccines
$5.00
Available
Scivita Closes $61 Million Round for Advanced Endoscopy Products
$5.00
Available
Zhaoke Says Novel Dry Eye Treatment Hits Endpoint in Phase III Trial
$5.00
Available
MediTrust Completes $308 Million Funding for China Healthcare Services Platform
$5.00
Available
Arthrosi Forms $59 Million China JV with ApicHope for Gout Therapy
$5.00
Available
Pulse Raises $100 Million for Imaging Diagnostics of Coronary Artery Disease
$5.00
Available
Ranok Closes $40 Million Series B for Protein Degredation Drugs
$5.00
Available
InnoCare In-Licenses CD19 Lymphoma Therapy in $117.5 Million Deal
$5.00
Available
Innovent's PD-1 Inhibitor Meets Endpoint as First-Line Gastric Cancer Therapy
$5.00
Available
Sino Biological Raises $772 Million in Shenzhen ChiNext IPO
$5.00
Available
Gracell Acquires CLDN18.2 Antibodies for CAR-T Candidates
$5.00
Available
Lynk Pharma Starts US Trials of Triple-Kinase Inhibitor for Myelofibrosis
$5.00
Available
Junshi Announces Second US Breakthrough Status for PD-1
$5.00
Available
Junshi Announces US Breakthrough Status for PD-1
$5.00
Available
XtalPi Raises $400 Million for US-China AI Drug Development
$5.00
Available
Innovent's Anti-Cholesterol Drug Meets Endpoint in Phase III Trial
$5.00
Available
Belief Biomed OK'd to Start China Trials of Gene Therapy for Hemophilia
$5.00
Available
PhaseBio and SFJ to Start China trial of Reverse Agent for Antiplatelet
$5.00
Available
PhaseBio and SFJ to Start China trial of Reverse Agent for Antiplatelet
$5.00
Available
Akeso and Sino Bio Approved to Launch PD-1 in China
$5.00
Available
ImmVira Approved to Start Trials of IV Oncolytic Virus Therapy
$5.00
Available
Henlius and Promega Form IVD Collaboration for PD-1 Candidate
$5.00
Available
Berry Oncology Completes $99 Million Funding for Genomic Testing
$5.00
Available
Zai Lab Forms $338 Million Collaboration with Schrödinger to Discover Oncology Drug
$5.00
Available
BeyondSpring Says Lead Asset Posts Positive Data in Phase III NSCLC Trial
$5.00
Available
Pacific Bio to Acquire Omniome for $800 Million in Sequencing Tie-up
$5.00
Available
Engrail Raises $32 Million From China Investors for CNS Drug Program
$5.00
Available
Transcenta's anti-Claudin18.2 mAb Granted Orphan Status in US
$5.00
Available
Zentera Raises $75 Million to Develop Three Cancer Candidates in China
$5.00
Available
IASO Approved to Start China Trials of Dual CAR-T for B-Cell Malignancies
$5.00
Available
Neukio Bio of Shanghai Raises $40 Million for Universal CAR-T Therapies
$5.00
Available
Lupeng Pharma Closes $35 Million Pre-B Funding for Novel Drugs
$5.00
Available
I-Mab to Start US Phase I Trial of Immunotherapy for Alzheimer's
$5.00
Available
Kumquat Announces $2 Billion Deal to Develop Small Molecule IO Drugs with Lilly
$5.00
Available
Bota Bio Adds $100 Million to B Round for Synthetic Biotech Manufacturing
$5.00
Available
Zion Pharma Raises $40 Million to Develop Therapies for Brain Metastases
$5.00
Available
Zai Lab and Entasis Complete Enrollment in Global Test of New Antibacterial
$5.00
Available
MicroPort CRM Raises $150 Million for Implantable CRM Devices
$5.00
Available
I-Mab Plans Second Listing on Shanghai's STAR Board
$5.00
Available
Sirnaomics Plans $300 Million Hong Kong IPO for RNAi Portfolio
$5.00
Available
Innovent Starts China Trial of PD-1/TIGIT Bispecific for Solid Tumors
$5.00
Available
ImmVira Opens In-House Production Facility for Oncolytic Viruses
$5.00
Available
Ascletis to Start China Phase III Trial of FASN Inhibitor for Brain Cancer
$5.00
Available
Qiming Launches $500 Million Fund to Invest in Listed Healthcare Companies
$5.00
Available
Qiming Launches $500 Million Fund to Invest in Listed Healthcare Companies
$5.00
Available
Qiming Launches $500 Million Fund to Invest in Listed Healthcare Companies
$5.00
Available
ProfoundBio Makes $246 Million Deal for Synaffix Linker-Payload Technology
$5.00
Available
Antengene to Start Trial of PD-L1/4-1BB Bispecific in Solid Tumors and NHL
$5.00
Available
Mabworks Plans Hong Kong IPO to Support Antibody/Multi-Specifics Pipeline
$5.00
Available
Qilu Pharma Starts China Bridging Trial for Bladder Cancer Drug
$5.00
Available
Junshi Forms $16 Million mRNA JV with Hangzhou's Immorna
$5.00
Available
GenFleet Partners with Insilico for AI-based Drug Discovery
$5.00
Available
Eluminex Acquires Synthetic Cornea Product in $108 Million Agreement
$5.00
Available
Juventas Closes $62 Million C Round for CAR-T/Stem Cells/Gene Editing
$5.00
Available
Frontier Says HIV Therapy Effective in Difficult-to-Treat Patients
$5.00
Available
Hailai Xinchuang Closes $77 Million Round for Tumor Treating Fields Device
$5.00
Available
Grit Bio Closes Series A+ Round for its Cell Therapy Oncology Therapies
$5.00
Available
Innovent and Ascentage Announce Three-Part, $245 Million Collaboration
$5.00
Available
PAQ Therapeutics Closes $30 Million Round for Autophagy-Caused Degredation
$5.00
Available
Ji Xing, a Shanghai Pharma, Completes B Round for Cardiovascular Drugs
$5.00
Available
Ascletis Starts China Bridging Trial of FXR Agonist for Hepatitis B
$5.00
Available
InnoCare Out-licenses BTK Inhibitor for MS to Biogen in $937 Million Deal
$5.00
Available
Adlai Nortye Completes $100 Million Funding for Immunotherapies
$5.00
Available
ProfoundBio Closes $55 Million Round for ADC and IO Candidates
$5.00
Available
Kintor to Start US Trial of Baldness Treatment
$5.00
Available
Innovent Starts China Trial of LAG-3/PD-L1 Bispecific Antibody
$5.00
Available
Keymed Stages $378 Million Hong Kong IPO for Antibody Portfolio
$5.00
Available
I-Mab Forms Discovery Partnerships with mRNA and AI Companies
$5.00
Available
China to Require Companies to Seek Approval before IPOing Outside of China
$5.00
Available
Chicago's Sparx Therapeutics to Build Biologics Manufacturing Facility in China
$5.00
Available
Nhwa Starts China Trial of Novel IV Opioid Analgesic
$5.00
Available
dMed-Clinipace Raises $50 Million for China-US Clinical CRO Operations
$5.00
Available
Eucure Approved for US Phase II Trials of Combination Therapies
$5.00
Available
EpimAb Bio Starts Clinical Trials of Two Bispecific Candidates
$5.00
Available
Abbisko Out-Licenses Rights to Non-Oncology Indications for CSF-1R Inhibitor
$5.00
Available
SciClone Files China BLA for Neuroblastoma Treatment
$5.00
Available
Harbour BioMed Reports Positive Data from Myasthenia Gravis Trial
$5.00
Available
Sirnaomics Closes $105 Million Funding for RNAi Portfolio
$5.00
Available
Denovo Acquires Alzheimer's Disease Candidate from Lundbeck
$5.00
Available
Zentalis Closes $150 Million Secondary Offering for US-China Operations
$5.00
Available
I-Mab Starts Clinical Development of Two 4-1BB Bispecific Candidates
$5.00
Available
HutchMed Completes $537 Million Hong Kong IPO for Oncology Drugs
$5.00
Available
ArriVent Raises $150 Million to In-license China Drugs for Global Markets
$5.00
Available
Simcere Acquires China Rights to Alzheimer's Drug in $565 Million Deal
$5.00
Available
Eight Roads Launches its Fifth China Healthcare Fund with $400 Million
$5.00
Available
Innovent Partners with Synaffix to Create ADC Candidate from Antibody
$5.00
Available
Neurophth Starts China Trial of Gene Therapy for Hereditary Blindness
$5.00
Available
Pulnovo Medical Completes Trial Enrollment for Pulmonary Hypertension Device
$5.00
Available
Hangzhou Jointech Raises $62 Million for Orthopedic Surgery Robots
$5.00
Available
InxMed Says FAK Inhibitor Effective Against Resistance to KRAS Inhibitors
$5.00
Available
Lynk Pharma to Start Trials of Novel Therapy for IBD
$5.00
Available
Nanjing's Triastek Completes $50 Million Round for 3D Printing of Drugs
$5.00
Available
HutchMed/AstraZeneca Approved to Launch Partnered MET Inhibitor in China
$5.00
Available
MindRank Completes $7 Million Angel Round for AI Drug Development
$5.00
Available
Fosun Kite's CAR-T Approved in China for Lymphoma
$5.00
Available
BeiGene's Anti-PD-1 Approved in China for 4th and 5th Indications
$5.00
Available
Asieris Starts EU Arm in Global Trial of Photodynamic Drug-Device Product
$5.00
Available
BeiGene Approved to Launch Brukinsa® for 3rd B-Cell Cancer Indication
$5.00
Available
HutchMed's Surufatinib Approved for 2nd Neuroendocrine Tumor Indication
$5.00
Available
Bioheng Granted US Orphan Drug Status for Universal CAR-T Therapy
$5.00
Available
HutchMed to Raise $600 Million in Hong Kong IPO
$5.00
Available
HuiGene, a Shanghai Gene Editing Company, Closes $62 Million B Round
$5.00
Available
Jacobio Starts Trial of SHP2 Inhibitor, Triggering $20 Million Payment from AbbVie
$5.00
Available
OncoNano Raises $50 Million from China Investor for pH-based Cancer Products
$5.00
Available
Sirnaomics to Start Clinical Trials of RNAi Candidate in China
$5.00
Available
Zai Lab Enters Four-Drug, $1.4 Billion Deal with MacroGenics
$5.00
Available
LinkDoc, a Beijing Cancer Data Company, to Raise up to $500 Million in US IPO
$5.00
Available
Innovent Starts China Trial of Dual Agonist Obesity Treatment
$5.00
Available
Asieris to Start US Combination Trial of MetAP2 Inhibitor for Bladder Cancer
$5.00
Available
HiFiBiO Raises $75 Million for Clinical Trials and Drug Discovery
$5.00
Available
ImmVira Starts China/US Phase II Trial of Oncolytic Virus for Cancer
$5.00
Available
BeiGene Reports BTK Inhibitor Posts Better Results than the Competition
$5.00
Available
CBMG Says Bi-Specific CAR-T Effective in Non-Hodgkin Lymphoma Trial
$5.00
Available
Ascentage Reports Bcl-2 Inhibitor Effective in Early Test
$5.00
Available
CARsgen Therapeutics to Raise $400 Million in Hong Kong IPO
$5.00
Available
Innovent and HutchMed Report Positive Results from Combo CRC Therapy
$5.00
Available
Dingdang Health Raises $220 Million for Online-Offline Health Services
$5.00
Available
Innovent and IASO Report Positive Data on BCMA CAR-T Therapy
$5.00
Available
OriginCell Posts Positive Data from Trial of GPC3 CAR-T for HCC
$5.00
Available
Ascletis Approved to Start China Trials of FXR Agonist for Hepatitis B
$5.00
Available
Junshi Reports PD-1 Effective in Nasopharyngeal Carcinoma
$5.00
Available
MicuRx Approved for China Launch of Next-Gen Antibiotic
$5.00
Available
Shanghai Stemirna Lands $200 Million to Develop mRNA COVID Vaccine
$5.00
Available
IASO BIO to Start Trials of CAR-T in Leukemia Patients
$5.00
Available
Innovent Bio and Lilly Announce Third China Approval for PD-1
$5.00
Available
Phanes Therapeutics Raises $40 Million for mAb and Bi-specific Portfolio
$5.00
Available
Neurophth and Hopstem Partner to Develop Stem Cell Therapies for Eye Diseases
$5.00
Available
Zai In-licenses KRAS Inhibitor from Mirati in $338 Million Deal
$5.00
Available
Guangzhou-Israel Biomed Fund to Raise $300 Million
$5.00
Available
Innovent Announces $189 Million Agreement for TKI from Hangzhou Company
$5.00
Available
Transcenta Reports Positive Results from Phase I Trial of PD-L1
$5.00
Available
CStone Reports PD-L1 Meets Endpoint in Phase III NSCLC Trial
$5.00
Available
AffaMed Approved to Start China Trial of Parkinson's Candidate
$5.00
Available
Esco Lifesciences Raises $200 Million to Expand Life Science Tools Portfolio
$5.00
Available
Sinovant Says Antibiotic Effective for Pneumonia; Transfers China Rights to Sumitomo
$5.00
Available
NiKang Raises $200 Million from US/China Investors for Oncology Drugs
$5.00
Available
IntoCare Completes $16 Million Financing for Powered Stapling Devices
$5.00
Available
TransThera Starts China Combination Trial of Lead Drug in GI Cancers
$5.00
Available
Innovent Doses First Patients in Phase III Cholangiocarcinoma Trial
$5.00
Available
Ascletis Says China Accepts Filing of Phase I GBM Trial for Review
$5.00
Available
HitGen Partners with Dorian to Discover Drugs for Age-Related Diseases
$5.00
Available
CARsgen to Invest $157 Million in US CAR-T Lab/Manufacturing Facility
$5.00
Available
BeiGene's PD-1 Meets Survival Endpoint in Nasopharyngeal Cancer Trial
$5.00
Available
DualityBio Raises $90 Million for Bispecific and ADC Drugs
$5.00
Available
GeneQuantum Completes C Round for Novel ADC Candidates
$5.00
Available
BioRay In-licenses Rights to Brain Cancer Drug from Nascent
$5.00
Available
Burning Rock Starts Large Pan-Cancer Early Detection Study
$5.00
Available
Hummingbird Bio Closes $125 Million Financing for Precision Medical Candidates
$5.00
Available
InnoCare to Start China Trial of TYK2 Inhibitor for Autoimmune Diseases
$5.00
Available
LianBio Acquires Two IBD Candidates from Landos in $218 Million Agreement
$5.00
Available
Ji Xing Acquires Tachycardia Treatment in $127.5 Million Deal
$5.00
Available
BioNovoGene Completes $15 Million Round for Metabolomics Services
$5.00
Available
Kinnate Raises $35 Million to Bring Assets to China
$5.00
Available
Reistone Starts Global Trial of JAK1 Inhibitor for Atopic Dermatitis
$5.00
Available
GenScript Raises $1 Billion in Investments from Hillhouse Capital
$5.00
Available
Elpiscience Raises $105 Million for Cancer Immunotherapy Portfolio
$5.00
Available
Pregene Out-Licenses India Rights for its CAR-T Therapy to Dr. Reddy's
$5.00
Available
Antengene Approved to Start China Trial of Endometrial Cancer Therapy
$5.00
Available
Hygea Medical Raises $77 Million for Minimally Invasive Surgery Devices
$5.00
Available
aTyr Developing Bi-Specific Platform for tRNA Synthetase-derived Targets
$5.00
Available
Connect Doses Asthma Patients in Global Trial of Interleukin Antibody
$5.00
Available
Fulgent Genetics Invests Another $19 Million in China Testing JV
$5.00
Available
Viva Bio and BioMap Form AI Biologic Drug Discovery Collaboration
$5.00
Available
BeiGene Announces Approval of PARP Inhibitor in China
$5.00
Available
Newsoara Says Lead Drug Effective in Gastrointestinal Surgery Patients
$5.00
Available
Shanghai Hope Medicine Closes $56 Million for Novel Drug Development
$5.00
Available
Beijing WeMed Completes $46 Million Funding for Angiography Devices
$5.00
Available
Asieris and BeiGene to Test Combination Therapy for Bladder Cancer
$5.00
Available
Ascletis Reports Initial Success in PD-L1 Trial for Chronic Hepatitis B
$5.00
Available
Shineco Plans to Acquire 51% of Taiwan's Mayah Biological
$5.00
Available
Jacobio to Start US/China Trials of KRAS Inhibitor in Solid Tumor Cancers
$5.00
Available
Galmed Adds China Arm to Global Trial of NASH/Fibrosis Treatment
$5.00
Available
CANbridge Acquires Rare Liver Disease Drug in $120 Million Agreement
$5.00
Available
Guangzhou Link Health to Form China Clinical CRO with George Clinical
$5.00
Available
Nanjing Legend Files for EU Approval of BCMA CAR-T Therapy
$5.00
Available
Adcentrx Raises $50 Million in Initial Funding for Novel ADC Therapies
$5.00
Available
Sirnaomics Out-Licenses siRNA Influenza Vaccine Candidate to Walvax
$5.00
Available
Clinical CRO Merger: China's dMed Joins Forces with US-Based Clinipace
$5.00
Available
Tianhong Shengjie Completes $12 Million Financing for Medical Devices
$5.00
Available
CANbridge in $591 Million Deal with LogicBio for Gene Therapies
$5.00
Available
Fosun Pharma Starts China Phase III Trial of Long-Lasting Botox
$5.00
Available
I-Mab Reports IL-6 Inhibitor Effective in Phase II Ulcerative Colitis Test
$5.00
Available
CStone Reports China to Review NDA for RET Inhibitor in Thyroid Cancer
$5.00
Available
Junshi Bio Says PD-1 Meets Endpoints in Esophageal Cancer
$5.00
Available
Ronovo Closes Series A to Develop Surgical Robotics Devices for China
$5.00
Available
Henlius Reports NDA for its PD-L1 Inhibitor Accepted for China Review
$5.00
Available
Zai Lab Raises $750 Million in Private Placement
$5.00
Available
EdiGene Completes $62 Million Round for Gene Editing Therapies
$5.00
Available
Junshi Bio Completes $50 Million Investment in US Partner, Coherus
$5.00
Available
Transcenta Starts US Arm of US-China Bi-specific PD-1 Trial for Solid Tumors
$5.00
Available
Porton Biologics Raises $61 Million for Cell/Gene Therapy CDMO Services
$5.00
Available
PhageLux AgriHealth Acquires New China Manufacturing Site
$5.00
Available
Qilu In-Licenses Preclinical ADC Candidate from Korea's Peptron
$5.00
Available
Kintor Starts China Trials of Topical Androgen Receptor Inhibitor
$5.00
Available
Ocumension Acquires Implant Therapy for Retina Diseases in $119 Million Deal
$5.00
Available
SciNeuro In-Licenses China Rights to Lilly Treatment for Parkinson's
$5.00
Available
StoneWise Raises $100 Million to Support AI Drug Development Services
$5.00
Available
BDgene Completes $9 Million Round for CRISPR/Cas9 mRNA Candidates
$5.00
Available
Innovent Reports Positive Data from Phase III Tyvyt Trial in NSCLC
$5.00
Available
LintonPharm Starts China Trial of Candidate for Bladder Cancer
$5.00
Available
Junshi's PD-1 Approved for Third Indication in China, Bladder Cancer
$5.00
Available
Gracell Reports Positive Data from Trial of Off-the Shelf CAR-T Candidate
$5.00
Available
Shanghai NewMed Medical Raises $100 Million for Heart Repair Devices
$5.00
Available
HutchMed Raises $100 Million in Private Placement for Oncology Portfolio
$5.00
Available
Biogen Acquires Rights to Bio-Thera RA Biosimilar for $30 Million Upfront
$5.00
Available
BeiGene Approved to Produce anti-PD-1 in New Guangzhou Biologics Facility
$5.00
Available
Antengene to Start Trial of I PAK4/NAMPT Inhibitor in Solid Tumors/NHL
$5.00
Available
Bridge Bio Starts Trial of Novel EGFR for NSCLC with Mutations
$5.00
Available
HitGen and BioAge Identify Alzheimer's, Cardiovascular Candidates
$5.00
Available
I-Mab and Korea's ABL Bio Start Phase I Trial of Partnered Bispecific
$5.00
Available
Sorrento Acquires ACEA, a San Diego-China Drug Developer, in $488 Million Deal
$5.00
Available
Long Hill Capital Raises $300 Million for Third China Healthcare Fund
$5.00
Available
Zai Lab's GIST Treatment Approved for China Use
$5.00
Available
Jiangxi Jemincare to Start US Trial of SARS-CoV-2 Neutralizing Antibody
$5.00
Available
Sinovac Raises Production of COVID-19 Vaccine to 2 Billion Doses Per Year
$5.00
Available
Immune-Onc Raises $73 Million for Novel Immunosuppressive Checkpoints
$5.00
Available
Neuracle Closes $16 Million Round for Brain-Machine Interface
$5.00
Available
BeyondSpring Files US/China NDAs for Novel Neutropenia Prevention Drug
$5.00
Available
OnQuality Raises $20 Million for Cancer Side Effect Treatments
$5.00
Available
Everest Approved for China Phase II trial of Trodelvy® in TROP-2 Cancers
$5.00
Available
AffaMed Closes $170 Million Financing for In-licensed Portfolio
$5.00
Available
Ascletis to Add Oncology Drugs to Infectious Disease and NASH Portfolios
$5.00
Available
LianBio in $200 Million Deal for China/Asia Rights to Tarsus Ophthalmology Drug
$5.00
Available
Simcere Announces $292 Million Deal for Novel Glioblastoma Treatment
$5.00
Available
Qihan Raises $67 Million for Gene Editing of Cell Therapies, Organ Transplant Drugs
$5.00
Available
Henlius Plans to File for China NDA Approval of PD-1 Inhibitor
$5.00
Available
Chime Biologics Announces $190 Million Round for Wuhan CDMO Operations
$5.00
Available
CASI Raises $32.5 Million for China In-Licensing Operations
$5.00
Available
Shanghai ImmuneOnco Raises $89 Million for Cancer Immunotherapies
$5.00
Available
AllianThera Partners with Insilico for Novel Cancer/Autoimmune Targets
$5.00
Available
Eucure Says anti-CTLA-4 Antibody Effective in Early Tests
$5.00
Available
Hutchison China MediTech Sells Stake in TCM Company for $169 Million
$5.00
Available
Bioheng Completes $80 Million Funding for Allogenic CAR-T Immunotherapies
$5.00
Available
Xtalpi Joins $46 Million Round for PhoreMost in Drug Discovery Tie-Up
$5.00
Available
SinoBio Acquires Stake in Belgium Inhaler Company in $200 Million Deal
$5.00
Available
Brii Bio Completes $155 Million Financing for Anti-infective/CNS Drugs
$5.00
Available
EpimAb of Shanghai Raises $120 Million for Bispecific Antibodies
$5.00
Available
Zenas, a China-US Startup, Breaks Cover with Seven Autoimmune Candidates
$5.00
Available
Hangzhou Innoforce Raises $96 Million for CRO/CDMO Biopharma Services
$5.00
Available
Tavotek Bio Raises $20 Million-plus for Novel US-China Antibodies
$5.00
Available
Citrine Approved to Launch Rare Disease Drug in China without Clinical Trial
$5.00
Available
Connect Bio Raises $191 Million in NASDAQ IPO for Autoimmune Portfolio
$5.00
Available
Hanyu Medical Lands $77 Million in D+ Round for Cardiovascular Devices
$5.00
Available
Yangtze River Pharma Signs $338 Million Deal for Gastro Reflux Therapy
$5.00
Available
Chance Pharma Acquires China Rights to Inhaled PAH Therapy
$5.00
Available
WuXi Biologics Acquires 90% Stake in CBC's Suzhou CDMO
$5.00
Available
BeiGene Forms Drug Delivery and Patient Communication Partnership with 111
$5.00
Available
Beijing Tide Out-Licenses Ex-China Rights to Fibrosis Therapy in $518 Million Deal
$5.00
Available
Hansoh Announces $122 Million Agreement to Acquire Rights to Antifungal
$5.00
Available
WuXi Biologics Buys Pfizer's Biologics Manufacturing Facility in Hangzhou
$5.00
Available
Adagene Starts Global Trial of CTLA-4 Inhibitor for Solid Tumor Cancers
$5.00
Available
Harbour Bio Starts China Phase III Trial of Novel Dry Eye Treatment
$5.00
Available
Delonix Bio Raises $14 Million in Seed Financing for Synthetic Vaccines
$5.00
Available
Uni-Bio Partners with DotBio to Develop Retinal Therapeutics
$5.00
Available
I-Mab Forms Two Novel Drug Discovery Collaborations
$5.00
Available
Lee's Pharm Affiliate OK'd for Phase III Trial of PD-L1 for NSCLC
$5.00
Available
Haohai Acquires China Rights to Eirion Dermatology Products in $527 Million Deal
$5.00
Available
Arctic Vision of Shanghai Completes $100 Million Series B Round
$5.00
Available
BeiGene Starts Trial of HPK1 Inhibitor, a Novel Immunocology Candidate
$5.00
Available
Alphamab Approved to Start US Trials of PD-L1/CTLA-4 Bispecific
$5.00
Available
Gannex/Ascletis Reports Positive Phase II Data for NASH Treatment
$5.00
Available
CASI Acquires China Rights to a p97 Inhibitor for Cancer in $85 Million Deal
$5.00
Available
WuXi Biologics Out-licenses mAb Panel to Exelixis for Development
$5.00
Available
AlphaBio In-licenses Off-the-Shelf NK/T-Cell Technology for Cancer
$5.00
Available
Taicang's Connect Biopharma Files for $100 Million NASDAQ IPO
$5.00
Available
Wuhan ABconal Acquires Boston mAb Drug Developer Yurogen
$5.00
Available
Kintor OK'd to Start US Trial of Androgen Receptor Antagonist for COVID-19
$5.00
Available
GenSciences Raises $124 Million for New Drug Development
$5.00
Available
Apollomics Starts China Trial of Immunotherapy for AML
$5.00
Available
SciClone IPOs on Hong Kong Exchange, Raising $279 Million
$5.00
Available
Biotheus Completes $100 Million Funding for Biologic Drugs
$5.00
Available
Innoforce and dMed Team Up to Develop/Manufacture Novel Biologics
$5.00
Available
WuXi AppTec Pays $135 Million to Acquire Oxgene, a Gene Therapy CDMO
$5.00
Available
LianBio Acquires China Rights to ReViral's RSV Therapy in $119 Million Deal
$5.00
Available
Innovent Starts US Trial of CD47/PD-L1 Bispecific Antibody
$5.00
Available
OrbiMed, a Life Sciences Investor, Raises $800 Million for Asia Partners IV
$5.00
Available
Suzhou Medilink Closes Initial $50 Million Funding for ADC Drugs
$5.00
Available
Junshi Out-Licenses Partial China Marketing Rights for PD-1 to AstraZeneca
$5.00
Available
Junshi Bio's PD-1 Approved as First-line Therapy for Nasopharyngeal Carcinoma
$5.00
Available
Harbour BioMed OK'd to Start China Trial of CTLA-4 Antibody for NSCLC
$5.00
Available
Innovent's CAR-T Therapy Awarded Breakthrough Status in China
$5.00
Available
I-Mab Doses First Patient in Phase III Trial of Novel Growth Hormone Therapy
$5.00
Available
YishengBio Raises $130 Million for Immunomodulating Therapies
$5.00
Available
Bioelectronica Closes $16 Million Funding from China Investors
$5.00
Available
ABclonal Completes $93 Million Round Led by China Investors
$5.00
Available
AnchorDx Completes $40 Million Financing for Cancer Diagnostics
$5.00
Available
BGI Genomics Raises $300 Million in Private Placement
$5.00
Available
New Horizon Stages $263 Million HK IPO for Cancer Screening Tests
$5.00
Available
Regor Therapeutics Completes $90 Million Round for Novel Drugs
$5.00
Available
Sciwind Closes $37 Million Round for Metabolic/Immunological Therapies
$5.00
Available
Citrine Acquires China Rights to Therapy for Pediatric Rare Disease
$5.00
Available
Yuanxin/Miaoshou Doctor Raises $465 Million for Online Healthcare
$5.00
Available
Zhongmei Huadong Forms $180 Million Collaboration for Autoimmune Drug
$5.00
Available
BeiGene In-Licenses TNF-based Immunotherapy in $126 Million Agreement
$5.00
Available
Qilu Announces $235 Million Deal for Cend's Immunotherapy
$5.00
Available
Hansoh Acquires China Rights to Novel Synexis Antifungal
$5.00
Available
Microport Cardioflow Completes $324 Million HK IPO for Heart Valve Devices
$5.00
Available
Lee's Pharma to File for China Approval of PD-L1 Under Breakthrough Rules
$5.00
Available
Apollomics Acquires Immunotherapy for Gastrointestinal Cancers
$5.00
Available
Apollomics Acquires Rights to Novel Iterion Oncology Candidate
$5.00
Available
Ascletis Participates in $80 Million Funding of US Partner, Sagimet
$5.00
Available
Hengrui Acquires PI3k? Inhibitor Rights from Shanghai Lingli Pharma
$5.00
Available
I-Mab Approved to Start China Trial of Complement Factor Inhibitor
$5.00
Available
Adagene Completes $140 Million US IPO, Climbs 56% Higher
$5.00
Available
Nuance Acquires China Rights to Osteoarthritis Pain Drug in $100 Million Deal
$5.00
Available
Wuhan's Neurophth Raises $62 Million for AAV-delivered Gene Therapies
$5.00
Available
Apollomics of Hangzhou Acquires Global (ex-China) Rights to Novel Cancer Candidate
$5.00
Available
China Medical System Acquires Luqa Ventures, a China Dermatology Company
$5.00
Available
Beijing InnoCare to Start Phase III Combination Trial of BTK Inhibitor
$5.00
Available
I-Mab Starts China and US Trials of CD73 Immunotherapy
$5.00
Available
Beijing InnoCare Raises $407 Million in Private Placements with Hillhouse and Vivo
$5.00
Available
Beijing neoX Biotech Closes $30 Million A Round for AI Drug Discovery
$5.00
Available
Adagene Licenses its mAb Masking Technology to Exelixis in Collaboration
$5.00
Available
Innovent's PD-1 Approved in China for First-Line NSCLC Indication
$5.00
Available
Kanghong's VEGF Fusion Drug Granted Three US SPAs for Retinal Diseases
$5.00
Available
Kira Starts Trial of Candidate for Complement-Mediated Diseases
$5.00
Available
Syapse, a Cancer Clinical Data Company, Closes $68 Million Round led by Ally Bridge
$5.00
Available
Lianya Pharma Completes $62 Million Round for Hard-to-Make Generics
$5.00
Available
Shanghai Junshi Bio to Invest $50 Million in Coherus, its US Partner
$5.00
Available
Junshi Announces $1.1 Billion Agreement for US-Canada Rights to PD-1
$5.00
Available
Sequoia and Illumina Launch Shanghai Genomics Incubator
$5.00
Available
GenFleet Closes $16 Million B+ Round for China-US Clinical Trials
$5.00
Available
Gan & Lee Awarded US Fast Track Status for Glioblastoma Treatment
$5.00
Available
BeiGene Says PD-1 Extends Survival in Global Phase III Trial for Esophageal Cancer
$5.00
Available
Sihuan Pharma Acquires Beijing Combio, an Antibody/Bispecific Company
$5.00
Available
BeiGene Files China BLA for Sylvant, a Rare Disease Therapy
$5.00
Available
Eucure Bio Starts China Trial of CTLA4 Treatment for Solid Tumors
$5.00
Available
Matridx Bio Closes $32 Million for Pathogen Metagenomics Analyzers
$5.00
Available
Adagene of Suzhou Files for $125 Million US IPO
$5.00
Available
Elpiscience Signs $117 Million Deal for TRIGR Bispecific
$5.00
Available
Immunotech of Beijing In-licenses Immunotherapy from T-Cure
$5.00
Available
Seneca Reports Mixed Results from China Stem Cell Trial for Stroke
$5.00
Available
Sinovent Completes Pre-IPO Financing of at least $30 Million
$5.00
Available
Neurophth to Develop AAV Capsids with AAVnerGene for Ophthalmology
$5.00
Available
Gracell to Start China Trial of CAR-T in Leukemia Patients
$5.00
Available
EdiGene Approved to Start China Trial of Gene-Edited Stem Cell Therapy
$5.00
Available
TenNor and Janssen to Collaborate on Lung Disease Treatments
$5.00
Available
EQRx Raises $500 Million to Develop China-Sourced Drugs for US Market
$5.00
Available
Raysight Completes $46 Million Funding for Cardiovascular Diagnosis
$5.00
Available
CICC Has Second Close of Biomedical Fund at $648 Million
$5.00
Available
Henlius In-licenses TPOR-2 mAbs from Chiome in $122.5 Million Deal
$5.00
Available
Gracell to Start China Trial of Donor-derived CAR-T Therapy for B-ALL
$5.00
Available
BeiGene Out-Licenses Rights for PD-1 to Novartis in $2.2 Billion Deal
$5.00
Available
Visen Pharma Closes $150 Million Financing for Endocrine Drugs
$5.00
Available
Inmagene Signs $920 Million Agreement to Acquire Four Chi-Med Immunology Therapies
$5.00
Available
BeiGene Acquires Rights to mRNA Cancer Therapy in $320 Million Deal
$5.00
Available
EOC Signs $271 Million Agreement for mTor Inhibitor from Aadi Bio
$5.00
Available
Gracell Raises $209 Million in US IPO for Novel CAR-T Therapies
$5.00
Available
Abbisko Announces $123 Million Financing for Cancer Portfolio
$5.00
Available
Zai Labs Acquires China Rights to Novel Autoimmune Drug in $175 Million Deal
$5.00
Available
APT Medical Closes $191 Million Shanghai STAR Board IPO
$5.00
Available
Keya Medical Completes $46 Million Round for AI-based Scanning Software
$5.00
Available
Everest to Start China Phase III Trial of ADC For Urothelial Cancer
$5.00
Available
Terns Completes $87 Million Financing to Advance Three NASH Candidates
$5.00
Available
Paratek Closes $60 Million Loan Using Zai Lab Royalties for Pay Off
$5.00
Available
Shanghai Pharma to Build $1.8 Billion Novel Drug Facility in Zhangjiang Park
$5.00
Available
Ocumension Invests $15.7 Million In EyePoint of the US
$5.00
Available
ImmVira Completes C Round for Oncolytic Virus and Vector Candidates
$5.00
Available
InnoCare Approved to Launch BTK Inhibitor for Three Indications in China
$5.00
Available
Ascletis Doses First Person in US Trial of Novel NASH Treatment
$5.00
Available
Medbanks Closes $305 Million Financing for China Oncology Mega-Data
$5.00
Available
Chi-Med Approved to Market Surufatinib for Neuroendocrine Tumors
$5.00
Available
DXY.cn Raises $500 Million for On-line Physician Support and Healthcare Services
$5.00
Available
Zai Lab In-licenses Novel EGFR Inhibitor in $233 Million Deal
$5.00
Available
Oceanpine Raises $400 Million for China-US Technology Companies
$5.00
Available
Synyi Closes $61 Million Round for AI-based Medical Data Analysis
$5.00
Available
China Adds 119 New Drugs to NRDL after 51% Price Cuts
$5.00
Available
Hasten Bio Pays $322 Million for China Rights to Five Takeda Drugs
$5.00
Available
Transcenta of China Raises $105 Million to Develop Antibody Drugs
$5.00
Available
CASI Granted Breakthrough Status in China for CD19 CAR-T Therapy
$5.00
Available
WuXi Biologics Pays $183 Million to Acquire Bayer German Manufacturing Facility
$5.00
Available
3E Bioventures Forms China JV for Peripheral Neuropathy Therapy with Regenacy
$5.00
Available
Ascentage's Bcl-xL Inhibitor Starts US Trials for Macular Edema
$5.00
Available
Jacobio, a Beijing Biopharma, Raises $174 Million in Hong Kong IPO
$5.00
Available
Legend Starts Submission for US Approval of BCMA CAR-T Therapy
$5.00
Available
SciClone Pharma Enters $120 Million Deal for Two Neuroblastoma Treatments
$5.00
Available
CANbridge to Start Trial of Novel Complement Dysfunction Therapy
$5.00
Available
Harbour BioMed Raises $221 Million in Hong Kong IPO
$5.00
Available
dMed Completes $100 Million Financing for China-US CRO Operations
$5.00
Available
Vivace Closes $30 Million Round for Novel Hippo Pathway Oncology Therapies
$5.00
Available
Overland Pharma Announces $117 Million China JV with Allogene Therapeutics
$5.00
Available
Singlera Closes $150 Million B Round for Early Cancer Screening
$5.00
Available
Overland Forms $50 Million China JV to Develop ADCs with Swiss Biopharma
$5.00
Available
Junshi's PD-1 Meets Survival Endpoint as First-Line NSCLC Treatment
$5.00
Available
Legend Bio Cleared to Start US Trials of CD4 CAR-T Candidate
$5.00
Available
Antengene Approved for Phase III Trial of SINE Candidate for Myeloma
$5.00
Available
Innovent Starts Phase II Trial of CTLA-4 mAb for Cervical Cancer
$5.00
Available
3D Medicines Acquires China Rights to Two Immunotherapies in $202 Million Deal
$5.00
Available
Wuzhong Pharma Out-licenses Cancer Drug to Hangzhou's Denovo
$5.00
Available
EOC to Start China Trial of Novel Immunotherapy for Breast Cancer
$5.00
Available
Overland, a China-US Pharma, Starts In-licensing Operations with Hillhouse Backing
$5.00
Available
JW Therapeutics Releases Positive Data from CAR-T Trial for Lymphoma
$5.00
Available
Sinovac Approved to Launch 23-Valent Pneumonia Vaccine in China
$5.00
Available
JD Health Completes $3.5 Billion HK IPO; Climbs 45% on First Day
$5.00
Available
Nuance Pharma Closes $181 Million D Round for In-licensed Drugs
$5.00
Available
SciNeuro of Shanghai Launches with $100 Million for CNS Drugs
$5.00
Available
Pegbio Raises $122 Million in Pre-IPO Round for Pegylated Drugs
$5.00
Available
Tolo Biotech and Sherlock Bio Cross-License CRISPR Diagnostic Platforms
$5.00
Available
I-Mab Advances AstraZeneca-Partnered CD-47 Candidate
$5.00
Available
Beijing Infervision Completes D1 Funding for AI-based Image Reading Products
$5.00
Available
Junshi Announces First Patient Dosed in China Trial of TROP2 ADC
$5.00
Available
HitGen Delivers Candidates to Cedilla for Cancer Caused by Protein Dysregulation
$5.00
Available
Simcere Approved to Start China Trial of Gout Treatment
$5.00
Available
CANbridge Completes $43 Million E Financing for Rare Disease Drugs
$5.00
Available
LianBio Cleared to Start China Phase II Trial of FGFR Inhibitor
$5.00
Available
Xbiome, an AI Company, Completes B+ Round for Microbiome Trials
$5.00
Available
Ascentage Acquires Global Rights to Protein Degrader Technology
$5.00
Available
Genetron to Screen High Risk Individuals for Liver Cancer in Wuxi City
$5.00
Available
PreGene Closes $21 Million Financing for Fusion/Nano-Antibody Drugs
$5.00
Available
CHHT-Alvotech JV Signs China Deal to Commercialize Biosimilars
$5.00
Available
Eluminex, a Suzhou Startup, Closes $50 Million Round for Ophthalmic Drugs
$5.00
Available
Beijing Gene+ Raises $38 Million for Cancer Diagnostics
$5.00
Available
Ascentage to Start China Trials of Bcl-2 Apoptosis Candidate
$5.00
Available
Antengene Completes $340 Million Hong Kong IPO for Oncology Drugs
$5.00
Available
RecBio Raises $227 Million for Novel Genetically Engineered Vaccines
$5.00
Available
Alphamab and 3D Medicines File China NDA for PD-L1 Therapy
$5.00
Available
Newsoara Forms $135 Million Novel Drug Deal with AUM Bio
$5.00
Available
BeiGene Plans to Raise up to $2.5 Billion in Shanghai Star IPO
$5.00
Available
GeneScience Acquires Rights to Prostate Cancer Therapy in $132 Million Agreement
$5.00
Available
WuXi Biortus Raises $15 Million for Cryo-EM Drug Discovery CRO
$5.00
Available
Innovent Bio Reports Novel Bi-Specific is Effective in AMD Trial
$5.00
Available
Zhimeng Biopharma Closes $35 Million Funding for Trials of HBV Therapy
$5.00
Available
Apollomics to Start China Trial of Multi-Kinase Inhibitor for Solid Tumors
$5.00
Available
RemeGen Raises $515 Million in Hong Kong IPO, Company Valued at $4.3 Billion
$5.00
Available
CStone's China NDA for Anti-PD-L1 Candidate Accepted for Review
$5.00
Available
Tencent Co-leads $50 Million Round for Congenica, a UK Genomics Company
$5.00
Available
HitGen Out-Licenses China Rights for Trk/ROS1 Inhibitor to Baiyunshan
$5.00
Available
I-Mab Reports Initial Positive Data from US Trial of CD47 Candidate
$5.00
Available
Ambrx Completes $200 Million in Crossover Financing
$5.00
Available
BeiGene's BLA for Neuroblastoma Therapy Accepted for Review in China
$5.00
Available
Pharmaron Beijing Pays Up to $137.5 Million to Acquire Absorption, a US CRO
$5.00
Available
Inmagene Closes $21 Million Round for Immune Therapies
$5.00
Available
Innoforce Forms Hangzhou CDMO JV with Thermo Fisher
$5.00
Available
Everest's Partner Calliditas Reports Positive Results for Rare Disease Therapy
$5.00
Available
Apollomics Completes $124 Million C Financing for Cancer Drug Development
$5.00
Available
Everest Medicines Starts China Trial of Triple-Negative Breast Cancer ADC
$5.00
Available
Green Valley to Start US Trial of Algae-based Alzheimer's Drug
$5.00
Available
Asieris Approved for Phase III Trial of Bladder Cancer Drug
$5.00
Available
LianBio to Start China Phase III Trial of Bile Cancer Drug
$5.00
Available
JW Therapeutics Completes $300 Million Hong Kong IPO for CAR-T Products
$5.00
Available
China Grand Pharma in $340 Million Deal for Telix's Radiation Products
$5.00
Available
CARsgen Raises $186 Million for CAR-T Portfolio
$5.00
Available
InnoCare Starts US Trial of BTK Inhibitor for MS
$5.00
Available
AffaMed in $103 Million Deal for Two Ocular Therapeutix Products
$5.00
Available
Zylox Medical Completes $45 Million Round for Vascular Devices
$5.00
Available
Zai Lab Starts Trial of Anti-PD1 Antibody for Endometrial Cancer
$5.00
Available
CStone Signs $363 Million Deal for Rights to LegoChem ADC Candidate
$5.00
Available
Beijing's Genecast Completes $149 Million E Round for Cancer Diagnostics
$5.00
Available
Gracell Closes $100 Million C Funding for Novel CAR-T Technologies
$5.00
Available
Citrine to Bring Treatment for Narcolepsy, a Rare Disease, to China
$5.00
Available
Aprinoia to Start China Trial of PET Tracing Agent for Alzheimer's
$5.00
Available
CStone Out-licenses Ex-China Rights for Two Immunotherapies in $1.3 Billion Agreement
$5.00
Available
CASI Enters $95 Million China Deal for BioInvent's Checkpoint Inhibitor
$5.00
Available
Reistone Reports Successful Test of JAK1 Inhibitor for Atopic Dermatitis
$5.00
Available
Gmax of Hangzhou Starts China-US Trials of Antibody Drug for PAH
$5.00
Available
Siranomics Closes $105 Million Funding from China Investors; Plans IPO
$5.00
Available
Gland Pharma, Fosun's Indian Subsidiary, Approved for $814 Million IPO
$5.00
Available
Ascentage Granted China Priority Review of NDA for BCR-ABL Inhibitor
$5.00
Available
Zhaoke Acquires China Rights to Myopia Treatment in $102 Million Agreement
$5.00
Available
Beijing Immunochina Raises $15 Million for CAR-T Portfolio
$5.00
Available
3DMed Completes $225 Million Round for Immunotherapy Candidates
$5.00
Available
Huadong Med Acquires ADC for Ovarian Cancer in $305 Million Agreement
$5.00
Available
Aslan Pharma Repurposes DHODH Inhibitor for Autoimmune, COVID-19 Indications
$5.00
Available
Qihan Biotech Applies Genome Editing to Create Allogenic Stem Cells
$5.00
Available
PPD Plans Major Suzhou Lab to Offer China Drug Development Services
$5.00
Available
CBC Merges Two Shanghai Companies, AffaMed and EverInsight, into One
$5.00
Available
Cue Health Announces $481 Million Grant for Coronavirus Tests
$5.00
Available
EdiGene Raises $67 Million for Clinical Trials of Gene Edited Drugs
$5.00
Available
ImmuneOnco Completes $25 Million Funding for Immunotherapies
$5.00
Available
Curon Announces $149.5 Million Deal for China Rights to Lymphoma Drug
$5.00
Available
HitGen Pays $25 Million to Acquire Vernalis, a UK Discovery CRO, from Ligand
$5.00
Available
Innovent and Lilly Announce China Approval for Rituxan Biosimilar
$5.00
Available
Ascletis Subsidiary OK'd to Start US Trials of NASH Candidate
$5.00
Available
Shanghai's Everest Medicines Stages $451 Million Hong Kong IPO
$5.00
Available
Creative Bio of Guangzhou Raises $90 Million for Oncology Tests
$5.00
Available
Chengdu's Hinova Pharma Raises $147 Million for Novel Prostate, Gout Drugs
$5.00
Available
Zai Lab Doses First Patient in China Trial of PD-1 for NSCLC
$5.00
Available
10x Genomics Pays $350 Million to Acquire ReadCoor, a Spatial-Omics Company
$5.00
Available
Two China Biopharmas Strike $65 Million Deal for Rights to Cell Therapy
$5.00
Available
Corvus Forms $106 Million China Subsidiary with China Rights to Four of its Assets
$5.00
Available
Harbour Bio Starts China Trial of Autoimmune Treatment
$5.00
Available
CARsgen Granted US Orphan Drug Status for Claudin18.2 CAR-T Drug
$5.00
Available
I-Mab to Start China Phase III Trial of Long-Acting Treatment for Dwarfism
$5.00
Available
Virogin Raises $62 Million for Oncolytic Virus Portfolio
$5.00
Available
Sumgen Completes $32 Million Round for Immunotherapy Antibodies
$5.00
Available
CStone Out-licenses China Rights for PD-1 to Pfizer in $480 Million Deal
$5.00
Available
Fosun Closes $182 Million In-licensing of Polyphor Cancer Treatment
$5.00
Available
Apollomics to Start China Trials of In-Licensed Leukemia Drug
$5.00
Available
Taimei Tech Completes $176 Million Raise for AI Clinical Trial Software
$5.00
Available
BioShin Raises $60 Million to Bring Biohaven's Drugs to China
$5.00
Available
Junshi Says its PD-1 Effective Against Nasopharyngeal Carcinoma
$5.00
Available
Zai Lab Raises $761 Million in Hong Kong IPO; Climbs 8.5% Higher
$5.00
Available
InventisBio Completes $147 Million Round for Small-Molecule Drugs
$5.00
Available
Bioray Lab Starts Tests of Gene Edited PD1-Knockin CAR-T Candidate
$5.00
Available
Sperogenix Acquires China Rights to Rare Disease Candidate in $78 Million Deal
$5.00
Available
BioDuro and Sundia Merge to Form China-US CRDMO Backed by Advent
$5.00
Available
Viva Biotech to Pay $80 Million to Acquire SYNthesis in CRO Tieup
$5.00
Available
ImmVira Raises $10 Million for Genetically Modified Oncolytic Viruses
$5.00
Available
XiangXue Life Sciences to Start US Trial of Novel T-cell Receptor Candidate
$5.00
Available
Sequoia Capital China Raising $2.2 Billion in RMB for China Fund
$5.00
Available
Genor Bio of Shanghai Conducting $370 Million IPO in Hong Kong
$5.00
Available
Sinovac Starts Phase III Trial of COVID-19 Vaccine in Turkey
$5.00
Available
Illumina to Acquire Grail, a Early Cancer Testing Company, for $8 billion
$5.00
Available
Legend Bio's CEO Placed on House Arrest after China Investigation
$5.00
Available
LinkDoc Raises $103 Million for Oncology AI/Big Data Services
$5.00
Available
Tianjin JuveStar Enters $74 Million Deal with Raziel for Body Fat Treatment
$5.00
Available
I-Mab and MorphoSys to Test C5aR1 Antibody in the US
$5.00
Available
Zai Lab Conducting $845 Million IPO in Hong Kong
$5.00
Available
XWPharma Completes $40 Million Round for Neurobiology Candidates
$5.00
Available
GenScript ProBio Extends Drug Development Collaboration with REMB
$5.00
Available
Biocytogen Raises $142 Million for Gene-Modified Animal CRO Services
$5.00
Available
Yufan Bio Partners with Pittsburgh's Abound to Develop Novel CAR-T Therapies
$5.00
Available
Singleron Raises $30 Million for Gexscope
$5.00
Available
Everest Med Reports Results from Trial of Antibiotic for MDR Infections
$5.00
Available
Forerunner Closes $28 Million Funding For Medical Devices
$5.00
Available
Ascentage Granted US Orphan Drug Status for Gastric Cancer Treatment
$5.00
Available
Hualan Genetic to Develop Three Harbour BioMed Antibodies in Return for China Rights
$5.00
Available
Junshi Granted US Breakthrough Status for PD-1 in Nasopharyngeal Cancer
$5.00
Available
Baidu Said to Be Raising $2 Billion for AI-based Novel Drug Discovery Company
$5.00
Available
Zai Lab's PARP Inhibitor Approved for First-Line Maintenance in Ovarian Cancer
$5.00
Available
Gannex Pharma, an Ascletis Subsidiary, Announces NASH Partnership
$5.00
Available
Huadong Medicine Partners with Excientia, a UK-based AI Drug Discovery Company
$5.00
Available
Zion Pharma Starts US Trial of Treatment for Breast Cancer Brain Metastases
$5.00
Available
CANbridge Approved for China Launch of First Rare Disease Treatment
$5.00
Available
AnHeart Acquires Two Additional Cancer Drugs from Daiichi Sankyo
$5.00
Available
CANbridge Starts Neuromuscular Gene Therapy Program with UMass
$5.00
Available
Everest Starts China Trial of Treatment for Rare Renal Disease
$5.00
Available
InxMed Completes $19 Million Series A+ Round for FAK Inhibitor Trials
$5.00
Available
Innovent Approved to Launch Humira Biosimilar in China
$5.00
Available
CoWin Biosciences Closes $36 Million Financing for Reagents Business
$5.00
Available
Innovent Starts China Trials of Novel Anti-Inflammatory Biologic
$5.00
Available
Carlyle Pays $260 Million for 5% Stake in Shenzhen Salubris
$5.00
Available
Waterstone Completes $63 Million Financing for Generic/Novel Drug Portfolio
$5.00
Available
Adlai Nortye Raises $100 Million for Immunoncology Portfolio
$5.00
Available
Innovent Reports Positive Data from PCSK9 Anti-Cholesterol Treatment
$5.00
Available
CStone Approved to Start US Trial of anti-PD-L1 in Lymphoma
$5.00
Available
Antengene Cleared to Stage $200 Million IPO in Hong Kong
$5.00
Available
Suzhou Sinovent Raises $145 Million for Biologic Drug Portfolio
$5.00
Available
ReViral Raises $44 Million in Funding Led by China Investor
$5.00
Available
HitGen Delivers Drug Candidates to Almirall for Skin Disease Targets
$5.00
Available
Yuce Bio Completes $43 Million Funding for Cancer Immunotherapy Testing
$5.00
Available
Connect Biopharma Closes $115 Million C Round for Immune Modulators
$5.00
Available
Xuanzhu Bio, a Sihuan Novel Drug Subsidiary, Completes $116 Million Funding
$5.00
Available
Dizai Pharma, a China AstraZeneca JV, Raises $100 Million
$5.00
Available
Keya Medical Closes $22 Million Funding for AI Imaging Software
$5.00
Available
Ascletis Completes Bridging Study of One-Pill Combination HCV Treatment
$5.00
Available
JD Health Raises $830 Million from Hillhouse for Online Health Services
$5.00
Available
Junshi Bio Invests $43 Million to Partner Impact's PARP Inhibitor in China
$5.00
Available
Ocumension Pays $9.5 Million to Add Korean Rights for Two Products
$5.00
Available
DK Medtech Closes $14 Million Series B+ for CV Medical Devices
$5.00
Available
Galixier Closes $10 Million Pre-A Round for AI Drug Discovery Services
$5.00
Available
I-Mab Starts China Trial of GM-CSF Inhibitor for RA
$5.00
Available
Innovent Expands Ex-China Alliance with Lilly in $1 Billion Agreement
$5.00
Available
Bayer Enters $658 Million Deal to Market Hua's Diabetes Drug in China
$5.00
Available
GNI Reports Positive Results from Trial of Liver Fibrosis Drug
$5.00
Available
JW Therapeutics Files for $300 Million Hong Kong IPO
$5.00
Available
Henlius Biotech Approved to Launch Herceptin Biosimilar in China
$5.00
Available
Ascletis Doses Patients in China Trial of PD-L1 for Hepatitis B
$5.00
Available
Shanghai Pharma Signs $165 Million Deal for ImmVira Oncolytic Virus Program
$5.00
Available
Shanghai Hanyu Completes $72 Million Round for Cardiovascular Devices
$5.00
Available
MicuRx Receives $7.8 Million for Phase I/II Trials of Novel Antimicrobial
$5.00
Available
Cellular Biomedicine Accepts $383 Million Management-led Privatization Offer
$5.00
Available
Vision Medicals Raises $29 Million to Support Genetic Testing for Infectious Diseases
$5.00
Available
Viva Biotech to Pay $368 Million to Acquire Controlling Stake in China CDMO
$5.00
Available
Suzhou Zanrong Completes $20 Million A+ Round for Cancer Drugs
$5.00
Available
Innovent Reports Positive Data from Phase III Trial of Tyvyt for NSCLC
$5.00
Available
NeuPharma Starts Phase II Trial of Novel Treatment for Glioblastoma Multiforme
$5.00
Available
ABM Therapeutics Completes $20 Million Round for Neural Cancer Drugs
$5.00
Available
CStone Reports Positive Results from Phase III Lung Cancer Trial of Immunotherapy
$5.00
Available
Biogen Enters $2 Billion Deal to Co-Develop Parkinson's Candidate in US and China
$5.00
Available
Lepu Biotech Closes $186 Million B Round for Cancer Immunotherapies
$5.00
Available
VistaGen Receives $5 Million Upfront Fee from EverInsight for SAD Therapy
$5.00
Available
Fosun Doses 72 Subjects in China Trial of mRNA COVID-19 Vaccine
$5.00
Available
Zai Lab Granted China Priority Review for GIST Treatment
$5.00
Available
Innovent Starts Phase I Trial of CD47/PD-L1 Bispecific for Solid Tumor Cancers
$5.00
Available
Sherpa Healthcare Closes $200 Million Life Science Venture/Growth Fund
$5.00
Available
Simcere Signs $170 Million Deal for Myelopreservation Therapy
$5.00
Available
Qilu Pharma In-licenses Bladder Cancer Drug in $35 Million Deal
$5.00
Available
Ascletis Approved to Market Dual All-oral HCV Treatment
$5.00
Available
Harbour BioMed and Viva Bio Partner to Offer Incubation Services
$5.00
Available
Henlius' Herceptin Biosimilar Approved for European Use
$5.00
Available
CanSino Enlists Pfizer to Market Meningitis Vaccine in China
$5.00
Available
YoFo Medical Raises $7 Million for Novel CT Imaging Technology
$5.00
Available
Hansoh In-licenses Novel BCR-ABL Inhibitor for CML in $68 Million Agreement
$5.00
Available
Viva Bio and Schr
$5.00
Available
NeuPharma Doses First Patient in Phase II Trial of Novel Inhibitor for Cancer
$5.00
Available
BrosMed Closes C Round for Vascular Devices Led by Hillhouse
$5.00
Available
HaiHe Bio Completes $171 Million B Round to Advance Novel Candidates
$5.00
Available
Thousand Oaks Bio Closes $64 Million Series B for CDMO Operations
$5.00
Available
Chi-Med Starts China Phase I Trial of Ninth Novel Cancer Candidate
$5.00
Available
Hansoh Out-Licenses Ex-China Rights for Lung Cancer Drug to EQRx
$5.00
Available
N.B. Quadriga Candidate Starts Australia Trial for LAT1 Cancers
$5.00
Available
CASI, a US-China Biopharma, Completes $38 Million Private Placement
$5.00
Available
Stroke Medical Raises $10 Million for Minimally Invasive Devices
$5.00
Available
Ascentage Starts Trial of MDM2-p53 Inhibitor in Hematologic Malignancies
$5.00
Available
Xpect Vision Raises $21 Million for Photon-Counting X-Ray Imaging Devices
$5.00
Available
BeiGene In-Licenses Three-Molecules for Hepatitis B in $540 Million Deal
$5.00
Available
Antengene Closes $97 Million Round to Develop Hematology/Oncology Portfolio
$5.00
Available
Shanghai's JW Therapeutics Acquires Hong Kong Cell Therapy Company
$5.00
Available
Tigermed, a China Clinical CRO, Seeks up to $1 Billion in Hong Kong IPO
$5.00
Available
Sunshine Guojian, a 3SBio Subsidiary, Plans $248 Million Shanghai STAR Board IPO
$5.00
Available
Junshi Bio Stages $692 Million IPO on Shanghai's STAR Board
$5.00
Available
Gland Pharma, a Fosun Subsidiary, Plans $650 Million IPO in India
$5.00
Available
BioAtla Closes $72.5 Million Round for Conditionally Active Biologics
$5.00
Available
Arctic Vision Raises $32 Million for Ophthalmology Drugs in China
$5.00
Available
Venus Medtech Acquires China Rights to Non-implant Heart Valve Treatment
$5.00
Available
BeiGene Raises $2 Billion in Private Placement; Amgen Participates
$5.00
Available
Ocumension Stages $184 Million HK IPO; Climbs 152% on First Day
$5.00
Available
Germany's Merck Opens Shanghai Collaboration Center
$5.00
Available
OBiO Raises $28 Million for Viral Vector CRO/CDMO Operations
$5.00
Available
Asieris Approved to Start Global Phase III Trials of Cervical Lesion Treatment
$5.00
Available
Zai Lab In-licenses NSCLC Candidate from Turning Point in $178 Million Deal
$5.00
Available
Evive Bio Reports Positive Late-Stage Results of Neutropenia Treatment
$5.00
Available
Livzon In-Licenses Schizophrenia Patch Product from Germany's LTS
$5.00
Available
Boehringer Ingelheim Launches Shanghai External Innovation Hub with $500 Million Commitment
$5.00
Available
Suzhou CF PharmTech Closes $50 Million F Round for Respiratory Drugs
$5.00
Available
CapitalBio Raises $113 Million in Pre-IPO Round for Molecular Diagnostics
$5.00
Available
Hua Reports Positive Interim Results from Novel Type 2 Diabetes Candidate
$5.00
Available
SciClone Acquires China Rights to Immunotherapy in $120+ Million Deal
$5.00
Available
Hygeia Healthcare Stages $282 Hong Kong IPO for Radiotherapy Services
$5.00
Available
Lianchuan Bio Completes $15 Funding for Genomics/Proteomics Services
$5.00
Available
Gan & Lee Raises $360 Million in Shanghai IPO; Trades up 44%
$5.00
Available
Burning Rock Partners with CStone for RET Companion Diagnostic
$5.00
Available
Henlius Approved in China to Launch Osteoporosis Biosimilar
$5.00
Available
Simcha Raises $25 Million from China Investors for Novel Immunotherapies
$5.00
Available
AnchorDx Developing $100 Diagnostic Test for Six Types of Cancer
$5.00
Available
Sophonix of Beijing Closes $14 Million Round for Point-of-Care-Tests
$5.00
Available
InxMed Says FAK Inhibitor Effective against Drug Resistance
$5.00
Available
Genor Signs $46 Million In-licensing Deal for Breast Cancer Candidate
$5.00
Available
WuXi NextCODE Morphs into Genuity Science Without Shanghai Operations
$5.00
Available
SinocellTech Closes $181 Million IPO on STAR Board; Triples in Initial Trading
$5.00
Available
Betta Pharma Signs $135 Million Deal for China Rights to Two Immunotherapies
$5.00
Available
Merck Announces China Approval of Fifth Indication for Keytruda
$5.00
Available
Innovent Approved to Launch Avastin Biosimilar in China
$5.00
Available
Engrail Raises $32 Million From Nan Fung to In-license Neurological Drugs
$5.00
Available
Ascentage Files China NDA for 3rd-Gen BCR-ABL Inhibitor
$5.00
Available
Shenzhen Immvira Completes $58 Million Funding for Oncolytic Virus Therapies
$5.00
Available
Shukun Raises $28 Million for AI-Based Scan Reading
$5.00
Available
Miaoshou Doctor Closes $85 Million Funding for Online-Offline Health Services
$5.00
Available
Cygnus Bioscience Raises $14 Million for Gene Sequencing Machines
$5.00
Available
Burning Rock Raises $223 Million In US IPO; Climbs 50% in Trading
$5.00
Available
Sinopharm Reports Positive Preclinical Results for SARS-CoV-2 Vaccine
$5.00
Available
Simcere Plans to Raise a Rumored $500 Million in Hong Kong IPO
$5.00
Available
GeneQuantum OK'd to Start US Trials of Novel HER2 ADC
$5.00
Available
JW Therapeutics Raises $100 Million to Support CAR-T Portfolio
$5.00
Available
Suzhou Innovent Signs $2 Billion-plus Bi-Specific/CAR-T Development Deal with Roche
$5.00
Available
CANbridge Forms Gene Therapy Research Program with UMass for Rare Diseases
$5.00
Available
MabPlex Raises $71 Million for Biopharmaceutical CDMO Services
$5.00
Available
Everest Medicines of Shanghai Closes $310 Million C Round for In-licensed Drugs
$5.00
Available
Nanjing Legend Bio Completes $424 Million NASDAQ IPO; Shares Rise 60%
$5.00
Available
Beijing Jiushi Shenkang Closes $14 Million Funding for Neurovascular Products
$5.00
Available
BeiGene Approved to Launch BTK Inhibitor in China for Two Cancer Indications
$5.00
Available
Deep Informatics++ Closes $14 Million Series B for AI-based Pathology Products
$5.00
Available
Innovent Reports Trial Data from PD-1 Drug in Three Separate Indications
$5.00
Available
Jiangsu Atom Raises $30 Million to Support Global Trial of Gout Drug
$5.00
Available
Harbour Biomed Approved for China Phase II/III Trials of Graves' Ophthalmopathy Treatment
$5.00
Available
Nanjing Legend Biotech Plans to Raise $350 Million in US IPO at $2.6 Billion Valuation
$5.00
Available
Genor Bio Closes $160 Million B Round to Develop Ten Biologic Clinical Candidates
$5.00
Available
Jacobio, a Beijing Pharma, Out-Licenses Two SHP2 Candidates to AbbVie
$5.00
Available
Kintor Pharma Stages $240 Million Hong Kong IPO for Androgen Receptor Drugs
$5.00
Available
MGI Tech, a BGI Subsidiary, Raises $1 Billion to Make Gene Sequencing Machines
$5.00
Available
I-Mab Starts Phase Ib Trial of Re-purposed RA Treatment for COVID-19
$5.00
Available
Mabspace Reports Positive Data from Phase I Trial of 2nd-Gen PDL1
$5.00
Available
Immunochina and EdiGene Team Up to Discover Allogeneic T-Cell Therapies
$5.00
Available
CStone Reports Updated Data from Phase I trial of anti-PD-L1 mAb in NSCLC
$5.00
Available
Burning Rock of Guangzhou Plans $100 Million IPO on NASDAQ
$5.00
Available
Innovent's IBI939 is First TIGIT Inhibitor to Start China Trials
$5.00
Available
CanSino Publishes Positive Data from COVID-19 Vaccine Trial in The Lancet
$5.00
Available
Apollomics Starts Global Phase II Trial of c-MET Inhibitor
$5.00
Available
Peijia Medical Raises $302 Million in Hong Kong IPO for Medical Devices
$5.00
Available
I-Mab to Start China Phase II Trial of Immunotherapy for GBM
$5.00
Available
Zentalis Raises $20 Million for China Subsidiary, Zentara Therapeutics
$5.00
Available
Primedicine In-Licenses China Rights to Heart Attack Treatment
$5.00
Available
Innovent and MD Anderson Partner to Test Tyvyt
$5.00
Available
CARsgen to Start US Trial of CAR-T for Gastric and Pancreatic Cancer
$5.00
Available
Zai Lab Doses First Patient in China Trial of Treatment for Drug-Resistant Infections
$5.00
Available
Nanjing Legend Approved for $100 Million US IPO on NASDAQ
$5.00
Available
SciMount of Chengdu to Start US Trials of Novel Irritable Bowel Treatment
$5.00
Available
Zai Lab Approved to Launch Tumor Treating Fields for Glioblastoma in China
$5.00
Available
Ascletis Approved to Start China Trials of Second Candidate for NASH
$5.00
Available
I-Mab Doses First Patient in China Trial of CD73 Antibody
$5.00
Available
Simcere Acquires China Rights to Novel Stroke Drug from Canadian Biotech
$5.00
Available
Invivoscribe Submits Biomarker Test for Astellas Cancer Drug to China's NMPA
$5.00
Available
Nantong Lianya/Novast Raises $140 Million for Generics and Extended-Release Drugs
$5.00
Available
Qujing Hengsheng Closes $14 Million Pre-A Round for Minimally Invasive Imaging
$5.00
Available
Innovent Reports Positive Results from Phase III NSCLC Trial of PD-1 Drug
$5.00
Available
HighTide Says Lead Drug Meets Endpoints in China Phase II Trial for NASH
$5.00
Available
CANbridge Approved to Launch HER-2 Cancer Adjuvant in China
$5.00
Available
Nanjing Immunophage Raises $14 Million for Novel Immune-Regulating Candidates
$5.00
Available
Ascentage Granted US Orphan Drug Status for Leukemia Candidate
$5.00
Available
TargetRx of Shenzhen Raises $21 Million for Novel Small Molecule Cancer Drugs
$5.00
Available
OrigiMed and Bayer Partner on Gene Fusion Companion Diagnostic
$5.00
Available
Ocumension Files for Hong Kong IPO to Advance Ophthalmology Portfolio
$5.00
Available
SmartNuclide Bio Completes $14 Million B Round for Nuclear Medicine Drugs
$5.00
Available
I-Mab Plans to Partner its CD-47 Immunotherapy in $2 Billion Deal
$5.00
Available
Mabwell Bio of Shanghai Closes $278.5 Million Series A Financing
$5.00
Available
RemeGen Cleared to Start US Trials of Novel ADC for HER2 Urothelial Cancer
$5.00
Available
Denovo to Acquire Gene Therapy Technology for Oncology from Tocagen
$5.00
Available
Innovent Starts China Trial of PI3K? Inhibitor for Indolent Lymphoma
$5.00
Available
Shanghai Green Valley Given US Go-Ahead for Phase III Alzheimer's Trial
$5.00
Available
AkesoBio Completes $335 Million Hong Kong IPO; Climbs 50% on First Trading Day
$5.00
Available
Innovent's sNDA for Use of PD-1 in NSCLC Accepted for China Review
$5.00
Available
Hansoh In-licenses Novel Anti-Viral from NiKang in Deal Worth up to $100 Million Plus
$5.00
Available
APTBIO of Shanghai Completes $28 Million Round for Proteomics Services
$5.00
Available
CStone Says NDA for GIST Precision Medicine Accepted for Review in China
$5.00
Available
Sinovac Reports Positive Animal Data on COVID-19 Vaccine; New Plant to Produce Vaccine
$5.00
Available
Magpie Pharma Closes $14 Million Funding for Modernized TCM Drugs
$5.00
Available
ChosenMed of Beijing Completes B Round for Oncology Precision Medicine
$5.00
Available
Harbour BioMed Starts China POC Trial of Novel mAb in Autoimmune Disease
$5.00
Available
New Horizon Health Raises $20 Million for China Early-Stage Cancer Tests
$5.00
Available
US Approves Fosun Pharma's COVID-19 Test Kit under Emergency Rules
$5.00
Available
Mabspace Cleared to Start US Trial of ADCC Molecule in Solid Tumor Cancers
$5.00
Available
Cloudbreak, a US-China Biopharma, Raises $25 Million for Ophthalmology Drugs
$5.00
Available
Chi-Med Granted US Fast Track Designation for Surufatinib in Pancreatic Neuroendocrine Tumors
$5.00
Available
Beijing Mabworks Closes $160 Million C1/C2 Round for Biologic Drugs
$5.00
Available
Chime Biologics of Wuhan BioLake Separates its CDMO Operations from JHL Biotech
$5.00
Available
Leo Pharma Acquires Global Rights to Atopic Dermatitis Treatment in $580 Million Deal
$5.00
Available
Ansun Starts US Proof-of-Concept Trial for COVID-19 Treatment
$5.00
Available
Sinovac Biotech Starts Trial of Inactivated SARS-CoV-2 Vaccine
$5.00
Available
Antengene Starts Clinical Trial of Novel Lymphoma/Solid Tumor Cancer Treatment
$5.00
Available
BeiGene Approved for China Launch of PD-L1 for Urothelial Cancer
$5.00
Available
Ascletis Approved for China Phase IIb Test of HIV-Combination Treatment
$5.00
Available
Guangzhou OptoMedic Raises $14 Million for Medical Devices
$0.00
Available
Astellas NDA for Leukemia Treatment Accepted for China Review
$5.00
Available
CanSino Announces Plan to Start China Phase II Trial of COVID-19 Vaccine
$5.00
Available
Qiming Closes Seventh Dollar Fund with $1.1 Billion for Life Science and TMT Companies
$5.00
Available
Sirnaomics Releases Positive Interim Data from Phase II Trial of siRNA Candidate
$5.00
Available
Zai Lab Acquires Greater China Rights to Regeneron Bi-Specific in $190 Million Agreement
$5.00
Available
Suzhou Ribo Life Science Completes $66 Million C Round for siRNA Portfolio
$5.00
Available
Cytovant Raises $23.5 Million for China Development of Immunotherapies
$5.00
Available
Immunomedics Phase III Trial of Breast Cancer Drug Stopped Early; Everest Owns Greater China Rights
$5.00
Available
RemeGen Closes $100 Million Round for China Launch of Novel Biologics
$5.00
Available
Xiamen Innovax Pairs COVID-19 Vaccine Candidates with GSK's Adjuvant
$5.00
Available
Shanghai Genechem Raises $56 Million for Biologic CRO/CMO Services
$5.00
Available
Gracell's IND for Allogenic CAR-T Accepted for Review in China
$5.00
Available
Ansun Reports Positive Results from China Trial of Inhaled Antiviral for COVID-19
$5.00
Available
Seneca Completes Stem Cell Manufacturing Plant in Suzhou
$5.00
Available
Nanjing Legend Raises $150 Million for Cell Therapies in an A Round/Pre-IPO Financing
$5.00
Available
Boston's Rgenta Raises $20 Million for RNA Therapies from China-Heavy Syndicate
$5.00
Available
Ping An Invests $311 Million in Japan's Shionogi for New Drug Development
$5.00
Available
Ocumension Enters $77 Million Deal for Stem Cell Therapies from Japan's SanBio
$5.00
Available
ZhenGe Biotech Completes $51 Million A Round for CDMO Operations
$5.00
Available
Tainuo Signs $42.5 Million China Deal for Knee Osteoarthritis Pain Treatment
$5.00
Available
Junshi Biosciences Approved for Shanghai STAR IPO, a Dual Listing with Hong Kong
$5.00
Available
Targene Closes $14 Million A Round for Early Diagnostics and Testing Services
$5.00
Available
BeyondSpring Starts Rolling Application of China NDA for Neutropenia Treatment
$5.00
Available
Chi-Med Starts Phase II Trial of FGFR Inhibitor in Mesothelioma Patients
$5.00
Available
GoBroad Healthcare, a Hillhouse Company, Starts Construction of Beijing Research Hospital
$5.00
Available
Alphamab and 3D Medicines Choose Simcere to Market Their PD-L1 Candidate
$5.00
Available
Shenzhen's BGI Genomics Approved to Launch SARS-CoV-2 Test in the US
$5.00
Available
Fosun Long March's COVID-19 Test Approved in China
$5.00
Available
CStone Files Taiwan NDA for Precision-Med GIST Candidate
$5.00
Available
China's Asieris Pharma Lands $14 Million for Genito-Urinary Tumor Treatments
$5.00
Available
Innovent Acquires China Rights to Novel Immunoncology Candidate from Alector
$5.00
Available
Abbisko of Shanghai Raises $70 Million for Novel Oncology-Immunocology Candidates
$5.00
Available
Apexigen Adds $65 Million to C Round in Funding Led by China Investors
$5.00
Available
Mabpharm Out-Licenses US-EU Rights for COVID-19 Fusion Protein to Sorrento
$5.00
Available
Junshi Bio Teams Up with IMCAS to Develop Neutralizing Antibodies for COVID-19
$5.00
Available
Laekna Acquires Global Rights to Novartis Clinical-Stage PD-L1
$5.00
Available
Clover to Add Dynavax's Adjuvant to its COVID-19 Vaccine Candidate
$5.00
Available
AnHeart Approved to Start Two China Trials of Cancer Drug
$5.00
Available
Sorrento Therapeutics Starts Pre-clinical Tests of SARS-CoV-2 Anti-viral
$5.00
Available
Zhejiang Hisun Pharma's Anti-Viral Effective Against COVID-19
$5.00
Available
Yizhun Intelligent Completes $14 Million B Round for AI-based Scaning Diagnosis
$5.00
Available
Roche Starts Global Trial of Actemra in Seriously Ill COVID-19 Patients
$5.00
Available
Hansoh Approved for China Launch of Ameile as Second-Line NSCLC Treatment
$5.00
Available
CanSino Bio Approved to Start China Trial for COVID-19 Vaccine
$5.00
Available
Zai Files for Approval of PARP Inhibitor as First-Line Maintenance Therapy for Ovarian Cancer
$5.00
Available
InnoCare (Beijing) Prices Hong Kong IPO at Top of Range, Raises $288 Million
$5.00
Available
InxMed of Shanghai Doses First Patient in US Trial of FAK Inhibitor
$5.00
Available
BioNTech and Fosun Partner mRNA Vaccine for COVID-19 in $135 Million Deal
$5.00
Available
Sanofi and Regeneron Start US Trial of Rheumatoid Arthritis Drug for COVID-19
$5.00
Available
Moderna Starts Clinical Trial of mRNA COVID-19 Vaccine in Seattle
$5.00
Available
I-Mab to Test Anti-Inflammatory for Cytokine Release Syndrome in COVID-19 Patients
$5.00
Available
Denovo Discovers Biomarker for Triple-Reuptake Depression Treatment
$5.00
Available
Exuma, a US-China CAR-T Company, Closes $19 Million B Funding
$5.00
Available
Arctic Vision Acquires China Rights to Macular Edema Treatment in $35.5 Million Deal
$5.00
Available
OBiO Completes $15 Million B+ Round for Gene Therapy CRO/CDMO Services
$5.00
Available
Legend, a Nanjing CAR-T Biotech, Files for a US IPO
$5.00
Available
HitGen Forms Second Drug Discovery Partnership with Japan's Kaken
$5.00
Available
China Immunotech Completes $6.5 Million Series A for TCR-T and CAR-T Candidates
$5.00
Available
Mesoblast to Start Trial of Stem Cell Product to Treat COVID-19 Respiratory Distress
$5.00
Available
Ascletis Reports Positive Results from Combination Treatment for COVID-19
$5.00
Available
GenFleet Closes $57 Million B Round for Oncology/Immunology Portfolio
$5.00
Available
Shanghai OPM Bio Raises $14 Million for Biologic CDMO Service Platform
$5.00
Available
Ascentage Pharma to Start Three Phase Ib/II Trials of Bcl2-Inhibitor
$5.00
Available
Harbour BioMed and NYC's Mount Sinai Form mAb Discovery Partnership
$5.00
Available
Realbio of Shanghai Lands Majority Investment for Microbiome/Pathogen Testing
$5.00
Available
Shanghai Zhimeng Starts US Phase I Trial of Novel HBV Treatment
$5.00
Available
Roche's RA Treatment, Actemra, Approved to Treat Seriously Ill COVID-19 Patients
$5.00
Available
Shenogen Pharma In-licenses Alopexx Fusion CD20 Protein for Lymphoma
$5.00
Available
Innovent Starts China Phase II Trial of FGFR1/2/3 Inhibitor for Cholangiocarcinoma
$5.00
Available
Abpro Bio Announces $1.1 Billion Deal for Asian Rights to Two Abpro Bi-specifics
$5.00
Available
3SBio Contributes to $126 Million MPM/Dana-Farber Fund for Cancer Start-Ups
$5.00
Available
Sihuan Pharma Starts China Trials of Favipiravir to Treat COVID-19
$5.00
Available
Merck Announces China Erbitux Approval for Head and Neck Cancer
$5.00
Available
Harbour BioMed to Begin US Trials of CLTA-4 Antibody
$5.00
Available
MapKure Doses First Patient in Australian Phase I Trial of BeiGene's B-RAF Inhibitor
$5.00
Available
Gilead Starts Two Phase III Trials of Remdesivir for COVID-19
$5.00
Available
Harbour BioMed Approved to Start US Trials of PD-L1 in Orphan Disease
$5.00
Available
Harvard and Guangzhou Institute of Respiratory Health Form $115 Million COVID-19 Collaboration
$5.00
Available
Cyagen Closes $41 Million Series B to Expand Animal Research Model Business
$5.00
Available
Moderna Ships Coronavirus Vaccine for Clinical Trials
$5.00
Available
WuXi Biologics and Vir Biotech Team up to Develop COVID-19 Antibodies
$5.00
Available
CICC Capital Closes $229 Million Fund for China Biologic Investments
$5.00
Available
Invetx Raises $15 Million from Anterra, AbCellear and WuXi Biologics
$5.00
Available
Clover Collaborates with GSK on COVID-19 Vaccine
$5.00
Available
Ascentage Approved to Start China Trial of Apoptosis Candidate for Pancreatic Cancer
$5.00
Available
Shanghai ImmuneOnco Raises $6.4 Million for Immunotherapies
$5.00
Available
WuXi Vaccines Signs $3 Billion, 20-Year Agreement to Manufacture Vaccine
$5.00
Available
Harbour BioMed Reports Successful Phase I Trial of Autoimmune Treatment
$5.00
Available
Anngeen Technolgies Raises $14 Million for Clinical Genetic Diagnosis Operations
$5.00
Available
Terns Announces Positive Data from Phase I Trial of NASH Candidate
$5.00
Available
CANbridge Closes $98 Million D Round for Rare Disease/Oncology Portfolio
$5.00
Available
Hisun Pharma's Favilavir Approved to Treat Wuhan Coranovirus
$5.00
Available
Ascletis Says China Accepts IND Filing for Novel NASH Treatment
$5.00
Available
Ascletis to Start Zhejiang Province Trial of Generic HIV/AIDS Drug for COVID-19
$5.00
Available
Roche's Tecentriq, a PD-L1, Approved in China for Small Cell Lung Cancer
$5.00
Available
Samsung Bioepis OK'd to Start China Trial for Rare Disease Biosimilar
$5.00
Available
TUS-Holdings of China Joins $22 Million Funding for Stilla, a French PCR Testing Company
$5.00
Available
Genetron Approved to Launch 8-Gene Lung Cancer Assay in China
$5.00
Available
BrightGene Copying Gilead's Remdesivir, Says It Wants to In-License the Anti-Viral
$5.00
Available
Sihuan Pharma Plans to Bring Anti-Infective Generics from India's Hetero Lab to China
$5.00
Available
J&J Collaborates with BARDA, a US Agency, to Develop COVID-19 Vaccine
$5.00
Available
Bio-Thera, an Antibody Company, Prices $241 Million Shanghai STAR Board IPO
$5.00
Available
Beijing Advaccine Raises $4.3 Million for Coronavirus Vaccine
$5.00
Available
Universal Medical Imaging Raises $86 Million to Expand China Imaging Centers
$5.00
Available
Clover Announces Vaccine Candidate for 2019-nCOV
$5.00
Available
Zai Lab's NDA for Novel Antibiotic Accepted for China Review
$5.00
Available
BGI and Partners Build Emergency Wuhan Coronavirus Testing Lab in Five Days
$5.00
Available
AkesoBio Files for $300 Million Hong Kong IPO to Develop Antibody Portfolio
$5.00
Available
Gates Foundation Commits up to $100 Million to Address Coronavirus Outbreak
$5.00
Available
Shenzhen Lachesis Mhealth Raises $21 Million in B+ Round
$5.00
Available
Gilead Starts China Phase III Trial of Remdesivir in Coronavirus Patients
$5.00
Available
Zai Lab Starts China Trials for Gastric Cancer and Breast Cancer Treatments
$5.00
Available
Bio-Thera Reports Positive Results from Phase III Trial of Avastin Biosimilar
$5.00
Available
CSPC Starts China Trial of Lymphoma Treatment
$5.00
Available
DelMar Reports VAL-083 Increases Progression-Free Survival in GBM
$5.00
Available
Ocumension Acquires China Rights to Ocular Inflammation Product in $12 Million Deal
$5.00
Available
Ascletis Files for Emergency Use of HIV Anti-Viral Combo as Coronavirus Treatment
$5.00
Available
Wuhan's BravoVax Signs Letter of Intent with Atlanta's GeoVax to Develop Coronavirus Vaccine
$5.00
Available
CStone Starts Phase I Trial that Combines its PD-L1 with Bayer's Stivarga
$5.00
Available
Sorrento Therapeutics Rejects $933 Million Take-Private Offer
$5.00
Available
Biotheus Acquires Rights to TILT Bio's Chimeric Adenovirus
$5.00
Available
Ningbo NewBay In-Licenses Novel Genentech Oncology Candidate
$5.00
Available
Zai Lab Raises $261 Million; Plans China NDA Filing for Ripretinib in Mid-2020
$5.00
Available
Roche's Kadcyla, a Breast Cancer Treatment, Is First ADC Approved in China
$5.00
Available
Beijing Hengsheng Medical Completes $6 Million Funding for Coronary Devices
$5.00
Available
Ascletis Approved to Start China Trial of PD-L1 in HBV Patients
$5.00
Available
China Medical In-licenses China Rights to Novel Anemia Drug from Zydus Cadila
$5.00
Available
Oncologie Collaborates with Genialis to Identify Patients for Clinical Trials
$5.00
Available
Celltrion Plans $513 Million Wuhan Biologics Facility, 18 Biologic Launches in China by 2030
$5.00
Available
TenNor Receives Orphan Drug Designation in the US for Biofilm Infection Candidate
$5.00
Available
I-Mab Completes $104 Million IPO in the US for Biologics Portfolio
$5.00
Available
China-US Trade Agreement Specifies Patent Protection Rules for Drugs
$5.00
Available
WuXi Biologics Leases German Biologics Manufacturing Facility from Bayer
$5.00
Available
Tisenc Medical Raises $12 Million for Point-of-Care Chemiluminescence Testing
$5.00
Available
HitGen Collaborates with Kymera to Identify Protein Degradation Targets
$5.00
Available
BeiGene Announces $160 Million Agreement for China Rights to Two EUSA Orphan Biologics
$5.00
Available
Innovent Out-licenses US-Canada Rights for Avastin Biosimilar to Coherus In $45 Million Deal
$5.00
Available
Chi-Med Starts China Phase II Trial of Surufatinib/Tuoyi Combo in Solid Tumors
$5.00
Available
Sino Biopharma Signs Deal to Develop Two Novel Ambrx Biologics in China
$5.00
Available
Innovent Reports Phase III Success of PD-1 in Lung Cancer Patients
$5.00
Available
Zhiyun Health Raises $142 Million for Online Diabetes Management Website
$5.00
Available
ASK Pharm Announces $51 Million Deal for China Rights to Iron Deficiency Product
$5.00
Available
Bio-Thera Approved to Market Humira Biosimilar in China
$5.00
Available
Nantong's IOVaxis Signs $103 Million Deal for RAS Cancer Vaccines
$5.00
Available
Adagene Raises $69 Million in D Round for Novel Immunotherapies
$5.00
Available
Zai Lab Starts China Trial of Tumor Treating Fields Device for Gastric Cancer
$5.00
Available
Transcenta of Suzhou Raises $100 Million to Develop 10 Innovative Biotherapies
$5.00
Available
RootPath Raises $11 Million for Personalized TCR/CAR-T Solid Tumor Treatments
$5.00
Available
Innovent and Sirnaomics to Test PD-L1-RNAi Combination in Hepatocellular Carcinoma
$5.00
Available
Gracell Starts China Trial of Allogenic CAR-T Candidate for ALL
$5.00
Available
CStone Starts China Trial of PD-L1/FGFR4 Inhibitor Combination for HCC
$5.00
Available
Apollomics Enters $189 Million Deal for China Rights to Two GlycoMimetics Immunotherapies
$5.00
Available
3D Med Diagnosis Completes a $40 Million Initial Funding for Cancer Diagnostics
$5.00
Available
Yisheng Forms Cancer IO Partnership with US-based Tavotek
$5.00
Available
Suzhou's CarrierGene Merges with NuProbe Global of Boston in Diagnostics Tie-up
$5.00
Available
I-Mab Announces Terms for $100 Million US IPO; Starts China Trial of Immunoncology Drug
$5.00
Available
BeiGene Forms $132 Million Collaboration for Asia Rights to Leap's DKK1 mAb
$5.00
Available
CF Pharma Raises $90 Million in Series E for Inhalation Medicines/Devices
$5.00
Available
Xuanzhu Bio Pays $4.5 Million to Acquire Anti-infective for Drug-Resistant Pathogens
$5.00
Available
BeiGene's PD-1 Antibody Approved in China to Treat Hodgkin's Lymphoma
$5.00
Available
Scientist Behind China CRISPR-Cas9 Scandal Sentenced to Three Years in Prison
$5.00
Available
Clover Bio Starts China Phase III Trial of Enbrel Biosimilar
$5.00
Available
Elpiscience Completes $100 Million Series B Financing for Immunotherapies
$5.00
Available
Zai Lab's PARP Inhibitor OK'd for China Use, the Company's First China Approval
$5.00
Available
Geneseeq Completes $114 Million Funding for Cancer Genetic Sequencing
$5.00
Available
Luye Pharma Submits NDA in US for Novel Depression Treatment
$5.00
Available
Sinovac's Varicella Zoster Vaccine Approved for China Use
$5.00
Available
Shanghai Zerun, a Novel Vaccine Company, Raises $29 Million to Reduce Debt
$5.00
Available
Roche Agrees to Nearly $3 Billion Package for ex-US Rights to Sarepta Gene Therapy; China a Major Target
$5.00
Available
Innovative Cellular Therapeutics Raises $28.6 Million for Next-Gen CAR-T Drugs
$5.00
Available
InxMed to Start China Trials of FAK Inhibitor for Gastric Cancer
$5.00
Available
Metabomed, a Cancer Metabolism Specialist, Closes $12.5 Million Financing Led by Yonjin Venture
$5.00
Available
AffaMed Ok'd to Begin Phase III Trial of Samsung Bioepis Biosimilar in China
$5.00
Available
Everest Approved to Start China Trials of Kidney Inflammation Therapy
$5.00
Available
Frontage Holdings Buys BRI Biopharma, a Canada/US CRO
$5.00
Available
Shandong Fontacea In-Licenses IL-17A Candidate from Janssen
$5.00
Available
KeChow Completes $45 Million Round for Novel Cancer Drug Development
$5.00
Available
FC Capital of Shanghai Leads $20 Million B Round for Switzerland's Cellestia Biotech
$5.00
Available
TransThera Approved for US Trials of Heart Failure Treatment
$5.00
Available
Ally Bridge Leads $140 Million of Investments in Three Medical Device Companies
$5.00
Available
BeiGene Says BTK Inhibitor Shows Improvement But Does not Meet Clinical Endpoints in WM
$5.00
Available
3SBio Has China Rights to Five Numab I-O Therapies following $15.2 Million Investment
$5.00
Available
AstraZeneca's Imfinzi, a PD-L1 Immunotherapy, Approved in China for NSCLC
$5.00
Available
Alphamab Oncology Closes $234 Million Hong Kong IPO; Climbs 35% in First Session
$5.00
Available
Zhejiang Medicine Reports Positive Data for HER2 Treatment in Pretreated Patients
$5.00
Available
Ascentage Reports 95% Complete Response of BCR-ABL Inhibitor in Leukemia Patients
$5.00
Available
JOINN Bio Raises $60 Million for US-China Biologic CDMO Operations
$5.00
Available
Innovent Announces 100% Response Rate for its CAR-T in Multiple Myeloma
$5.00
Available
BJ Bio Starts US Trials of Targeted IL-15 Fusion Protein in Solid Tumors
$5.00
Available
BeiGene Reports More Clinical Data on BTK-inhibitor Brukinsa
$5.00
Available
CARsgen Approved to Start China Trials of Third Oncology Candidate
$5.00
Available
Beijing Hygea Medical Closes $28 Million Funding for Cryogenic Cancer Treatments
$5.00
Available
Innovent Starts China Trials of Novel LAG-3 Immunotherapy
$5.00
Available
Suzhou Ribo Raises $29 Million for siRNA Drug Development
$5.00
Available
AstraZeneca/Merck PARP Inhibitor Approved in China for Ovarian Cancer
$5.00
Available
ICT Approved to Start US Trials of CD-19 CAR-T for Lymphoma
$5.00
Available
Bio-Thera Ok'd to Start China Trial of Biosimilar to JNJ Immune Disease Therapy
$5.00
Available
CASI's In-licensed CAR-T Candidate to Start China Trials for Leukemia/Lymphoma
$5.00
Available
Alphamab Oncology Tees Up $350 Million Hong Kong IPO
$5.00
Available
Luye Pharma to Pay $205 Million to Acquire Shandong Boan Biological
$5.00
Available
Aslan Pharma Raises $12.8 Million in NASDAQ Secondary Offering
$5.00
Available
China Adds 70 Drugs to Insurance Reimbursement List; Negotiates 61% Average Price Cuts
$5.00
Available
EOC Pharma Raises $71 Million in C Round for China Development of In-Licensed Oncology Drugs
$5.00
Available
Munich's ViGeneron Closes Series A from WuXi and Sequoia for Gene Therapies
$5.00
Available
Pharmaron Stages $434 Million Hong Kong IPO, after Completing Shenzhen IPO in January
$5.00
Available
Clover Biopharma Completes $43 Million Financing for Biologic Drug Development
$5.00
Available
Ennovabio Closes $14 Million Series A Round for Novel Drug Development
$5.00
Available
GensKey Raises $14 Million for Genetics-based Diagnosis of Pathogens
$5.00
Available
Merck Announces Third Approval of Keytruda for Lung Cancer in China
$5.00
Available
Innovent and Hanmi Start China Trials of PD-1/HER2 Bispecific
$5.00
Available
Chi-Med's Surufatinib Granted Orphan Status in US
$5.00
Available
Lee's Pharm Affiliate Conducting China Phase III Trial of Combo Treatment for Severe Acne
$5.00
Available
Ascentage Building Headquarters, R&D Center, Manufacturing Facility in Suzhou
$5.00
Available
CStone Starts Bridging Trial of Leukemia Treatment in China
$5.00
Available
Clover Starts Fifth Clinical Trial of TRAIL-Trimer Fusion Candidate
$5.00
Available
BrightGene Completes $74 Million Shanghai Star Board IPO; Trades 141% Higher
$5.00
Available
Lansion Bio Closes $14 Million C Round for IVD Portfolio
$5.00
Available
3SBio and Verseau Choose First Candidate in Microphage Immunotherapy Partnership
$5.00
Available
Fosun Kite In-licenses CAR-T Candidates for Solid Tumors from Phanes
$5.00
Available
Novartis Refocuses Shanghai Research Institute on Drug Development, not Discovery
$5.00
Available
Fosun to Pay up to $148 Million for China Rights to MimiVax Glioblastoma Treatment
$5.00
Available
GenScript Forms Bispecific Partnership with Korea's ABL Bio
$5.00
Available
BeiGene BTK Cancer Drug Approved in US for Lymphoma
$5.00
Available
Everest Starts China Phase III Trial of Ulcerative Colitis Treatment
$5.00
Available
BeiGene's PD-1 Recommended for Approval by China's CDE
$5.00
Available
Chi-Med's NDA for Surufatinib Accepted by China's NMPA for Review
$5.00
Available
Shanghai Anovent Closes Funding Led by Sequoia for Respiratory Drugs
$5.00
Available
Aslan's Varlitinib Fails to Meet Goals in Phase III Trial
$5.00
Available
Hua Reports Positive Phase III Data for Novel Type 2 Diabetes Drug
$5.00
Available
Leo Pharma Licenses Novel Dermatology Molecules Discovered by HitGen
$5.00
Available
TenNor Announces Positive Results from US Trial of Novel Anti-bacterial
$5.00
Available
Akeso Presents Positive Trial Results from PD-1/CTLA-4 Candidate
$5.00
Available
Tot Biopharm Completes $66.5 Million Hong Kong IPO
$5.00
Available
Antengene Acquires Global Rights to AstraZeneca Cancer Candidate
$5.00
Available
Bio-Thera Approved to Launch Humira Biosimilar in China
$5.00
Available
Peijia Medical Raises $100 Million for Medical Device Development
$5.00
Available
Ark Bio Reports Positive Results from Phase II Trial of Novel RSV Treatment
$5.00
Available
BeiGene Enters $160 Million Deal for Rights to Seattle Genetics Cancer Molecule
$5.00
Available
Genecast Closes $43 Million VC Funding for Cancer Diagnostics
$5.00
Available
Simcere In-Licenses China Rights to Clinical-Stage Stroke Treatment
$5.00
Available
CANbridge OK'd to Launch Breast Cancer Drug in Hong Kong
$5.00
Available
SinoMed, a Medical Device Company, Stages $50 Million IPO on the Shanghai STAR Exchange
$5.00
Available
Akeso Closes $150 Million Series D for Antibody Development
$5.00
Available
Harbour BioMed Starts Australian Trial of CTLA-4 Checkpoint Inhibitor
$5.00
Available
Ascentage and Henlius to Test Two-drug Combination in China Leukemia Trial
$5.00
Available
Shanghai Green Valley Surprises with China Approval for Alzheimer's Treatment
$5.00
Available
QYuns Out-Licenses Ex-China Rights for Autoimmune Portfolio to Seneca
$5.00
Available
Denovo Closes $43 Million B Round for Biomarker Driven Drug Development
$5.00
Available
I-Mab Files for $100 Million IPO on the NASDAQ Exchange
$5.00
Available
QnQuality Pharma Raises $15 Million for Oncotherapy Side-Effect Drugs
$5.00
Available
QnQuality Pharma Raises $15 Million for Oncotherapy Side-Effect Drugs
$5.00
Available
Terns Granted US Fast Track Status for NASH Candidate
$500.00
Available
Ascentage Pharma Rises 10% in First Trading Session after IPO
$5.00
Available
Ansun Biopharma Reports China Approvals for Two Trials of Anti-Infective
$5.00
Available
China Aesthetics Company Completes $30 Million US IPO
$5.00
Available
YiXi Biotech Closes Angel Round for Microbial Treatments
$5.00
Available
Visen Pharma Approved for China Phase III Trial of Growth Hormone Drug
$5.00
Available
Ascentage Pharma Completes $53 Million Hong Kong IPO
$5.00
Available
Beijing's Fountain Medical Raises $62 Million for Clinical CRO Services
$5.00
Available
NeuroRx Lines Up $95 Million for US-China Trials of Suicide-Prevention Drug
$5.00
Available
Taiwan's TLC Completes $27 Million Secondary Offering
$5.00
Available
Milu Labs Signs MOU with Thermo Fisher for Women's Health Diagnostics in China
$5.00
Available
NovoCodex Acquires China Rights to Second Ambrx ADC Candidate
$5.00
Available
HighTide Completes Enrollment in US Phase II Trial of NASH Candidate
$5.00
Available
Brii Bio In-licenses China Rights to Three Novel Qpex Anti-Infectives
$5.00
Available
WuXi Biologics to Build Facility for $3 Billion Vaccine in Ireland
$5.00
Available
New Horizon Health Signs Up Prenetics to Market Colorectal Test
$5.00
Available
Verseau Raises $50 Million for Macrophage Immunotherapies; 3SBio Has China Rights
$5.00
Available
Merck Opens Shanghai Innovation Hub with $14 Million for China Startups
$5.00
Available
Exegenesis Bio Closes $10 Million Initial Funding from China Investors
$5.00
Available
Taimei Technology Raises $212 Million to Advance CRO/Life Science Software
$5.00
Available
Boji Medical and Great Bay Bio Form JV for Long-Acting Anemia Biologic
$5.00
Available
Eisai Approved to Launch Antiepileptic Drug in China
$5.00
Available
dMed Biopharma, a China, US, EU Clinical CRO, Raises $50 Million
$5.00
Available
Shaanxi Micot Raises $16 Million for Bispecific Polypeptide Candidates
$5.00
Available
Chengdu's HitGen Partners with Galapagos for Drug Discovery
$5.00
Available
San Diego's Ansun Bio Closes $80 Million B Round from China Investors for Novel Antiviral
$5.00
Available
Luqa Pharma Approved to Market Adare Diarrhea Treatment in China
$5.00
Available
CanSino to Add Shanghai Star Board IPO to Hong Kong Listing
$5.00
Available
I-Mab Approved for Two China Trials of Multiple Myeloma Treatment
$5.00
Available
BJ Bio Selects CMAB for CMC and Manufacturing of Cancer mAb
$5.00
Available
Harbour BioMed Completes China Phase II Trial of Dry Eye Treatment
$5.00
Available
Kangpu Completes Phase I Trial of Cancer Immunomodulator
$5.00
Available
China Grand Pharma Pays $30 Million for Majority Stake in US-Based OncoSec
$5.00
Available
Innovent and Chi-Med Add Second Chi-Med Drug to Combo Partnership
$5.00
Available
Chengsheng Bio Delisted following Major Vaccine Scandal
$5.00
Available
CTFH and Insilico Form $200 Million AI-Based Drug Discovery Partnership
$5.00
Available
Chi-Med Starts Global Trial of Syk Inhibitor In Lymphoma Patients
$5.00
Available
Chipscreen Bio Partners with Novogene on Diagnostics for Chiauranib
$5.00
Available
CBMG Announces Plans to Build US R&D Facility for Immunotherapies
$5.00
Available
Beijing Gene+ Completes $28 Million B Round for Genetic Test Services
$5.00
Available
Innovent Bio Completes $300 Million Secondary Offering in Hong Kong
$5.00
Available
I-Mab Approved to Start China Trials of CD73 Antibody
$5.00
Available
Merck's Keytruda Approved as Monotherapy for Lung Cancer in China
$5.00
Available
IASO and Innovent Approved to Start Trial of Novel CAR-T Immunotherapy
$5.00
Available
Hrain Biotech Raises $28 Million in B Round for Immunotherapies
$5.00
Available
CanSino Partners with Ocugen to Develop Gene Therapy Eye Treatment
$5.00
Available
Aslan and Bukwang Form JV to Develop Aslan's Immunoncology Assets
$5.00
Available
Clover Starts Fourth Phase I Trial of TRAIL-Trimer Fusion Candidate
$5.00
Available
Simcere In-licenses Novel Gout Treatment from JW Pharma of Korea
$5.00
Available
Changmugu Completes $3 Million Pre-A Round for AI-Orthopedics Plans
$5.00
Available
Frontier Bio and Thermo Fisher to Collaborate on Novel HIV Candidate
$5.00
Available
Shandong's Blue Sail Acquires New Valve Technology for $160 Million
$5.00
Available
Guanhao Bio Pays $3.1 Million to Acquire Stake in US-based ZY Therapeutics
$5.00
Available
Henlius Sells Southeast Asia Rights for PD-1 to Kalbe Genexine in $692 Million Deal
$5.00
Available
I-Mab to Test CD47 mAb in Combination with Merck's Keytruda
$5.00
Available
CARsgen Announces EU PRIME Review Status for BCMA CAR-T Candidate
$5.00
Available
Sinopharm Invests in US Aesthetics Company; Acquires China Rights to Gel Implant
$5.00
Available
Qihan Biotech's Series A Reaches $25.5 Million for Animal-to-Human Transplants
$5.00
Available
CStone Reports Positive Results from PD-L1 Trial in Solid Tumors
$5.00
Available
AllinMD Closes $100 Million Series B for Online/Hospital Orthopedic Services
$5.00
Available
Chipscreen's NDA for Novel Type 2 Diabetes Drug Accepted for China Review
$5.00
Available
China Biologic Products Receives $4.6 Billion Takeover Offer
$5.00
Available
Henlius Prices Hong Kong IPO at the Bottom of the Range, Raising $410 Million
$5.00
Available
Innovent's Avastin Biosimilar Matches Efficacy of Original in Phase III Trial
$5.00
Available
Ping An Leads $15 Million Round in Riverain, a US Imaging Software Company
$5.00
Available
Covance Opens New Clinical CRO Facility in Shanghai
$5.00
Available
Shanghai Pharma Forms $250 Million China Antibody JV with Russia's Biocad
$5.00
Available
Genecast (Beijing) and US-based Interpace Form Diagnostics Partnership
$5.00
Available
EdiGene Adds $11 Million to Pre-B Round for Novel Drugs Based on Gene Editing
$5.00
Available
Vision Medicals Closes $14 Million A Round for Early Pathogen Detection
$5.00
Available
CASI Files for China Trials of CD19 CAR-T Candidate
$5.00
Available
Jiuzhou Pharma Pays $16 Million to Acquire US-based API CDMO
$5.00
Available
Stroke Medical of Shanghai Lands $14 Million for Medical Devices
$5.00
Available
Hansoh Forms $1.5 Billion Partnership with Atomwise, an AI Drug Discovery Company
$5.00
Available
Genenta Science of Milan Raises $14.6 Million in Funding Led by China Investor
$5.00
Available
Gracell Reports Positive Results from FasT CAR-19 Cell Gene Therapy
$5.00
Available
Cellular Bio Starts China Trial of Stem Cell Treatment for Arthritic Knees
$5.00
Available
Henlius Biotech Prices Hong Kong IPO to Raise $477 Million
$5.00
Available
SoliPharma of Hangzhou Raises $36.5 Million to Develop High End Generics
$5.00
Available
Insilico Closes $37 Million Series B for AI Drug Discovery from China Investors
$5.00
Available
I-Mab to Test its CD73 Antibody in Combination with Junshi's PD-1 mAb
$5.00
Available
Sichuan Clover Doses First Patient in China Trial of Novel Cancer Biologic
$5.00
Available
CANbridge Granted China Priority Review for Rare Disease Treatment
$5.00
Available
JHL Biotech Settles IP Suit with Genentech, Discontinuing Development of Four Genentech Biosimilars
$5.00
Available
Laviana Raises $14 Million for CDMO Operations in China
$5.00
Available
AstraZeneca, Wuxi City Partner to Open New China Life Science Park
$5.00
Available
PAG Pays $540 Million for Majority Stake in Hisun BioRay, a Biologics Company
$5.00
Available
Novartis Sells Suzhou API Plant to Zhejiang Jiuzhou for $110.5 Million
$5.00
Available
Meditool Shanghai Raises Capital for 3D Printed Neuro/Spine Implants
$5.00
Available
Beijing's Immunotech Plans to Raise up to $200 Million in Hong Kong IPO
$5.00
Available
BrightGene Plans $50 Million Shanghai STAR Board IPO
$5.00
Available
Just Medical, an Orthopedics Device Company, Raises $14.5 Million
$5.00
Available
Quan Capital Closes Second Healthcare Fund at $275 Million
$5.00
Available
WuXi AppTec Launches DELight, a Self-Service Drug Discovery Hit Finding Kit
$5.00
Available
AstraZeneca's Tagrisso Approved in China as First-Line Lung Cancer Treatment
$5.00
Available
Temasek, Hillhouse Pay $259 Million for 2% Stake in China's Aier Eye Hospital
$5.00
Available
Chunli to Market Novel Orthopedic Implants from Germany's Syntellix in China
$5.00
Available
CARsgen Awarded US Orphan Drug Status for BCMA CAR-T Candidate
$5.00
Available
Huimei Closes $30 Million Round for AI-based Hospital Clinical Decision Support
$5.00
Available
China Passes Comprehensive New Drug Administrative Law
$5.00
Available
Innovent Reports $46 Million of Revenue for its PD-1 in 2019 First Half
$5.00
Available
HiFiBiO Closes $67 Million C Round for Immune Modulators
$5.00
Available
CC-Pharming Acquires Rights to Rituxan Biosimilar from Partner iBio
$5.00
Available
Ascletis Pharma's NASH Treatment Approved for China Trials
$5.00
Available
Zuga Raises Funds for Personalized Dental Implant Products Made in the Dentist's Office
$5.00
Available
Harbour BioMed to Collaborate with PPD on Clinical Development
$5.00
Available
BeiGene's US NDA Filing for BTK Inhibitor Accepted by FDA
$5.00
Available
China Allows Importation of "Small" Amounts of Non-China-Approved Drugs
$5.00
Available
CStone to Begin Australian Trials of Solid Tumor Cancer Drug
$5.00
Available
Luye Pharma Approved to Start Japan Trials of Novel Anti-depressant
$5.00
Available
Yaoyanshe Raises $42 Million for On-Line CRO/CMO Services
$5.00
Available
Biotheus Signs $142 Million Deal for Alligator Bio TNFR Antibody
$5.00
Available
Innovent Acquires China Rights to Novel Diabetes Drug from Lilly
$5.00
Available
Kintor Pharma Starts CDMO Cooperation with CMAB for ALK-1 Cancer Drug
$5.00
Available
China's LHHC Signs Up Vancouver's Enlighta to Market AI Early Test for Cancer
$5.00
Available
Shenzhen Xpect Vision Closes $14 Million Round for New Imaging Tech
$5.00
Available
CMS Acquires China Rights to Seven Generic Drugs from India's Sun Pharma
$5.00
Available
India's Natco Joins the March to China's Market by Indian Pharmas
$5.00
Available
Nanjing Frontier Biotech Plans $285 Million IPO on Shanghai STAR Exchange
$5.00
Available
Beijing Baicare Closes $9 Million Round for Clinical Diagnostic Devices
$5.00
Available
Qiyu Biotech of Shanghai Completes A Funding Round for Novel Biologics
$5.00
Available
Bio-Thera Starts China Trials of an Arthritis Biosimilar
$5.00
Available
Aslan Presents Progress Update on its Three Clinical Candidates
$5.00
Available
CStone Starts China Arm of Global RET Inhibitor Phase I Trial
$5.00
Available
DelMar Reports Positive Phase II Data from China Trial of GBM Treatment
$5.00
Available
Chipscreen Bio Climbs 367% on First Trading Day following Shanghai IPO
$5.00
Available
Shanghai's Stemirna Raises $14 Million for RNA Drug Development
$5.00
Available
Vapo Health Completes Series A Round for Medical Device Business
$5.00
Available
Zai Lab Granted Expedited China Review for Brain Cancer Medical Device
$5.00
Available
Kangpu Bio-Pharma Completes $14 Million Pre-B Round for Immuno-Modulators
$5.00
Available
Gilead Approved to Bring New Three-Drug HIV Treatment to China
$5.00
Available
Biocytogen, a China Animal Model CRO, Closes $77 Million Series D
$5.00
Available
Nanjing King-Friend Acquires Majority Stake in US Generic Injectables Company for $95 Million
$5.00
Available
PackGene, a Viral Vector/CRISPR company, Completes Venture Round
$5.00
Available
CStone to Build Major R&D and Manufacturing Complex in Suzhou Park
$5.00
Available
Shanghai Newsoara Signs $78 Million Deal for Cancer Treatment
$5.00
Available
Innovent and Shenogen to Test PD-1/Brain Cancer Candidate Combo
$5.00
Available
Ascletis Leads Second Tranche of Sagimet's $25 Million Financing
$5.00
Available
Eureka Therapeutics Starts US Trial of Liver Cancer T-Cell Therapy
$5.00
Available
CGene Tech of Suzhou Raises $14.5 Million in Series A+ Round to Develop Small-Molecule Drugs
$5.00
Available
Shenzhen Chipscreen Raises $148 Million in Shanghai STAR IPO at $1.2 Billion Valuation
$5.00
Available
Jiangsu Zecheng Completes $26 Million Round to Develop Diagnostics
$5.00
Available
Qyuns Therapeutics Announces $20 Million Series B for Autoimmune Treatments
$5.00
Available
I-Mab and Tracon Begin US Trials of CD73 Antibody
$5.00
Available
China's United Family Healthcare Acquired by New Frontier for $1.44 Billion
$5.00
Available
Huadong Signs $60 Million Deal for MediBeacon Medical Diagnostic Devices
$5.00
Available
Zspeplib Announces $14 Million Round for Novel Peptide Drug Discovery
$5.00
Available
Xynomic to Start Two China Pivotal Trials of Novel HDAC Inhibitor
$5.00
Available
TriArm Therapeutics Completes $20 Million Series A Round for Cell Therapies
$5.00
Available
Xiamen Weiyang In-Licenses Low-Dose Interferon Alfa Technology for China
$5.00
Available
Hinova Pharma Completes $40 Million Series B for US-China Trials of Prostate Cancer Drug
$5.00
Available
Sihuan Pharma Forms JV with India's Strides, the Third China-India Pharma JV in Three Months
$5.00
Available
CANbridge Files China NDA for Hunter Syndrome Drug
$5.00
Available
Mingdu Tech Completes $14 Million Series A to Develop Efficient Pharma Programs
$5.00
Available
Qihan Raises $20 Million for Gene Editing to Enable Xenotransplants
$5.00
Available
Wanbang Biopharma In-Licenses Infant Seizure Treatment from Aucta
$5.00
Available
Innovent Tests PD-1 and Avastin Biosimilar Combo in China Lung Cancer Trial
$5.00
Available
UCB's Rheumatoid Arthritis Treatment Approved for China
$5.00
Available
Accuray-CNNC JV Breaks Ground on China Manufacturing Center
$5.00
Available
Initial 25 IPOs on the Shanghai STAR Board Jump 140% Higher in First Session
$5.00
Available
Yisheng's New $60 Million Rabies Vaccine Facility Approved by NMPA
$5.00
Available
CStone Approved to Start China Bridging Trial of Leukemia Drug
$5.00
Available
Ascentage to Start US Trial of Treatment for Drug-Resistant Leukemia Treatment
$5.00
Available
Celltrion Forms JV with Nan Fung to Develop Three Biosimilars in China
$5.00
Available
Shanghai Fosun Partners In-Vitro Lung Cancer Diagnostic with VolitionRx
$5.00
Available
Chipscreen Poised to be One of the First IPOs on Shanghai's STAR Exchange
$5.00
Available
Chengdu New Radiomedicine Raises $14 Million; Will Develop BTG's TheraSphere
$5.00
Available
Abbisko Acquires China Rights to Anti-Immunosuppresive Drug from Boston's X4
$5.00
Available
Cipla Forms $30 Million China Respiratory Drug JV with Jiangsu Acebright
$5.00
Available
EdiGene, a Beijing CRISPR/Cas9 Editing Company, Sells Knockout Cell Line Library to Abcam
$5.00
Available
Suzhou's Alphamab Oncology Approved to IPO on Hong Kong Exchange
$5.00
Available
Harbour Antibodies Partners with Abveris, a Boston Drug Discovery CRO
$5.00
Available
I-Mab Ok'd to Start China Trials of CD47 Immunotherapy
$5.00
Available
HitGen Approved for $97 Million IPO on Shanghai's STAR Board
$5.00
Available
Ascentage Starts China Trial of Apoptosis Cancer Drug
$5.00
Available
Miaoshou Doctor Completes $73 Million C+ Round at $1 Billion Valuation
$5.00
Available
Novartis Plans to File 50 NDAs in China over the Next Five Years
$5.00
Available
I-Mab Forms $150 Million China Immunotherapy Partnership With MacroGenics
$5.00
Available
Gilead Sciences Plans Western China Ops Center in Chengdu
$5.00
Available
SinoMab Bioscience, a Hong Kong Biotech, to IPO on Hong Kong Exchange
$5.00
Available
CStone Starts China Bridging Trial of GIST Candidate
$5.00
Available
Politics Reduces China VC Investing in US Life Science Companies by 60%
$5.00
Available
Fosun Pharma Pays $36 Million to Acquire GSK Suzhou Manufacturing Facility
$5.00
Available
BeiGene Granted Second China Priority Review for PD-1 Candidate
$5.00
Available
Zhongyianke Bio Raises $36 Million to Expand Vaccine Portfolio
$5.00
Available
SynyiAI Completes $36 Million Funding for AI Healthcare Big Data
$5.00
Available
Ocumension Signs $13.5 Million Deal for China Rights to Nicox Anti-Inflammatory Eye Drug
$5.00
Available
Lepu Bio Raises $131 Million in Series A Funding for Immunotherapies
$5.00
Available
Zai Lab Announces $77.5 Million Collaboration for Incyte's PD-1 mAb
$5.00
Available
Asieris Enters $73 Million Agreement for Global Rights to Cervical Lesion Treatment
$5.00
Available
Yuhan Out-Licenses NASH Treatment to Boehringer in $870 Million Deal
$5.00
Available
Chi-Med's Parent, C.K. Hutchison, Sells $288 Million of Chi-Med Stock
$5.00
Available
China Medical In-Licenses Dry Eye, Psoriasis Treatments from India's Sun Pharma
$5.00
Available
Beijing's ChosenMed Partners with Integrated DNA of the US on Cancer Diagnostics
$5.00
Available
J&J Opens JLABS @ Shanghai, a Life Science Incubator with 31 Resident Startups
$5.00
Available
Yisheng Cleared to Start China Trials of PIKA-based Cancer Immunotherapy
$5.00
Available
Tasly Biopharma Files for Hong Kong IPO That Could Raise $1 Billion
$5.00
Available
MicroPort Ortho Launches Improved Knee Replacement Product
$5.00
Available
Terns Enters $228 Million Agreement with Genfit for NASH Candidate
$5.00
Available
Sinopharm Leads $20 Million Investment in Singapore's Novena; Plans Joint $150 Million Healthcare Fund
$5.00
Available
dMed and Target Join to Offer China-US Clinical CRO Services
$5.00
Available
Eddingpharm In-Licenses Shionogi Thrombocytopenia Treatment
$5.00
Available
Wuhan's XW Labs Gains US Orphan Drug Status for Narcolepsy Drug
$5.00
Available
Gracell Reports Positive Results for FasT CAR-19 in Leukemia Patients
$5.00
Available
Henlius Has First China-Developed Biosimilar Accepted for EU Review
$5.00
Available
Akeso Forms $100 Million JV with CTTQ to Develop PD-1 Candidate
$5.00
Available
dMed, a Shanghai Clinical CRO, Opens Washington Office
$5.00
Available
Cellular Bio Starts Phase I China Trial of CD20 CAR-T
$5.00
Available
CARsgen Given Green Light for US Trials of BCMA CAR-T Candidate
$5.00
Available
BeiGene and SpringWorks Form MapKure to Test B-RAF Inhibitor in Solid Tumor Cancers
$5.00
Available
CASI Acquires Global Rights To CD19 T-Cell Therapy; Will Make $11.6 Million Investment
$5.00
Available
Chi-Med's Surufatinib Meets Survival Endpoint -- Trial Stopped Early
$5.00
Available
Innovent's BCMA CAR-T Produces 100% Response Rate in Myeloma Patients
$5.00
Available
Jiangsu Hengrui In-Licenses Treatment for Yeast Infection from Mycovia
$5.00
Available
Hansoh Completes $1 Billion Hong Kong IPO; Rises 37% in First Trading Session
$5.00
Available
Shanghai Launches New Exchange for High-Tech Companies Including Biopharmas
$5.00
Available
Reistone Starts Global Trial of China-Discovered JAK1 Inhibitor for IBD
$5.00
Available
Tessa Forms $120 Million China JV to Develop Cell Therapies for Cancer
$5.00
Available
Terns Starts US Trial of Lead Drug, a NASH Candidate
$5.00
Available
Deepwise Completes C Round for China AI Medical Imaging Diagnostics
$5.00
Available
Xynomic Completes Pre-IND Conference with US FDA for RAF Inhibitor
$5.00
Available
Zai Lab Acquires China Rights to GIST Treatment in $205 Million Deal
$5.00
Available
Shanghai's Brii Bio Invests in Artizan; Gains China Rights to Microbiota Treatment for IBD
$5.00
Available
Shanghai GT Apeiron Launches; Partners with AI Drug Discovery Company Excientia
$5.00
Available
CStone to Start Combo Trial of its PD-L1 with Bayer's Stivarga for Gastric Cancer
$5.00
Available
Everest Acquires China Rights to Kidney Disease Treatment in $121 Million Pact
$5.00
Available
Oncologie Completes $80 Million B Round for US-China Oncology Development
$5.00
Available
China to Audit 77 Pharmas after Kangmei Reports $4.4 Billion Fraud
$5.00
Available
RemeGen Announces Positive Results for HER2 ADC in Urothelial Cancer
$5.00
Available
Xynomic Starts US Trial of Abexinostat-Inbruvica Combo for Lymphoma
$5.00
Available
CStone OK'd to Start China Combination Trials of PD-L1 in HCC
$5.00
Available
Ascentage Reports Positive Trial Data for Two Apoptosis Candidates
$5.00
Available
Shanghai's EpimAb Completes $74 Million Series B for Bi-Specific Antibodies
$5.00
Available
BioMarin Approved in China for Very-Rare Disease Treatment
$5.00
Available
Frontage, a US-China CRO, Completes $205 Million Hong Kong IPO
$5.00
Available
Innovent Announces Data on Four China Trials of Approved PD-1 Drug
$5.00
Available
HitGen Forms Drug Discovery Partnership with Gilead Sciences
$5.00
Available
Innovent Releases Positive Phase III Data on Avastin Biosimilar at ASCO
$5.00
Available
Hansoh Seeks to Raise $1 Billion at Top of Hong Kong IPO Range
$5.00
Available
Hengrui Medicine's PD-1 Drug Approved in China for Lymphoma
$5.00
Available
Pfizer Upjohn Opens Global Headquarters in Shanghai
$5.00
Available
Benchmark Botanics Forms $10 Million Cannabis JV with Yatai Pharma
$5.00
Available
Harbour BioMed Signs mAb Discovery Deal with Global Top Ten Biopharma
$5.00
Available
Sihuan Pharma Approved to Start China Trials of Third-Gen EGFR Inhibitor
$5.00
Available
Suzhou's Alphamab Closes $60 Million Series B for Biologic Oncology Portfolio
$5.00
Available
Panacea Venture Raises $180.5 Million to Back Early Stage Healthcare Companies
$5.00
Available
New Horizon Health Closes $66 Million C Round for Diagnostics
$5.00
Available
Shanghai Allist Pharma Completes $174 Million A Round
$5.00
Available
Joinn Labs to Acquire US-Based Biomere, a Pre-clinical CRO, for $27.3 Million
$5.00
Available
CStone's In-Licensed Cancer Treatment Meets Endpoints in Phase III Trial
$5.00
Available
WuXi Biologics Signs LOI for $3 Billion Vaccine Manufacturing Contract
$5.00
Available
Xynomic Presents Positive Long-Term Data on Lead Oncology Candidate
$5.00
Available
Exuma Reports Positive Early Results from China Trial of Conditionally Active Biologics
$5.00
Available
Sandoz Approved to Launch Crestor, a Generic Statin, in China
$5.00
Available
Hangzhou's AnHeart Completes $14.6 Million A Funding from Decheng
$5.00
Available
ChemPartner Adds B Cell Discovery to Berkeley Lights Collaboration
$5.00
Available
Leads Biolabs Grants License for Inhaled Delivery of Immunotherapies
$5.00
Available
WuXi Biologics Starts Building Chengdu Manufacturing Plant, its 12th Globally
$5.00
Available
Xynomic Closes $191.6 Million Merger with Bison Capital; Now Listed on Nasdaq Exchange
$5.00
Available
Winhealth to Market Two Cumberland Pharma Pain Drugs in China
$5.00
Available
Mindray Signs Agreement to Use Masimo's Pulse Oximetry Technology in Monitors
$5.00
Available
Innovent and Lilly Report MabThera/Rituxan Biosimilar Meets Endpoints
$5.00
Available
MGI Tech, a BGI Subsidiary that Makes Gene Sequencers, Raises $200 Million
$5.00
Available
HanX Biopharma Signs $51.5 Million Agreement for Onconova MDS Treatment
$5.00
Available
Viva Biotech Completes $194 Million Hong Kong IPO; Trades Higher
$5.00
Available
Ally Bridge Leads $65 Million Round in Pulmonx, a COPD Device Company
$5.00
Available
Innovative Cellular Presents Data on Novel CD19 CAR-T Therapy
$5.00
Available
Harbour BioMed and CTTQ Partner to Discover New Cancer/Immune Drugs
$5.00
Available
GeneQuantum Raises $15 Million for Novel ADC Drug Discovery
$5.00
Available
India's Alembic Pharma Forms JV to Market Generics in China
$5.00
Available
India's Alembic Pharma Forms JV to Market Generics in China
$5.00
Available
TAKE2 Health In-licenses IP for Nasopharyngeal Cancer Blood Test
$5.00
Available
WuXi AppTec Acquires San Diego's Pharmapace, a Biometrics CRO
$5.00
Available
Connect Bio Reports Positive Phase I Data for Atopic Dermatitis Treatment
$5.00
Available
Zai Completes $200 Million Follow-on Financing as It Nears Commercialization of Two Products
$5.00
Available
QTC Care Raises $7 Million for Online Healthcare in an A Funding Led by Tencent
$5.00
Available
CStone Acquires China Rights to Tri-Specific Cancer Immunotherapy from Numab
$5.00
Available
Ascletis and 3-V Bio Start US-China Trial of NASH Candidate
$5.00
Available
Viva Biotech Raising $194 Million in Hong Kong IPO for CRO Operations
$5.00
Available
Digital China Participates in $17 Million Funding for UK's Congenica
$5.00
Available
I-Mab Starts Second China Trial of CD38 Antibody for Multiple Myeloma
$5.00
Available
Everest Pays $65 Million Upfront in $835 Million Agreement for Greater China Rights to Immunomedics ADC
$5.00
Available
Luye Pays $5 Million Upfront for China Rights to PharmaMar's SCLC Treatment
$5.00
Available
Sinovant to Start China Trials of Derazantinib for Bile Duct Cancer
$5.00
Available
Sirnaomics, a US-China RNAi Company, Completes $47 Million C Funding
$5.00
Available
MicroPort Co-Leads $20 Million Investment in Israel's Rapid Medical
$5.00
Available
TaiGen and HEC Start China Phase III Trial of Dual-Drug HCV Treatment
$5.00
Available
Tencent Trusted Doctors Raises $250 Million for Online/Off-line Healthcare
$5.00
Available
Adagene and ADC Therapeutics Partner to Discover Novel Drug Conjugate
$5.00
Available
Hua Medicine Starts New US Combination Trial of GKA Diabetes Candidate
$5.00
Available
WuXi AppTec Pays $46.4 Million to Acquire 15% Stake in its STA Subsidiary
$5.00
Available
Sinovac Reports Positive Polio Vaccine Results
$5.00
Available
Golden Meditech Collaborates to Develop Stem Cells for Neurodegeneration
$5.00
Available
CStone Starts Phase III Trial of PD-L1 Candidate in Gastric Cancer Patients
$5.00
Available
Innovent Starts China Trials of Bi-Specific Wet AMD Treatment
$5.00
Available
CASI Pharma Pays $7.7 Million for Global Rights to CD38 Immunotherapy
$5.00
Available
I-Mab Forms CDMO Partnership with WuXi Biologics
$5.00
Available
BioSense Acquires China Rights to Rexahn's Pancreatic Cancer Drug in $226 Million Deal
$5.00
Available
GenScript Starts Construction of Cell Therapy and Antibody Manufacturing Facility
$5.00
Available
BioAtla and Sinobiopharma Form JV to Develop CAB Cancer Drugs in China
$5.00
Available
Servier Partners with Mitsubishi to Promote Diabetes Treatment in China
$5.00
Available
CStone Approved to Start China Bridging Trial of GIST Candidate
$5.00
Available
Chi-Med Plans $500 Million IPO in Hong Kong, its Third Listing
$5.00
Available
Hansoh Pharma Re-Files for $500 Million to $1 Billion Hong Kong IPO
$5.00
Available
Creative Bio of Guangzhou Raises $45 Million for Early Colorectal Cancer Test
$5.00
Available
Luqa Acquires China Rights to Topical Antibiotic from Spain's Ferrer
$5.00
Available
Shiyu Capital Closes Second China Healthcare Fund with $473 Million
$5.00
Available
Cullgen of San Diego Raises $16 Million in Series A from China Investors
$5.00
Available
I-Mab and Roche Collaborate on US Trials for Dual Immunotherapy Regimen
$5.00
Available
Shanghai Miracogen Signs $125 Million Deal to Use Synaffix ADC Technologies
$5.00
Available
Hengrui and LSK Approved to Start US Trial of PD-1/VEGF-2 Combination
$5.00
Available
BeiGene Enters $269 Million Agreement for BioAtla's CTLA-4 Inhibitor
$5.00
Available
Fosun Pharma Acquires Rights to ReNeuron Cell Therapies in $113 Million Deal
$5.00
Available
Junshi and Ascentage Partner to Test PD-1/IAP Combination
$5.00
Available
I-Mab Bio and Jiangsu Nhwa Pharma Join China-US-Canada CNS Collaboration
$5.00
Available
US Government Forces US Healthcare Company to Divest Investment From China's iCarbonX
$5.00
Available
Cytovant of China Enters $1 Billion Deal for Four Medigene Immunotherapies
$5.00
Available
Ally Bridge and LifeTech Form Medical Device JV with France's Quantum
$5.00
Available
Ally Bridge and LifeTech Form Medical Device JV with France's Quantum
$5.00
Available
Novartis' First-in-Class Biologic Psoriasis Treatment Approved in China
$5.00
Available
Jia Miao Announces $74.4 Million C Round for Online Health Management
$5.00
Available
China Approves Merck's Keytruda, a PD-1 Drug, for First Line NSCLC
$5.00
Available
Sichuan Haisco Invests $6 Million in eXithera, Gains China Rights to Novel Anti-Coagulant
$5.00
Available
Transcenta In-licenses Rights to Bone Disease Biotherapies from Lilly
$5.00
Available
AstraZeneca Signs MOU to Become Founding Partner of Life Science Park in Wuxi, China
$5.00
Available
Luye Pharma Files for US Approval of Schizophrenia Treatment
$5.00
Available
CanSino Biologics Climbs 58% Following $161 Million Hong Kong IPO
$5.00
Available
Dingdang Raises $89 Million for Online Drug Delivery Service
$5.00
Available
Shanghai Fosun Long March Signs MOU with VolitionRx, a Diagnostics Company
$5.00
Available
Shuidichou Closes $74 Million Series B for Internet Health Insurance Platform
$5.00
Available
Hefei Tianhui OK'd to Start China Trials of In-licensed Oral Insulin
$5.00
Available
Medtronic Launches Collaborative Shanghai Accelerator for Medical Devices
$5.00
Available
Lee's Pharm Accelerates Eye Drop Development as Part of New Ophthalmic Division
$5.00
Available
HitGen Forms Dermatology Lead Discovery Partnership with Spain's Almirall
$5.00
Available
Shanghai's Abbisko Therapeutics Raises $28 Million for Cancer Drugs
$5.00
Available
Innovent Starts US Trial of "Pivotal" CD47 Immunotherapy
$5.00
Available
I-Mab Starts Greater China Trials of CD38 Antibody for Myeloma
$5.00
Available
Tianjin's CanSino to Raise $160.5 Million for Novel Vaccines in Hong Kong IPO
$5.00
Available
BGI's GenoImmune Raises $18 Million for Neoantigen Discovery Services
$5.00
Available
Merck Signs MOU with GenScript for China Plasmid and Viral Vector Manufacturing
$5.00
Available
I-Mab Starts US Trial of GM-CSF Immunotherapy for Rheumatoid Arthritis
$5.00
Available
Sinopharm Partners with ImmBio on Broad-Spectrum Pneumonia Vaccine
$5.00
Available
Xynomic Extends Phase III Abexinostat Trial to China and Europe
$5.00
Available
Yunhu Completes A+ Round for Internet-based China Primary Medical Care
$5.00
Available
HitGen to Discover Small Molecule Leads for India's Sun Pharma Unit
$5.00
Available
Dr. Zhengqing Li, an Experienced China Pharma Exec, Joins Ascletis
$5.00
Available
CStone Approved to Start China Trial of HDAC6 Inhibitor
$5.00
Available
CASI Pharma Signs Up CR Guokang Pharma to Distribute Evomela in China
$5.00
Available
Shanghai's InventisBio Closes $70 Million C Round for Novel Drug Portfolio
$5.00
Available
CARsgen Approved to Start China Trials of BCMA CAR-T Candidate
$5.00
Available
BGI Genomics Pays $50 Million for China Rights to Natera Cancer Test
$5.00
Available
Newsoara Acquires Asia Rights to NASH Candidate in $26 Million Deal
$5.00
Available
Spain's Grifols Acquires Stake in Shanghai RAAS, a Plasma Company, for $1.9 Billion
$5.00
Available
Novo Nordisk Launches New Collaborative Innovation Platform in China
$5.00
Available
CASI Pharma Approved To Start China Trial of Leukemia Treatment
$5.00
Available
Ambrx and BeiGene Form $475 Million Protein Drug Discovery Partnership
$5.00
Available
China Finalizes IPO Listing Rules for Shanghai High-Tech Board
$5.00
Available
I-Mab Starts China Trial of In-licensed Interleukin for Solid Tumors
$5.00
Available
WuXi Biologics Signs $220 Million Bi-Specific Deal with ABL Bio of South Korea
$5.00
Available
3SBio Will Pay $50 Million Upfront for China Rights to Two TLC Products
$5.00
Available
China Strengthens Clinical Trial Approval Rules for Cell and Gene Therapies
$5.00
Available
Aslan Out-Licenses Korean Rights for Oncology Drug in $13 Million Deal
$5.00
Available
Nanjing's NJCTTQ Signs $4 Billion In-Licensing Deal for Bi-Specific Immunotherapies from Abpro
$5.00
Available
Innovent Combines PD-1 with Avastin Biosimilar in China HCC Trial
$5.00
Available
Beijing Surgerii Completes A Round for Next-Gen Robotic Surgery Device
$5.00
Available
Shanghai Henlius' Rituxan Biosimilar is First Biosimilar Approved in China
$5.00
Available
Xynomic Starts Phase III Trial of HDAC Inhibitor in South Korea
$5.00
Available
Solasia Announces China Approvals for Two Cancer Side-Effect Treatments
$5.00
Available
WuXi STA Pharma Forms Drug Delivery Collaboration with BioLingus
$5.00
Available
Happy Life and PPD to Offer China Clinical Trial/Post-Marketing Services
$5.00
Available
Hangzhou Sciwind Completes $29.5 A Round for NASH Treatments
$5.00
Available
Shukun Raises $29.5 Million for AI-based Hospital Diagnosis in China
$5.00
Available
HuaSin In-licenses China Rights to HPV Diagnostic from Spain's Genomica
$5.00
Available
Owlstone to Test Breath Biopsy Diagnostic at Shanghai Renji Hospital
$5.00
Available
GenomePrecision Raises $15 Million for Molecular Diagnostics
$5.00
Available
HaiHe Pharma Forms Drug Development/Marketing JV with CSPC
$5.00
Available
Suzhou's CStone Pharma Schedules $304 Million Hong Kong IPO for Next Week
$5.00
Available
Burning Rock of Guangzhou Raises $126 Million for NGS Diagnostics
$5.00
Available
Bioheng Closes $15 Million Funding from Decheng Capital for CAR-T Products
$5.00
Available
Magpie Guangzhou Pharma Completes $15 Million B Round
$5.00
Available
Ascletis Acquires Rights to 3-V Bio's NASH Candidate and Leads $18 Million E Financing
$5.00
Available
Shanghai HaiHe Raises $146.6 Million for Innovative Cancer Drugs
$5.00
Available
China Cuts Value Added Tax on Rare Disease Drugs to 3%
$5.00
Available
C-Bridge In-Licenses China Rights to Three Samsung Bioepis Biosimilars
$5.00
Available
3SBio Forms China Partnership with Verseau for Macrophage Checkpoint Modulators
$5.00
Available
China Resources Launches $300 Million Life Science Fund
$5.00
Available
China to Review IND Filing for CStone/Impact PD-L1/PARP Combo
$5.00
Available
HiberCell Raises $61 Million to Target Cancer Metastases; China Investors Participate
$5.00
Available
Innovent Approved to Start China Trials of Bi-Specific PD-1 Candidate
$5.00
Available
Bolt Bio Closes $54 Million Round Led by Hong Kong's Pivotal/Nan Fung
$5.00
Available
MicuRx Acquires China Rights to Gram-Negative Anti-Microbial
$5.00
Available
WuXi NextCODE Participates in $68 Million DNAnexus Funding
$5.00
Available
Indivior Out-Licenses China Rights To Opioid Treatment in $122.5 Million Pact
$5.00
Available
EdiGene Completes $10 Million Round for Gene Editing-based Discovery
$5.00
Available
Suzhou GeneQuantum Collaborates with MITRO on ADC Candidates
$5.00
Available
Qiming to Raise $250 Million for Second US Dollar Healthcare Fund
$5.00
Available
I-Mab Signs Collaboration MOU with Hong Kong's Bio-Cancer Treatment
$5.00
Available
Hua Starts US Trial of Lead Type 2 Diabetes Treatment, a GKA Activator
$5.00
Available
Health Hope, an AI Healthcare Company, Completes $15 Million A Round
$5.00
Available
Lyndra Raises $55 Million for Long-Acting Drug Delivery; HOPU Participates
$5.00
Available
Innovent Filing for Approval of Avastin Biosimilar is Accepted in China
$5.00
Available
China Medical System Pays $11 Million for 77% Stake in UK's Midatech
$5.00
Available
CStone to Start China Trial of FGFR4 Inhibitor for Liver Cancer
$5.00
Available
CARsgen Cleared to Start China Trials of CAR-T Liver Cancer Treatment
$5.00
Available
Advent Makes Majority Investment in BioDuro, a US-China CRO
$5.00
Available
I-Mab Approved to Start US Trials of Immunotherapy, its Third US Approval This Month
$5.00
Available
China to Start Shanghai NASDAQ-like Exchange for Young Tech Companies
$5.00
Available
Circassia Enter $35.7 Million Deal for US/China Rights to Neo-Natal Drug
$5.00
Available
Merck CEO: China Will Have a Top 50 Biopharma Company
$5.00
Available
Bio-Thera Starts Global Phase III Trial of Arthritis-targeted Biosimilar
$5.00
Available
Immunochina Closes $20 Million Round for CAR-T Portfolio
$5.00
Available
I-Mab Approved to Start US Trials of Immunotherapy for Solid Tumors
$5.00
Available
iKang Healthcare Closes $1.4 Billion Privatization, Led by Alibaba
$5.00
Available
Nanning Xinzizhu to Distribute AOTI Wound Healing Device in China
$5.00
Available
MabPlex, a China Biologic CDMO, Closes $59 million Series A
$5.00
Available
Boehringer Ingelheim Expands Shanghai Biologics CDMO Facility
$5.00
Available
Cellular Biomedicine Approved to Start China Stem Cell Trial
$5.00
Available
Tyto Care Adds $9 Million to Series C for Telehealth Device/Services
$5.00
Available
Luye Selects AstraZeneca to Market its Anti-Cholesterol Drug in China
$5.00
Available
Ironwood/AstraZeneca Approved to Market IBS-C Treatment in China
$5.00
Available
Innovent Doses First Patient in China Trial of "Don't Eat Me" Inhibitor
$5.00
Available
BeiGene Receives Breakthrough Status in US for BTK Inhibitor
$5.00
Available
Ascletis Acquires China Rights to Alphamab's PD-L1 for Hepatitis B
$5.00
Available
Bio-Thera Out-Licenses Emerging Marking Rights for Avastin Biosimilar to Cipla
$5.00
Available
Medbanks Closes $59 Million D Round for China Oncology Database
$5.00
Available
AirDoc of Beijing Completes Series B for AI-Powered Diagnoses and Data-Mining
$5.00
Available
Aslan Pharma OK'd to Start US Arm of Phase II Trial of AML Treatment
$5.00
Available
Everest Medicines Signs $61.5 Million Deal for Drug Resistant Antibiotic
$5.00
Available
Ascentage Out-Licenses Candidate for Age-Related Eye Disease to Unity Bio
$5.00
Available
Cellular Biomedicine Starts China Trial of CAR-T Drug for Multiple Myeloma
$5.00
Available
Biohaven's IND Filing for Novel Migraine Drug Accepted in China
$5.00
Available
3SBio to Commercialize Multiple Samsung Bioepis Biosimilars in China
$5.00
Available
Ascentage Pharma Forms Clinical Collaboration with MD Anderson Center
$5.00
Available
CANbridge and WuXi Biologics Expand Rare Disease Partnership
$5.00
Available
Adagene Collaborates with NIH Lab to Develop Novel CAR-T Candidate
$5.00
Available
Apollomics, a US-China Company, Raises $100 Million to Develop Cancer Therapies
$5.00
Available
Schr
$5.00
Available
Suzhou's BrightGene Bio-Medical Completes $80 Million Pre-IPO Funding
$5.00
Available
Apic Bio of Massachusetts Raises $40 Million in Series A, Led by Morningside
$5.00
Available
Beijing InnoCare Raises $160 Million for Cancer/Autoimmune Drugs
$5.00
Available
Athenex Out-Licenses China Rights to Keratosis/Oncology Drug for $29.5 Million
$5.00
Available
Connect Biopharma of Suzhou Raises $55 Million for Immune Disease Therapies
$5.00
Available
Thousand Oaks Biopharma Closes $45 Million Series A Funding Round
$5.00
Available
Ascletis's IND Filing for Third HCV Treatment Accepted in China
$5.00
Available
Antengene Completes $120 Million Series B for China Clinical Trials
$5.00
Available
Betta Acquires China Rights to InventisBio EGFR-Inhibitor for $33.5 Million
$5.00
Available
Zai Lab Launches Electric Field Treatment for GBM in Hong Kong
$5.00
Available
Shanghai Industrial Investment to Launch $7.3 Billion Biomedical Fund Next Year
$5.00
Available
Bio-Thera Files to Start China Trials of Cancer Antibody Drug Conjugate
$5.00
Available
FibroGen/AstraZeneca Novel Anemia Drug Approved in China -- Before US/EU Approvals
$5.00
Available
Innovent/Lilly PD-1 Approved in China for Hodgkin's Lymphoma
$5.00
Available
Xynomic Files Three China INDs for Lead Oncology Candidate
$5.00
Available
Venus Medtech Merges with Keystone in China-Israel Medical Device Tie-up
$5.00
Available
Crystal Pharmatech, a China-US Drug Manufacturing Process CRO, Raises $14.5 Million
$5.00
Available
Junshi Biosciences Rises 22% Following $394 Million Hong Kong IPO
$5.00
Available
Shanghai Cell Therapy Closes $136 Million C Round
$5.00
Available
Xynomic Acquires Boehringer Cancer Candidate in $800 Million Deal
$5.00
Available
Ascentage and Genor to Collaborate on Immunotherapy Combination
$5.00
Available
Gan & Lee Out-Licenses Ex-China Rights for Three Diabetes Biosimilars to Sandoz
$5.00
Available
GenomiCare Completes $30 Million Round for China Precision Medicine
$5.00
Available
Autobio Forms $19 Million China IVD JV with Mobidiag and Invests $11.4 Million in the Company
$5.00
Available
Lee's Pharma Enters $22.5 Million Deal for AI-Discovered Preclinical Molecule
$5.00
Available
Junshi Biosciences's Tuoyi is First China-Developed Anti-PD-1 Drug Approved for Marketing
$5.00
Available
Hong Kong's Aptorum Stages $12 Million US IPO for Drug Development
$5.00
Available
VoxelCloud Raises $50 Million for AI-based Clinical Decision Support
$5.00
Available
Innovent Forms Three-Drug $391.5 Million Collaboration with Incyte
$5.00
Available
I-Mab Out-Licenses Rights for Diabetes Drug to CSPC for $22 Million
$5.00
Available
Cerveau Announces Singapore Test of Neuro PET Imaging Agent
$5.00
Available
WuXi AppTec Completes Hong Kong IPO; Finishes First Trading Session Unchanged
$5.00
Available
Innovent Sees Positive Data from China Phase III Trial of Avastin Biosimilar
$5.00
Available
Zai Lab's NDA for PARP Inhibitor Accepted for China Review
$5.00
Available
Lonza to Build Biologics CDMO in China Using GE's Prefabricated Factory
$5.00
Available
Shanghai Junshi Bioscience to Raise $414 Million in Hong Kong IPO
$5.00
Available
WuXi Biologics Announces $450 Million Bispecific Deal with Oxford BioTherapeutics
$5.00
Available
WuXi Biologics Forms BiSpecifics Collaboration with Brii Bio
$5.00
Available
HiFiBiO Forms JV to Develop Novel Cancer Research
$5.00
Available
WuXi AppTec Raises $1 Billion in Hong Kong IPO
$5.00
Available
China Conducts Drug Tenders for Shanghai Market; Prices Drop 46%
$5.00
Available
Brii Bio Forms $128.5 Million Collaboration for Therapeutic Hepatitis B Vaccine
$5.00
Available
China Approves Mundipharma China/Helsinn Anti-Emetic Treatment
$5.00
Available
Fosun Pharma Acquires Rights to Next-Gen Botox-type Drug in $260 Million Deal
$5.00
Available
Fresenius Building China Dialysis Centers Network through Acquisitions
$5.00
Available
Innovent Approved to Start US Trials of Novel Immunotherapy
$5.00
Available
Shenzhen Salubris Invests $10 Million in Viracta; Signs $58 Million Deal for Cancer Drug
$5.00
Available
Legend/Janssen CAR-T Therapy Posts Strong Results in Multiple Myeloma Trial
$5.00
Available
Immunochina Collaborates with Sartorius Stedim for CAR-T Production
$5.00
Available
Chi-Med to Start Four Combination Trials of its VEGFR Inhibitors with PD-1 Candidates
$5.00
Available
Biohaven Sets Up China Subsidiary for Migraine/CNS Drugs
$5.00
Available
WuXi AppTec to Price $1 Billion Hong Kong IPO on December 6
$5.00
Available
Zai Lab Forms $165 Million Cancer Drug Partnership with MacroGenics
$5.00
Available
I-Mab Forms Partnership with Tracon for US Development of Immunotherapies
$5.00
Available
Zhejiang Bossan Out-Licenses Ex-China Rights for EGFR Drug to CBT Pharma
$5.00
Available
BeiGene Forms Cancer Collaborations--Worth up to $1.3 Billion--with Zymeworks
$5.00
Available
WuXi NextCODE to Sequence 400,000 Irish Genomes in $400 Million Study; Closes $200 Million C Round
$5.00
Available
Shanghai Cell Therapy Closes $40 Million C1 Round for Cancer Drugs
$5.00
Available
Chi-Med Launches Fruquintinib, First China-Discovered Cancer Treatment
$5.00
Available
WuXi Biologics Starts Construction on Large Shanghai CDMO Facility
$5.00
Available
Ascletis Acquires China Marketing Rights to Roche's Pegylated Interferon
$5.00
Available
HitGen Forms Neurological Drug Discovery Partnership with Biogen
$5.00
Available
Huadong Medicine Closes $220 Million Acquisition of the UK's Sinclair Pharma
$5.00
Available
Gilead Approved in China to Market Vemlidy for Hepatitis B
$7.00
Available
Alphamab Oncology of Suzhou Closes $100 Million A Round for Cancer Drugs
$5.00
Available
Lilly Seeking Up to $300 Million for China Rights to Off-Patent Medications
$5.00
Available
I-Mab Acquires China Rights to I-O mAb from MorphoSys in $105 Million Deal
$5.00
Available
NextCure Closes $93 Million B Round Led by China Investors for IO Therapies
$5.00
Available
Agilent Closes $250 Million Acquisition of ACEA, a US-China Lab Tools Maker
$5.00
Available
CStone Pharma Plans Hong Kong IPO to Support its Oncology Portfolio
$5.00
Available
YITU Raises $15 Million for AI-Supported Cancer Diagnosis
$5.00
Available
Shanghai Exuma to Develop Conditionally Active CAR-T Candidates
$5.00
Available
Sinovant In-licenses China Rights to HGH Mimetic from Angion
$5.00
Available
Innovent's NDA Filing for Humira Biosimilar Accepted in China
$5.00
Available
LG Chem Forms IO Collaboration Worth Up to $1 Billion with Cue Biopharma
$5.00
Available
Generon to Start China Phase I Trial of IO Drug in B Cell Malignancies
$5.00
Available
bioM
$5.00
Available
Denmark's Ascendis Forms $80 Million China Rare Disease JV with Vivo Capital
$5.00
Available
Innovent Starts Phase III Trial of PD-1 Candidate in Lung Cancer Patients
$5.00
Available
Berry Genomics and Prenetics Team up to Offer Consumer Genetic Testing
$5.00
Available
HuiyiHuiying Raises Funds from Intel for Medical Imaging AI
$5.00
Available
Ping An Good Doctor Announces AI-Based Freestanding One-Minute Clinics
$5.00
Available
Zhejiang Jingxin Makes $10 Million Investment in Mapi Pharma of Israel
$5.00
Available
Ocumension Acquires China Rights to Uveitis Treatment in $12 Million Agreement
$5.00
Available
Shanghai Stock Exchange to Set Up New Board for Innovative Science and Tech Companies
$5.00
Available
I-Mab Approved to Start China Trials of Interleukin-7 Immunotherapy
$5.00
Available
Bio-Thera Starts China Phase III Trial of HER2 Conjugate Drug
$5.00
Available
Adagene Starts US Trial of Lead Molecule; Also Approved for China Trials
$5.00
Available
Ark Bio to Release Positive Clinical Data on RSV Candidate
$5.00
Available
Suzhou's Innovent Rises 19% in First Trading Day on the Hong Kong Exchange
$5.00
Available
Biothus of Guangdong Has $140 Million to Develop 8 Candidates
$5.00
Available
Terns Closes $80 Million Round to Develop NASH Drugs
$5.00
Available
WuXi AppTec and Schr
$5.00
Available
Insight Capital Raises $72 Million for New China Healthcare Fund
$5.00
Available
Fullerton Enters $72 Million of Deals for Shanghai Healthcare
$5.00
Available
Alphamab and 3D Medicines Start Phase III Trial of PD-L1 Candidate in China
$5.00
Available
Xgene Pharma of Shanghai Closes $20 Million B Round for Pain Drugs
$5.00
Available
Shanghai's Green Valley Files for China Approval of Alzheimer's Drug
$5.00
Available
Innovent Completes $421 Hong Kong IPO; Trading Begins in One Week
$5.00
Available
XtalPi Raises $46 Million for Computer-Driven Drug Research
$5.00
Available
CStone Pharma Approved to Begin US Trial of PD-1 Candidate
$5.00
Available
WuXi AppTec Forms Medical Big Data JV with China Electronics Data
$5.00
Available
CANbridge Forms Rare Disease Drug Partnership with WuXi Biologics
$5.00
Available
Fosun Acquires China Rights to HCC Diagnostic with $10 Million Glycotest Investment
$5.00
Available
CASI Pharma Acquires HBV Treatment for China Use from Indian Pharma
$5.00
Available
Jiangsu Hengrui Forms Global Clinical Collaboration with LSK BioPharma
$5.00
Available
China Everbright Raises $155 Million for Third Life Science Fund
$5.00
Available
Zai Lab Ok'd to Launch PARP Inhibitor in Hong Kong
$5.00
Available
Reistone of Shanghai Approved for US Phase II Trial of UC Treatment
$5.00
Available
Genecast Acquires China Rights to Tumor Test from Cancer Genetics
$5.00
Available
Ascletis's Second HCV Treatment on Priority Review List in China
$5.00
Available
Singlera Reports Positive Results from Blood-based Diagnostic for Colorectal Cancer
$5.00
Available
Chi-Med Starts China Trials of Syk Inhibitor in Acute Myeloid Leukemia Patients
$5.00
Available
Alphamab to Start US Phase I Clinical Trial of HER2 Bispecific Antibody
$5.00
Available
iCell Partners with LineaRx for new CAR-T Manufacturing Platform
$5.00
Available
CStone Approved to Start US Trials of PD-L1 Candidate
$5.00
Available
Innovent to Raise $422 Million in Hong Kong IPO at $2 Billion Valuation
$5.00
Available
HiFiBiO Acquires H-Immune, a French Immunotherapy Biotech
$5.00
Available
I-Mab Starts China Trial of Ulcerative Colitis Treatment
$5.00
Available
Suzhou's Amor Medical Collaborates with IME to Develop Resorbable Devices
$5.00
Available
BeiGene and MEI Pharma to Test Drug Combination Therapy in B-Cell Malignancies
$5.00
Available
Alphamab Starts Australian Trial of PD-L1/CTLA-4 Bispecific
$5.00
Available
Deep Intelligent Pharma Raises $15 Million for AI Drug Development from Sequoia
$5.00
Available
Jinxin Fertility Completes Financing Led by Warburg and CNCB
$5.00
Available
Yisheng Cleared to Start China Phase III Trial of PIKA Rabies Vaccine
$5.00
Available
Biosense Acquires China Rights to Immunotherapy in $75 Million Deal
$5.00
Available
Daiichi Sankyo in $32.5 Million Deal for China Rights to Australian Non-Opioid Analgesic
$5.00
Available
PharmaBlock Acquires China Manufacturing Plant from Porton Pharma
$5.00
Available
Ping An Good Doctor Joins with CR Sanjiu to Promote OTC and TCM Products
$5.00
Available
Cellular Bio Acquires Rights to Solid Tumor Immunotherapy from National Cancer Institute
$5.00
Available
Go Therapeutics Signs $195 Million Licensing Deal with Roche
$5.00
Available
HiFiBiO Forms Cell Therapy Discovery Collaboration with Kite Pharma
$5.00
Available
CANbridge Files to Start Clinical Trials of Breast Cancer Drug in China
$5.00
Available
Fosun Pharma Officially Announces Plan for Henlius Hong Kong IPO
$5.00
Available
Shanghai Aohua Endoscopy Completes $44 Million Series D Funding
$5.00
Available
Innovent Approved to Start US Clinical Trial of CD47 Immunotherapy
$5.00
Available
ACEA, a US-China Cell Analysis Device Company, Acquired for $250 Million
$5.00
Available
Bellen Chemistry of Beijing, a CRO/CMO, Raises $30 Million-Plus in C Round
$5.00
Available
Fosun Pharma Acquires China Rights to Stroke Drug in $32.5 Million Agreement
$5.00
Available
CSPC Acquires China Rights to Verastem Cancer Drug in $45 Million Deal
$5.00
Available
WuXi Biologics Collaborates with I-Mab to Develop Three BiSpecifics
$5.00
Available
Flow Pharma Forms JV with Button Capital for China Clinical Trials
$5.00
Available
Everest Acquires China/Asia Rights to VenatoRx Drug-Resistant Anti-Infective
$5.00
Available
Zhejiang Anglikang Pharma Approved for $87 Million IPO in Shenzhen
$5.00
Available
Changchun High & New Forms $200 Million Biosimilar JV with Alvotech of Iceland
$5.00
Available
Ping An Leads $70 Million Round in MeMed, an Israeli Diagnostics Company
$5.00
Available
Beijing's Hillhouse Closes Latest Fund with $10.6 Billion, a Record
$5.00
Available
China Medical In-Licenses China Rights to VAXIMM's Immunotherapies
$5.00
Available
Innovent's PD-1 Candidate Effective Against NSCLC; Will Start Phase III Trial
$5.00
Available
WuXi AppTec Files for $1 Billion-Plus IPO in Hong Kong
$5.00
Available
General Atlantic Invests $150 Million in Asia Holding, a Hospital/Clinic Company
$5.00
Available
Digital China Health to Promote Genomics Diagnostic Support System in China
$5.00
Available
CASI Pharma Raises $48.5 Million to Acquire New Drugs
$5.00
Available
Shuwen Biotech of Hangzhou Launches PD-L1 Test Kit
$5.00
Available
Hua Medicine Stages $110 Million Hong Kong IPO at $1.1 Billion Valuation
$5.00
Available
EpimAb Files US/China INDs for Bispecific Cancer Antibody
$5.00
Available
111, a Shanghai Online-Offline Pharmacy, Raises $100 Million in US IPO
$5.00
Available
Xynomic, a US-China Oncology Pharma, Acquired for $450 Million
$5.00
Available
Vivo Capital Closes Latest US-China PE Fund at $635 Million
$5.00
Available
Shanghai Pharma Signs MOU to Develop BIOCAD's mAb Portfolio in China
$5.00
Available
Zai Lab Pays $15 Million for China Rights to Electric Field Therapy for Brain Cancer
$5.00
Available
Tianjin Tasly Out-licenses US Rights to TCM Angina Drug in $50 Million Deal
$5.00
Available
CARsgen Reports Positive Results from CAR-T Trial in Solid Tumor Cancers
$5.00
Available
Cadrock Raises $5 Million from China Investor for Antibiotic CAD Treatment
$5.00
Available
Innovent Approved for China Trial of CD47 I-O Drug
$5.00
Available
Hansoh Pharma Plans Hong Kong IPO that Could Raise $1-$3 Billion
$0.00
Available
Driver, "A Cure for Cancer Treatment," Launches in US and China
$5.00
Available
Zai Lab Raises $150 Million in US Secondary Offering
$5.00
Available
Eccogene of Shanghai Completes $14.6 Million Funding Led by Sinopharm
$5.00
Available
BeiGene and SpringWorks to Pair RAF and MEK Inhibitors in Solid Tumor Combo
$5.00
Available
Ming Capital Leads $33 Million Round in Belgium's Miracor Medical
$5.00
Available
Chi-Med OK'd for China Use of Fruquintinib, its First Drug Approval
$5.00
Available
Eisai Announces China Approval for Liver Cancer Treatment
$5.00
Available
Quan Capital Files to Raise $300 Million for Second Drug Development Fund
$5.00
Available
Guangdong Jianke Raises $130 Million for China Online Pharmacy
$5.00
Available
Guangzhou Wondfo Forms $16 Million Diagnostics JV with Biocartis
$5.00
Available
BI and Tsinghua to Use Immunology for New Infectious Disease Drugs
$5.00
Available
Ark Biosciences In-Licenses Pulmonary Fibrosis Candidate from Roche
$5.00
Available
WeDoctor and other Investors to Acquire Fertility Company Genea for $510 Million
$5.00
Available
BeiGene's PD-1 Antibody Accepted for NDA Review in China
$5.00
Available
XingImaging Announces China Neuro-PET Scanning for Alzheimer's Trial
$5.00
Available
Jacobio Pharma of Beijing Raises $55 Million in C Round
$5.00
Available
RootPath Completes $7 Million Seed Funding for Next-Gen I-O Development
$5.00
Available
Ping An Good Doctor Partners with Jointown for Online/Offline Healthcare
$5.00
Available
Huadong Medicine Poised to Acquire Sinclair of Britain for $210 Million
$5.00
Available
Shenzhen Lachesis Completes $29 Million B Round for Smart Hospital Ward System
$5.00
Available
CStone OK'd to Start China Trials of Third I-O Candidate
$5.00
Available
Harbour BioMed, a US-China Company, Closes $85 Million Series B Round
$5.00
Available
China Pioneer, a Medical Device Distributor, Pays $33 Million for Stake in Australia's Paragon Care
$5.00
Available
Strategia Forms Drug Development Partnership with Shanghai's JS InnoPharm
$5.00
Available
Mabpharm Becomes 11th China Biotech to File for Hong Kong IPO
$5.00
Available
China Biologic Nixes Privatization; Raises $590 Million in PE Deal
$5.00
Available
Oxford Biodynamics Raises $12.5 Million from China's GL Capital for Biomarkers
$5.00
Available
Hengrui Medicine Approved to Market HER2 Cancer Drug in China
$5.00
Available
Zai Lab Plans Hong Kong IPO to Raise up to $300 Million
$5.00
Available
BMS to Set China Price of Opdivo, a PD-1 Drug, at 50% of US Cost
$5.00
Available
Ascentage Pharma Officially Announces its Hong Kong IPO
$5.00
Available
Roche Gets Speedy China Approval for New Lung Cancer Treatment
$5.00
Available
Bio-Thera BLA for Humira Biosimilar Accepted in China
$5.00
Available
China Biologic Management Makes $3.9 Billion Take-Private Offer
$5.00
Available
Harbour BioMed in $350 Million Deal for Sichuan Kelun PD-L1 Candidate
$5.00
Available
Harbin Gloria Partners Four of its Drug Candidates in $53 Million Agreement
$5.00
Available
Shanghai ChemPartner Closes Reverse Merger with Quantum
$5.00
Available
Adlai Nortye of Hangzhou Opens Boston Innovation Center
$5.00
Available
YiChang HEC Pharm Raises $400 Million from Blackstone Group
$5.00
Available
Sirnaomics to Start US Trial of siRNA Treatment for Bile Duct Cancer
$5.00
Available
Buck Institute, Insilico and Juvenescence Form Napa to Develop Anti-Aging Drug
$5.00
Available
CrownBio Acquires Rights to Drug Development Models from Shanghai Model Organisms
$5.00
Available
CANbridge Approved for China Phase Ib/III Trial of Esophageal Cancer Drug
$5.00
Available
Sihuan Pharma Starts China Phase II Lung Cancer Trial
$5.00
Available
Haisco Invests $10 Million in Pneuma Respiratory; Acquires Rights to Asthma/COPD Inhaler
$5.00
Available
Ascletis and BeiGene Trade Lower Following Hong Kong IPOs
$5.00
Available
BeiGene Starts China Phase III Trial of PD-1 Drug in Squamous NSCLC
$5.00
Available
I-Mab Approved to Start China Trials of Novel Diabetes Treatment
$5.00
Available
Tot Biopharm of Suzhou Closes $102 Million Round for Cancer Drugs
$5.00
Available
Beijing's EdiGene Completes $15 Million Pre-B Round
$5.00
Available
I-Mab Biopharma Files China IND for I-O Multiple Myeloma Treatment
$5.00
Available
Shanghai Junshi Files for $500 Million HK IPO; Has $2 Billion Valuation
$5.00
Available
Nanjing Sanpower Transfers Dendreon to Cenbest for $868 Million
$5.00
Available
Shandong Luoxin Acquires Constipation Drug in $68 Million Agreement
$5.00
Available
Harbour to Pay Up To $120 Million for China Rights to HER2 Bispecific
$5.00
Available
CMS Gains China Rights to Two Can-Fite Candidates in $74.5 Million Agreement
$5.00
Available
Cure Genetics (Suzhou) Closes $17 Million Series A Financing
$5.00
Available
Gilead Sciences OK'd for China Sales of HIV Combination Drug
$5.00
Available
Impact Therapeutics Closes $30 Million C Round for Cancer Drugs
$5.00
Available
CY Biotech Acquires China Rights to Obesity Treatment from Eisai
$5.00
Available
Clover Biopharma Starts China Phase I Trial of Enbrel Biosimilar
$5.00
Available
Ascletis Completes $400 Million IPO; Valuation is $2 Billion
$5.00
Available
China Diagnostics Medical Raises $292 Million led by Legend's $100 Million
$5.00
Available
CMS in $70 Million Deal for French Thrombotic Therapy
$5.00
Available
Curon Biopharma of Shanghai Completes $150 Million Initial Financing
$5.00
Available
Medlinker Raises $147 Million for China MD-Peer Online Network
$5.00
Available
HiFiBiO Forms Drug Discovery Partnership with Takeda
$5.00
Available
Omniome Raises $60 Million in Funding Led by China Investors
$5.00
Available
BeiGene Accepting Bids from Investors for $1 Billion Hong Kong IPO
$5.00
Available
CStone to Start China Trial of its MEK Inhibitor
$5.00
Available
HitGen Forms Another Drug Discovery Partnership -- This One with Sanofi
$5.00
Available
CBT Starts Phase Ib Trial of PD-1 Candidate in Australia
$5.00
Available
I-Mab Out-Licenses Bi-Specific to South Korea's ABL Bio in $100 Million Deal
$5.00
Available
China Uses New Rules for Fast Approval of Keytruda, a Merck/MSD PD-1 Drug
$5.00
Available
Innovent Approved to Start Trials of Novel I-O and Osteoporosis Candidates
$5.00
Available
Terumo Pays $130 Million to Acquire Essen, a Beijing Stent Company
$5.00
Available
Beijing Allcure Completes $103 Million Funding for China Oncology Centers
$5.00
Available
BMS Forms Translation Partnership with Tsinghua University
$5.00
Available
Tencent Partners with WebMD to Provide Online China Medical Content
$5.00
Available
Long Hill Capital Closes $265 Million Second Fund for China Health Investments
$5.00
Available
BeiGene Reports Positive PD-1 Data; Plans China NDA Filing This Year
$5.00
Available
Shanghai Fosun Pharma Considering $500 Million IPO of Gland Pharma
$5.00
Available
Kolon Life Science to Export $207 Million of Gene Therapy Treatment to China's Hainan Province
$5.00
Available
China Investors Lead $15.5 Million Round in Quantapore, a US Sequencing Co.
$5.00
Available
Laurel VC Acquires Asthma/COPD Technology; Will Form China Biopharma
$5.00
Available
Ascletis' Hong Kong IPO to Raise $457 Million at $2 Billion Valuation
$5.00
Available
Tianjin Tasly in $24 Million Deal for EA Pharma Kidney Disease Drug
$5.00
Available
Shanghai Green Valley Reports Positive Results from Phase III Trial of Alzheimer's Drug
$5.00
Available
CanSino Biologics Files for Hong Kong IPO
$5.00
Available
Sinovant Formed with 11 China Drug Candidates and CITICPE Support
$5.00
Available
Fosun Pharma to Invest $17.6 Million in EOS Imaging of France
$5.00
Available
Ascentage Closes $150 Million C Round to Develop Apoptosis Drugs
$5.00
Available
Tasly In-licenses Two Cell Therapy Treatments in $90 Million Deal
$5.00
Available
Lyvgen Biopharma Raises $30 Million for IO Drug Candidates
$5.00
Available
Cyrcadia Asia Raises $3.8 Million for Breast Cancer Detection Device
$5.00
Available
Tasly Biopharma Raises $84.5 Million in Pre-IPO Round
$5.00
Available
Haitong Invests in Orig3n, a Boston Genetics/Regenerative Medicine Company
$5.00
Available
CStone Approved to Start China Clinical Trials of PD-1 Candidate
$5.00
Available
Merck to Market Xian Janssen's SGLT-2 Diabetes Drug in China
$5.00
Available
GT Healthcare and Sonder Invest $26.6 million in Potero Medical
$5.00
Available
Hillhouse Capital of Beijing Co-Leads $15 Million Round for Antiva
$5.00
Available
Dian Diagnostics to Market Agena's MassARRAY
$5.00
Available
Tasly Biopharma Pays $48 Million to Buy Out JV Partner, Transgene
$5.00
Available
Adagene Approved to Begin US Trials of I-O Cancer Candidate
$5.00
Available
Adlai Nortye Acquires Global Rights to Novartis Cancer Drug
$5.00
Available
CC-Pharming Pays $4.7 Million to be iBio's China Antibody Partner
$5.00
Available
IDS Medical Partners with Tencent to Distribute Medical Devices in China
$5.00
Available
China's Hybio and Yunfeng Capital Acquire AMW, a German Pharma
$5.00
Available
Suzhou Kintor Forms Biomarker Collaboration with Predicine
$5.00
Available
Two US Biopharmas -- Stealth and AOBiome -- File for IPOs on Hong Kong Exchange
$5.00
Available
China Grand Enterprises in Talks to Acquire Sinclair, a $156 Million Company
$5.00
Available
Beijing's LinkDoc Completes $151 Million D Round for Big Data
$5.00
Available
Sinovac Raises $86.7 Million, Scraps Privatization
$5.00
Available
Athenex Forms $145 Million Immunoncology JV with Xiangxue and Raises $100 Million
$5.00
Available
Innovent Files for Hong Kong IPO; May Raise $500 Million
$5.00
Available
Bain PE to Pay $700 Million to Buy DSM Sinochem Pharma
$5.00
Available
Sanofi Opens $77 Million Clinical Big Data R&D Facility in Chengdu
$5.00
Available
China's I-Mab Raises $220 Million in C Round for Biotech Development
$5.00
Available
Zai Lab Starts Phase III China Trial of PARP Inhibitor
$5.00
Available
Nuance Raises $35 Million in B Round Led by C-Bridge
$5.00
Available
HaploX of Shenzhen Closes B Round for Cancer Liquid Biopsy Products
$5.00
Available
China Accepts Solasia's Filing for Anti-Nausea/Vomiting Patch
$5.00
Available
WuXi Bio Pays $47 Million to Alter OmniAb Pact with Ligand Pharma
$5.00
Available
Amyris Forms Microbiome JV with Shenzhen's BGI Genomics
$5.00
Available
Shanghai's Everest Medicines Acquires Global Rights to Novartis Liver Cancer Treatment
$5.00
Available
Ascletis Signs Up with CR Pharma to Distribute Novel HCV Treatment
$5.00
Available
Harbour BioMed Collaborates with WuXi Biologic for Supply of Novel Antibody
$5.00
Available
CSL Pays $102 Million to Acquire Remaining 20% of China's RuiDe Bio
$5.00
Available
Los Altos Pharma In-licenses China Rights to Sedor's Pain Candidate
$5.00
Available
CASI Forms Alliance with Yiling to Manufacture Two Generics for China
$5.00
Available
Tot Biopharm Opens New Biologics Facility in Suzhou
$5.00
Available
Nuance Enters $58 Million Deal for Non-Opioid Pain Treatment in China
$5.00
Available
WuXi Biologics to Build $20 Million ADC Facility in Wuxi City
$5.00
Available
CStone Starts Australian Trial of MEK Inhibitor
$5.00
Available
Luye Files to Start China Trials of Class 1.1 Novel Analgesia Candidate
$5.00
Available
CITIC Capital Bids $3.6 Billion to Acquire China Biologic Products
$5.00
Available
Stealth Bio Raises $100 Million from China Investors for Mitochondrial Candidates
$5.00
Available
AlphaBio of Shanghai Announces $65 Million Series A Round
$5.00
Available
Baltimore's WindMIL Closes $32.5 Million B Round Led by Qiming
$5.00
Available
Aptose Acquires China Rights to Leukemia Candidate in $125 Million Agreement
$5.00
Available
China Approves First PD-1 Treatment: Bristol-Myer Squibb's Opdivo
$5.00
Available
Mervion Raises $150 Million from China Investors for Proton Therapy Machines
$5.00
Available
Yaoshibang Closes $65.7 Million C Round for Online Pharmacy
$5.00
Available
Ascletics' Novel HCV Treatment is Approved by CFDA
$5.00
Available
CStone Starts Pivotal China Phase II Trial of PD-L1 Candidate
$5.00
Available
Shanghai Kinetic Acquires US Device Maker Elliquence for $77 Million
$5.00
Available
Everest Files IND for China Phase III Trial of Novel Antibiotic
$5.00
Available
WuXi AppTec Leads Investment in Insilico, an AI Drug Discovery Company
$5.00
Available
WuXi Biologics to Build New Biologics Plant Near Boston -- Announces Four New Facilities with $792 Million Investment in Two Months
$5.00
Available
Xiangxue to Build Cell-Therapy Manufacturing Plant in Guangzhou
$5.00
Available
Hua Medicine Files for Hong Kong IPO -- Rumors Predict a $200 Million Debut
$5.00
Available
Oncologie Launches with $16.5 Million for IO Combinations in China and the US
$5.00
Available
Hangzhou Just Bio Raises $35 Million for Biologics in B+ Round
$5.00
Available
Frontier Biotech's HIV Drug Approved, First China-Developed HIV Treatment
$5.00
Available
Quantum Surgical Raises Series A Capital from Ally Bridge
$5.00
Available
Harbour BioMed Teams Up with Wistar to Discover Novel mAbs
$5.00
Available
Denovo Licenses Previously Unknown Use of Cancer Drug for PAH
$5.00
Available
CR Pharma to Acquire Jiangzhong Pharma for $667 Million
$5.00
Available
Xynomic Pharma Closes Series B from China Investors
$5.00
Available
vTv Therapeutics Out-licenses COPD Treatment to China's Newsoara
$5.00
Available
Luye Pharma to Bring Elpis CAR-T Therapies to China
$5.00
Available
Zai Lab Gains Global Rights to Topical Biologic for Psoriasis
$5.00
Available
Link Health In-licenses China Rights to Lidocaine Patch
$5.00
Available
Legend/Janssen CAR-T Immunotherapy to Start US Trial in Myeloma
$5.00
Available
Alibaba Sells Online Pharmacy Unit to Ali Health for $1.4 Billion
$5.00
Available
JHL Biotech Raises $106 Million in Pre-IPO Funding
$5.00
Available
HitGen Closes $39 Million B Round for Drug Discovery/Development
$5.00
Available
Shuwen Develops Companion Diagnostics for BlissBio in New Collaboration
$5.00
Available
WuXi Biologics Plans Big Increase in Manufacturing Capacity
$5.00
Available
Antegene to Pay $162 Million for China Rights to Four Karyopharm Assets
$5.00
Available
Brii Bio Starts Operations with $260 Million to Bring Drugs to China
$5.00
Available
Pivotal Partners China Closes $150 Million Fund to Incubate New Companies
$5.00
Available
Shanghai Pharma Extends Research Collaboration with Bracco Imaging
$5.00
Available
Shanghai Pharma Acquires Majority Stake in JV Techpool in $280 Million Deal
$5.00
Available
WuXi Biologics Invests $60 Million in Another New Plant -- In Singapore This Time
$5.00
Available
Grail Raises $300 Million from China Investors for Early Cancer Diagnostics
$5.00
Available
Legend Capital Closes $156 Million Phase II for RMB Healthcare Fund
$5.00
Available
Salubris Acquires China Rights to MedAlliance CV Balloon for $30 Million
$5.00
Available
CR Pharma in Talks for $613 Million Acquisition of Jiangzhong Pharma
$5.00
Available
BeiGene Starts China Trial of PARP Inhibitor in Ovarian Cancer Patients
$5.00
Available
WuXi Biologics Plans Another New CDMO Plant -- A $240 Million Facility in Shijiazhuang
$5.00
Available
Innovent Reports Positive Results for PD-1 Candidate; Files China NDA
$5.00
Available
Boston's HiFiBiO Raises $37.5 Million from China Investors
$5.00
Available
China to Extend Drug Patent Protection to 25 Years, Up from 20
$5.00
Available
Jiangsu Ambition In-licenses Prostate Treatment from Sweden's Lidds
$5.00
Available
Dongbao Pharma Acquires Two Diabetes Treatments in $135 Million Deal
$5.00
Available
Asymchem Starts Fund to Bring Novel Western Drugs to China
$5.00
Available
CStone Pharma Starts Phase I Trial of PD-1 Molecule
$5.00
Available
Fosun to Bid in $2 Billion Auction for Novartis' US Generic Drug Assets
$5.00
Available
Ansun Raises $85 Million for Novel Influenza Therapeutic from China Investors
$5.00
Available
Changshan Pharma Signs $9.5 Million Deal for Osteoarthritis Combo Drug
$5.00
Available
Unisound Closes $100 Million Round for Medical AI and Voice Recognition
$5.00
Available
BangEr Raises $47 Million for its Chain of China Orthopedic Hospitals
$5.00
Available
Armo, Backed by China Investors, To Be Acquired by Lilly for $1.6 Billion
$5.00
Available
MabSpace Biosciences of Suzhou Closes $40 Million B Round
$5.00
Available
CStone Pharma Completes Record-Breaking $260 Million B Financing
$5.00
Available
Ascletis, a Pre-Revenue China Biopharma, Files for Hong Kong IPO
$5.00
Available
Luye Pharma Enters $538 Million Deal for AstraZeneca's Seroquel
$5.00
Available
WuXi AppTec IPOs in Shanghai Exchange
$5.00
Available
CDH Investments Makes Surprise Offer to Acquire Sirtex Medical for $1.4 Billion
$5.00
Available
Refuge Biotechnologies Closes $25 Million Series B from Chinese Investors
$5.00
Available
Chinese Medical AI Start-up Synyi Raised $15.7 Million Series B
$5.00
Available
WuXi Biologics to Build Biomanufacturing Facility in Ireland
$5.00
Available
Zoetis Starts New Site Construction in Suzhou
$5.00
Available
WuXi AppTec Expands Operation Site in New Jersey
$5.00
Available
Tocagen Granted ApolloBio Greater China Rights of Immunotherapy Candidate for $127 Million
$5.00
Available
Prenetics Acquires British Consumer Genetic Testing Firm
$5.00
Available
Philip Partners with Digital China Health to Launch Cloud-Based Imaging Services
$5.00
Available
Qiming Closes $120 Million US Healthcare Fund, Two General China Funds with $1.2 Billion
$5.00
Available
Shuwen Biotech Reports "Multi-Million Dollar" Investment from Tasly
$5.00
Available
Suzhou Alphamab to Start China Trial of Bispecific HER2 Inhibitor
$5.00
Available
Ping An Healthcare and Technology Plans $1 Billion HK IPO for May
$5.00
Available
MabSpace Starts US Trial of PD-L1 Drug; China Trial to Begin Soon
$5.00
Available
Beijing's AK Medical Buys JRI Orthopedics of the UK for $24 Million
$5.00
Available
Beigene Initiated Global Phase II Clinical Trial for PD-1 Antibody
$5.00
Available
Biocytogen Closes $65 Million Round for Animal Model CRO Services
$5.00
Available
DXY Completes $100 Million Series D Round for China Doctor Academic Portal
$5.00
Available
Bliss Biopharma of Hangzhou Licenses Cancer ADC from Morphotek
$5.00
Available
Panacea Ventures Files to Raise $150 Million for China Healthcare
$5.00
Available
New World Development Invests in New Century Healthcare; Plans More China Clinics/Hospitals
$5.00
Available
Frontage Labs, a US-China CRO, Acquires Concord Biosciences
$5.00
Available
US-China Trade War May Affect Life Science Products
$5.00
Available
Denovo Starts US-China Phase III Study of Leukemia Treatment
$5.00
Available
Concord Medical Announces $238 Million Investment from CCIC
$5.00
Available
Terns Acquires Three Lilly Candidates; Raises $30 Million from Lilly Asia Ventures
$5.00
Available
China Moves to Encourage Higher Quality China-made Generic Drugs
$5.00
Available
Fosun Pharma Stays Committed to Expanding through R&D and M&A
$5.00
Available
CMAB Biopharma of Suzhou Announces $34 Million Series B
$5.00
Available
GDCC Acquires China Rights to Anti-Seizure Drug from Biscayne Neuro
$5.00
Available
Guangzhou MaxiNovel Awarded US Orphan Drug Status for AML Treatment
$5.00
Available
Ascentage Chooses Hong Kong Exchange for its IPO
$5.00
Available
Roivant Enters $95 Million Deal for China Rights to Novel Antibiotic
$5.00
Available
WuXi AppTec Approved for $910 Million Shanghai IPO
$5.00
Available
Hua Medicine Completes $117 Million Funding for Novel Diabetes Treatment
$5.00
Available
Aslan Pharma of Singapore Files for $86 Million US IPO
$5.00
Available
Singlera Raises $60 Million in A+ Round for Cancer Tests
$5.00
Available
Adagene Completes $50 Million C Round for Oncology Clinical Trials
$5.00
Available
BI Forms $134 Million JV with Two China Partners for Foot-and-Mouth Vaccine
$5.00
Available
CBT Acquires Global Rights to CTLA-4 Checkpoint Inhibitor in $46 Million Deal
$5.00
Available
Simcere Partners with Agena for Companion Diagnostics in China
$5.00
Available
Fosun Acquires China Rights to Dove's Oral Thrombocytopenia Drug
$5.00
Available
China Accepts Chugai's NDA Submission for Novel Osteoporosis Treatment
$5.00
Available
Senju Acquires China-Japan Rights to Diabetic Macular Edema Treatment
$5.00
Available
Avita Medical Starts China Trial of "Spray-on Skin" for Burns
$5.00
Available
TCR2 Therapeutics Closes $125 Million B Round for Immunoncology Program
$5.00
Available
China Proposes to Eliminate Tax on Imported Cancer Drugs
$5.00
Available
Oxford Nanopore Completes $140 Million Funding Led by Asian Investors
$5.00
Available
CASI Raises $50 Million to Launch Drugs in China
$5.00
Available
Akonni and Righton Form Two-Way US-China Diagnostics Deal
$5.00
Available
Cellular Biomedicine Will Focus on China, Closing California Operations
$5.00
Available
Shenzhen Breaks Ground on James Watson-led Life Science Research Center
$5.00
Available
Infervision Closes $47 Million B+ Round for AI-aided CT Scan Analysis
$5.00
Available
HitGen to Discover Leads for BASF Crop Protection Products
$5.00
Available
China Plans to Move the CFDA into a New Agency
$5.00
Available
United Biopharma of Taiwan to Build $40 Million mAb Manufacturing Facility in China
$5.00
Available
Timwell Forms $20 Million JV with ReWalk for China Sales of Exoskeleton
$5.00
Available
Alibaba Re-Starts $1.4 Billion Bid to Acquire iKang Healthcare
$5.00
Available
Chi-Med Expects Approval of First Novel Cancer Drug in 2018
$5.00
Available
XW Labs Starts Phase I Trial of Novel Narcolepsy Candidate
$5.00
Available
Hua Medicine in Hong Kong IPO Queue; Plans to Raise $400 Million
$5.00
Available
Adagene to Collaborate with WuXi Biologics for Antibody Manufacturing
$5.00
Available
JW, a Juno-WuXi AppTec China JV, Raises $90 Million for CAR-T Drugs
$5.00
Available
US FDA Approves Drug-Resistant HIV Treatment from Taiwan's TaiMed
$5.00
Available
Oxford Vacmedix Raises $12.5 Million for Therapeutic Vaccines from Asian Investors
$5.00
Available
23Mofang Raises $15.8 Million for China Personal DNA Test
$5.00
Available
MicuRx will Receive $5.2 Million to Advance Drug-Resistant Antibiotic
$5.00
Available
Chi-Med Starts China Trial of Epitinib in Glioblastoma Patients
$5.00
Available
Tasly Pharma Planning $1 Billion Hong Kong IPO for Biologics Operations
$5.00
Available
Shanghai's CARsgen Heads Towards IPO with $60 Million Pre-C Round
$5.00
Available
Is This the Future? China Nanorobots Fight Cancer Tumors
$5.00
Available
Grail, a US-Hong Kong Diagnostics Company, May Stage $500 Million Hong Kong IPO
$5.00
Available
Viela, a New MedImmune Spinout, Raises $250 Million from China Investors
$5.00
Available
Mindray Medical Nixes Shenzhen IPO; Seeks New Venue
$5.00
Available
Shenzhen Hepalink Forms Anti-infective mAb JV with Aridis Pharma
$5.00
Available
Fosun Subsidiary's Aesthetic Laser Approved for US Use
$5.00
Available
Merck KGaA to Add Mobius
$5.00
Available
Yisheng Biopharma Granted US Orphan Drug Status for Immunotherapy
$5.00
Available
China's STA Collaborates with Regulus for microRNA Drug Manufacturing
$5.00
Available
MabSpace's Second-Gen PD-L1 Candidate Approved for US Trial
$5.00
Available
JHL Biotech Approved to Start European Trial of Avastin Biosimilar
$5.00
Available
Everest Acquires China Rights to Tetraphase's Antibiotic in $23.5 Million Deal
$5.00
Available
Taiwan Liposome Plans to Stage $50 Million IPO in the US
$5.00
Available
Fosun Forms Investment/Commercialization Partnership with Arix, a UK Accelerator
$5.00
Available
Oncologie Enters $126 Million Deal for China Rights to Cancer Drug
$5.00
Available
Lee's Pharma Acquires China Rights to GC Pharma Anticoagulant
$5.00
Available
Harbin Pharma to Acquire 40% of US-based GNC for $300 Million
$5.00
Available
Chi-Med Enrolls 527 Lung Cancer Patients for China Trial of Fruquintinib
$5.00
Available
NovaBay Raises $6 Million from Hong Kong's OP Financial
$5.00
Available
Tsinghua University Commits $276 Million to Cambridge UK Biohub
$5.00
Available
Beijing InnoCare Pharma Raises $55 Million in Vivo-led Round
$5.00
Available
China's GeneScience Pharma Participates in Rani's $53 Million Funding
$5.00
Available
Zhejiang Haichang to Re-formulate Liver Cancer Drug for Rexahn Pharma
$5.00
Available
Roivant Strikes $5.5 Million China Deal with ArQule for Cancer Drug
$5.00
Available
Golden Meditech Gains US OK for Houston T-Cell Processing Center
$5.00
Available
Jing Medicine Forms $100 Million Collaboration with ShanghaiTech University
$5.00
Available
China's Luqa Pharma Closes $15 Million B Round for Dermatology/Aesthetic Products
$5.00
Available
Chengdu's NetVation DL Forms Partnership with Pfizer
$5.00
Available
CR Pharma In-licenses Rights To Prostate Cancer Drug from Xbrane
$5.00
Available
BeiGene Launches Third Celgene Cancer Drug in China
$5.00
Available
Cellular Biomedicine Raises $30.6 Million from Sailing Capital
$5.00
Available
CANbridge Acquires China Rights to Puma Cancer Candidate in $70 Million Deal
$5.00
Available
JHL Shareholders Approve Voluntary De-Listing from Taiwan Exchange
$5.00
Available
Krane Offers China Healthcare ETF with China, Hong Kong, US-listed Companies
$5.00
Available
NCPC GeneTech Acquires China Rights to Anemia Drug from Korean Firm
$5.00
Available
Engine Biosciences Raises $10 Million for AI Drug Discovery from Asian/US Investors
$5.00
Available
Ping An Good Doctor Files for Hong Kong IPO Expected to Raise $1 Billion
$5.00
Available
TytoCare Raises $25 Million for Telehealth Devices; Forms China Partnership with Ping An
$5.00
Available
C-Bridge Raising $650 Million for Third China Healthcare PE Fund
$5.00
Available
CASI Pharma Acquires 29 Generic Drug Candidates from Sandoz
$5.00
Available
Lee's Pharm to Start China Trials of In-licensed PD-L1 Candidate
$5.00
Available
ARMO, Backed by China Investors, Completes $128 Million IPO in US
$5.00
Available
Shanghai Pharma Plans San Diego Office for US/EU M&A
$5.00
Available
Generon (Shanghai) Says Neutropenia Candidate Meets Phase III Targets
$5.00
Available
Luye Considering $500 Million IPO for Healthcare Assets
$5.00
Available
Clover Using GE FlexFactory for China Biologic Manufacturing Plant
$5.00
Available
Neuspera Raises $26 Million in B Round, Led by China's 6 Dimensions
$5.00
Available
XtalPi Closes $15 Million for AI-Aided Drug Design
$5.00
Available
GSK Launches Triple-Therapy HIV Drug in China at a Low-Cost $450/Month
$5.00
Available
Tmunity Closes $100 Million Funding for T Cell Therapies; Ping An Participates
$5.00
Available
China Sees Promise, not Danger in Crispr Gene-Editing Trials
$5.00
Available
Taiwan Liposome Forms China Commercialization JV with Jixi Biotech
$5.00
Available
Harbour BioMed Raises Additional Capital in Series A+
$5.00
Available
BeiGene Completes $750 Million Secondary Offering
$5.00
Available
Ascletis Plans $100 Million C Round; Then Hong Kong IPO
$5.00
Available
China's Adlai Nortye Acquires Immuno-oncology Candidate from Eisai
$5.00
Available
Ping An Raises $1 Billion for Healthcare Management Unit
$5.00
Available
3SBio to Market Japanese Pruritis Treatment in China
$5.00
Available
Shanghai Henlius Completes $190 Million Funding; Is a Hong Kong IPO Next?
$5.00
Available
Sinocare Mulls $4 Billion Bid for J&J's Diabetes Device Companies
$5.00
Available
Eddingpharm Starts China Trial of Amarin's Hypertriglyceridemia Treatment
$5.00
Available
CR Pharma Negotiating for China Rights to Two Xbrane Candidates
$5.00
Available
Suzhou's Innovent Plans Capital Raise Followed by $200 Million IPO
$5.00
Available
BeiGene Acquires Asia Rights to Mirati Cancer Treatment in $133 Million Deal
$5.00
Available
Suzhou Zelgen Biosciences Completes $62 Million B Round
$5.00
Available
UK's Vaccitech Raises $27 Million, Co-Led by Sequoia China
$5.00
Available
Hua Medicine to Raise $200 Million to Support Novel Diabetes Drug
$5.00
Available
Suzhou Kintor Raises $44 Million for Novel Drug Portfolio
$5.00
Available
Ferring Collaborates with Chinese Academy of Science on Women's Health
$5.00
Available
CFDA Plans to Double Drug Review Staff: From 800 to 1,600
$5.00
Available
WuXi AppTec Forms Clinical Testing JV with the Mayo Clinic
$5.00
Available
Ping An Signs Strategic Oncology Partnership MOU with Varian
$5.00
Available
Shanghai Fosun Forms $50 Million US JV -- With Itself
$5.00
Available
Fosun Pays $18 Million for China Rights to Novel Parkinson's Disease Drug
$5.00
Available
Aslan Says New CFDA Rules Shave One Year Off Development Time for Lead Drug
$5.00
Available
3SBio Approved to Market Once-Weekly Type 2 Diabetes Treatment in China
$5.00
Available
Biostage Raises $4.2 Million from China Investor for Bioengineered Organs
$5.00
Available
Sinobioway and F1 Oncology to Build Shenzhen CAR-T Manufacturing Facility
$5.00
Available
Shenzhen's HEC Pharm Invests in US Novel Imaging Contrast Company
$5.00
Available
CFDA Accepts Ascentage's IND Filing for Lead Drug in Hepatitis B
$5.00
Available
Ally Bridge and LifeTech Scientific Join to Invest in MedTech Companies
$5.00
Available
Simcere Acquires China Rights to Three Bi-Specific Immunoncology Drugs
$5.00
Available
Lepu Medical Pays $23.3 Million for 13% Stake in Australia's Viralytics
$5.00
Available
BeiGene to Generate New mAbs Using Harbour BioMed's Mouse Platform
$5.00
Available
Berry Genomics Collaborates with 10X Genomics for Next-Gen Prenatal Tests
$5.00
Available
Jiangsu Hengrui Out-Licenses Novel Dermatology Drug for $233 Million
$5.00
Available
China's KBP Closes $76 Million A Round; Opens Philadelphia Global Headquarters
$5.00
Available
Genetron Health Raises $61 Million for Genomics-Oncology Services
$5.00
Available
Zhejiang DTRM Completes $60 Million A Round for US-China Clinical Trials
$5.00
Available
iCarbonX Leads $200 Million Funding in SomaLogic of Colorado
$5.00
Available
Illumina Collaborates with KingMed on China Oncology IVD Assays
$5.00
Available
Miracor Closes $30 Million D Round, Led by Shenzhen's Ming Capital
$5.00
Available
Genostics Invests $13.5 Million in UK's Oncimmune for China Rights to Lung Cancer Test
$5.00
Available
Perennial Real Estate Announces $1.2 Billion China Healthcare Center JV
$5.00
Available
Aslan Pharma Pays $129 Million for Global Rights to Lead Asset
$5.00
Available
ApolloBio and Inovio Alter $43 Million China Deal for HPV Immunotherapy
$5.00
Available
Hong Kong's Xinogen Acquires China Rights to Angiochem Cancer Drug
$5.00
Available
Sansure Biotech Raises $77 Million in Funding Led by Lilly Asia
$5.00
Available
CMAB, a Suzhou Biologic CRO/CMO, Completes $38 Million A Round
$5.00
Available
Laviana Pharma Closes $15 Million Financing for China CRO/CMO Services
$5.00
Available
Shanghai Henlius Announces $192.5 Million Funding for Biosimilars, Novel mAbs
$5.00
Available
Cellular Biomedicine Raises $14.5 Million for CAR-T Immunotherapy, Stem Cells
$5.00
Available
Shanghai's SARI to Acquire NMS, an Italian Oncology Company, for $359 Million
$5.00
Available
Kangning to Raise $30 Million in China Psychiatric Hospital IPO
$5.00
Available
Merck Serono, WuXi AppTec, Pontifax Form Israeli Life Science Incubator
$5.00
Available
Asieris Pharma Closes $15 Million B Round Financing
$5.00
Available
CG Capital of Beijing to Acquire 37% of NovaBay for $28 Million
$5.00
Available
LP Pharma of Xiamen Raises $30 Million for Drugs with Mucosa/Oral Delivery
$5.00
Available
Walgreens Boots Alliance Reduces Stake in China Drug Distribution JV
$5.00
Available
China's I-Mab Inks $548 Million Immunoncology Pact with Genexine
$5.00
Available
Huadong Medicine Enters $83 Million Deal for GLP-1r Diabetes Treatment
$5.00
Available
Yonghua Capital Leads $25 Million B Round in Taris Biomedical
$5.00
Available
Nanjing Legend Lands $350 Million Upfront for CAR-T Partnership with Janssen
$5.00
Available
JHL Biotech Proposes Voluntary Delisting from Taiwan Exchange
$5.00
Available
Ambrx Enters $143.5 Million China Deal for Liver Cancer Treatment
$5.00
Available
CANbridge Files to Start China Trials of Esophageal Cancer Treatment
$5.00
Available
CrownBio Agrees to be Acquired by JSR of Japan in $400 Million Deal
$5.00
Available
Zai Lab Pays $44 Million for China Rights to Gastric Cancer Immunotherapy
$5.00
Available
Jacobson Invests $15 Million in Shanghai Henlius; Obtains Hong Kong Rights to Biosimilar
$5.00
Available
BeiGene Starts China Phase II Trial of PARP Inhibitor
$5.00
Available
GBIL Pays $29 Million to Acquire Surgical Robot for China from TransEnterix
$5.00
Available
Chi-Med Starts First US Trial of Fruquintinib, an Anti-Angiogenesis Drug
$5.00
Available
Clover Bio of Chengdu Completes $9.5 Million Series A for Biotech/Biosimilar Portfolio
$5.00
Available
Sinopharm Co-Leads $18 Million Round in Nebraska's Virtual Incision
$5.00
Available
BGI Genomics Forms $7.6 Million JV with TCM Company Kangmei
$5.00
Available
Fosun Enters $125 Million China Deal for Ardelyx IBS Treatment
$5.00
Available
China Investor Syndicate Acquires Esaote, an Italian Imaging Device Company
$5.00
Available
Shenzhen BioScien Acquires China Rights to Generex Cancer Vaccine
$5.00
Available
BGI Genomics Partners with Sanguine to Build Databases of Clinical Trial Patients
$5.00
Available
Etong Healthcare Completes $30 Million Series B Funding for Online Services
$5.00
Available
WuXi Biologics Opens Expanded $150 Million Biomanufacturing Facility
$5.00
Available
Genova Biotech (Changzhou) Raises $50 Million in Tasly-led Funding
$5.00
Available
MicuRx Raises $15 Million to Complete China Antibiotic Trial
$5.00
Available
Johnson & Johnson Plans JLABS Incubator in Shanghai
$5.00
Available
Xynomic to Start US Trial Combining its Abexinostat with Janssen's Imbruvica
$5.00
Available
Everest Enters $224 Million Two-Drug China Partnership with Arena
$5.00
Available
Pfizer Enters $226 Million China/Asia Deal for Basilea's Anti-Fungal Drug
$5.00
Available
BMS Reports Successful China NSCLC Trial of PD-1 Drug Opdivo
$5.00
Available
BeyondSpring's Plinabulin Designated "National Major Product" in China
$5.00
Available
Walgreens Boots Alliance Acquires 40% Stake in Sinopharm Drugstore Chain for $420 Million
$5.00
Available
12 Sigma, a US-China Startup, Raises $30 Million for AI-Imaging
$5.00
Available
GenomicCare (Shanghai) Completes Series A; Brings Total Funding to $25 Million
$5.00
Available
Zhenxing Biopharma, a Plasma Company, Sells 19% Stake for $322 Million
$5.00
Available
I-Mab Obtains China Rights to Myeloma Candidate in $120 Million Deal
$5.00
Available
Ping An Good Doctor Plans $1 Billion Hong Kong IPO in 2018
$5.00
Available
Gilead Launches Hepatitis C Treatment in China at 20% of US Price
$5.00
Available
Fullerton Raises $121 Million for China Healthcare Clinics; Ping An Leads Funding
$5.00
Available
HitGen of Chengdu Forms Drug Discovery Partnership with Boehringer Ingelheim
$5.00
Available
AstraZeneca Forms $265 Million China Drug Development JV with China Fund
$5.00
Available
Aspen Pharma of South Africa to Expand in China via Partnerships
$5.00
Available
3D Medicines Raises $101 Million for Cancer Diagnostics and Drugs
$5.00
Available
China Renaissance to Triple its Investment Fund Assets; Healthcare a Focus
$5.00
Available
Immunochina Lands $7.5 Million for CAR-T Drug Trials
$5.00
Available
Lee's Pharm Forms Second China Cancer Partnership with Beijing Shenogen
$5.00
Available
Guangzhou RiboBio Partners with GE to Build Oligonucleotide CRO/CMO Facility
$5.00
Available
Shanghai's MicroPort Acquires CRM Business from Liva Nova for $190 Million
$5.00
Available
Canada's Acasti Signs $133 Million Non-Binding Term Sheet with China Pharma
$5.00
Available
Zensun Raises $76 Million for Novel Drug Portfolio
$5.00
Available
Adlai Nortye In-Licenses Oncolytic's Cancer Drug in $86.6 Million Deal
$5.00
Available
Ascentage's IND Accepted in US for Inhibitor of Apoptosis Blocker
$5.00
Available
Shanghai Pharma Plans to Use M&A to Expand Overseas
$5.00
Available
Shanghai Pharma Acquires Cardinal's China Drug Distribution Business for $1.2 Billion
$5.00
Available
CorestoneBio Plans China JV with Boston's Respiratory Motion
$5.00
Available
Cygnus Raises $19.6 Million for Highly Accurate Sequencing Technology
$5.00
Available
RiboQuark Doses First Patient in China siRNA Trial
$5.00
Available
Arcus Completes $107 Million C Round with China VC Participation
$5.00
Available
Pfizer Sells 49% Stake in China Generic Drug JV
$5.00
Available
Valeant Sells Obagi to Fund that Includes China Regenerative Medicine
$5.00
Available
Ark Biosciences Partners with Calibr on Novel COPD Treatment
$5.00
Available
Genovis Finds Second China Distribution Partner for Enzyme Portfolio
$5.00
Available
US Denies Approval for Creat's $1.5 Billion Acquisition of Germany's Biotest
$5.00
Available
Cellular Biomedicine Opens Shanghai CAR-T Facility
$5.00
Available
Zhejiang Huahai In-licenses Immuno-Oncology Drug in $65 Million Deal
$5.00
Available
EOC, an Eddingpharm Spin-out, Closes $32 Million B Round for Oncology Assets
$5.00
Available
Guangzhou's AnchorDx Raises $28 Million for Precision Oncology Offerings
$5.00
Available
Luye Pharma Leads $11.2 Million Funding of Chicago's Exicure
$5.00
Available
Guangzhou Pharma May Form China Generics JV with Teva Pharma
$5.00
Available
WuXi Biologics Partners with Pall to Reduce mAb Production Costs
$5.00
Available
Shanghai Fosun To Take Control of Taiwan's Henlix for $98 Million
$5.00
Available
iPharma in-licenses Global Rights to FAK inhibitor from Boehringer Ingelheim
$5.00
Available
Annoroad, a Beijing Gene Services Company, Raises $100 Million in C Round
$5.00
Available
Two China Companies to Bid in $765 Million Auction for I-Med Radiology of Australia
$5.00
Available
Eye Tech Care's Ultrasound Glaucoma Treatment Approved for China Use
$5.00
Available
Shanghai Fosun Pays $73 Million for African Drug Distributor
$5.00
Available
Cyrano Partners with Shanghai Newsummit to Develop Treatment for Loss of Smell
$5.00
Available
Xynomic In-Licenses RAF Inhibitor from Boehringer in $502 Million Deal
$5.00
Available
Sumitomo Dainippon Acquires Asian Rights to Poxel's Diabetes Drug in $300 Million Agreement
$5.00
Available
Sinotau and Navidea Sign MOU for Beta-Amyloid Imaging Agent
$5.00
Available
MabSpace Biosciences Files China IND for Second-Gen PD-L1
$5.00
Available
CR Pharm Files for $368.5 Million China Pharma Fund
$5.00
Available
Chi-Med to Raise $301 Million in US Secondary Offering
$5.00
Available
China Approves Tianjing CanSino's Ebola Vaccine
$5.00
Available
Denovo Approved to Start US-China Phase III Trials of Lymphoma Drug
$5.00
Available
Transgene Reports Positive Data on its Tasly-Partnered HBV Therapy
$5.00
Available
Hong Kong's Nan Fung Leads $45 Million Round for US Hearing Device Maker
$5.00
Available
Suzhou's CStone Pharma Starts Phase I Trial of PD-L1 Candidate
$5.00
Available
FibroGen Says CFDA Accepts Novel Anemia NDA for Review
$5.00
Available
GIMDx/Improve Medical Gain China Rights to PD-L1 Quantifying Assay
$5.00
Available
Prenetics of Hong Kong Raises $40 Million for Individual DNA Testing
$5.00
Available
WuXi AppTec to Acquire Texas-Based Global Clinical Trial CRO
$5.00
Available
Chi-Med/AstraZeneca Drug Shows Efficacy Against Lung Cancer
$5.00
Available
Shenzhen Hepalink Invests $69 Million in Canada's Resverlogix
$5.00
Available
Huawei and Phillips Building AI Healthcare Platform for China
$5.00
Available
CASI Pharma Raises $23 Million in Private Placement
$5.00
Available
Innovent Licenses Use of Harbour Biomed's Biologic Drug Discovery Platform
$5.00
Available
China Biologic to Acquire TianXinFu, a Device Company, in $536 Million Deal
$5.00
Available
Samsung BioLogics' New Plant Approved by FDA
$5.00
Available
Generon Announces SPA for US Phase III Trial of Neutropenia Drug
$5.00
Available
Gentris and Shanghai Institute Sign MOU for Biomarker Collaboration
$5.00
Available
China's State Council Endorses CFDA's New Foreign Clinical Trial Data Policies
$5.00
Available
Shanghai Pharma in Second Round Bidding in $1.5 Billion Cardinal China Deal
$5.00
Available
Beijing is Home to Gates-Backed $100 Million Global Health Institute
$5.00
Available
Zhejiang Huahai Raises $152 Million for New Biopharma Facility
$5.00
Available
Hong Kong's Jacobson Pharma Raises $64 Million for M&A
$5.00
Available
ImmunoMet, a US HanAll Spinoff, Starts Clinical Trial of Cancer Drug
$5.00
Available
Fosun Pharma in $350 Million Auction to Acquire India's Symbiotec Pharma
$5.00
Available
MicroPort/LivaNova JV's Pacemaker Approved for China Use
$5.00
Available
Zai Labs Starts China Phase III Trial of Lead Drug in Ovarian Cancer
$5.00
Available
CR Gosun In-Licenses Antibiotic from Basilea in $153 Million Deal
$5.00
Available
Novo Nordisk Approved to Launch New Diabetes Treatment in China
$5.00
Available
Simcere to Market Four Amgen Biosimilars in China
$5.00
Available
Ping An Pays $245 Million for Stake in Japan's Tsumura, a TCM Company
$5.00
Available
Chengyuan Genomics to Market Single Cell RNA Sequence Device in China
$5.00
Available
Salubris Pharma Invests $5 Million in Boston's GO Therapeutics
$5.00
Available
Shanghai Pharma May Acquire US Operations of $4 Billion Generic Drugmaker
$5.00
Available
Sinovac Announces Early Positive Results for Chickenpox Vaccine
$5.00
Available
Shandong Weigao Pays $850 Million to Acquire Argon Medical Devices
$5.00
Available
Gilead Sciences Approved to Market HCV Drug in China
$5.00
Available
Bellen of Beijing Raises $38 Million to Support CRO Operations
$5.00
Available
Germany's Merck Opens Biologics CRO/CMO in Shanghai
$5.00
Available
Sisram Medical, Majority-Owned by Fosun, Stages $125 Million Hong Kong IPO
$5.00
Available
Infervision Raises $18 Million to Develop Automated Scan Reader
$5.00
Available
Wuhan's XW Labs Closes $17.5 Million B Round to Develop CNS Drugs
$5.00
Available
DelMar Pharma OK'd to Start Trial of Lead Drug in Ovarian Cancer Patients
$5.00
Available
Fosun Pharma Scales Back Purchase of India's Gland
$5.00
Available
Shuwen Biotech Approved for European Use of EGFR Test
$5.00
Available
Shanghai United Imaging Healthcare Raises Record $500 Million at $5 Billion Valuation
$5.00
Available
Spineology Raises $5 Million from Shanghai's Hermed Capital
$5.00
Available
China Resources Invests $4.6 Million in Hangzhou's Converd
$5.00
Available
Grid Therapeutics Closes A Round from Longview Intl. of Singapore
$5.00
Available
Zai Lab Plans $90 Million IPO at $800 Million Valuation
$5.00
Available
Ennovabio of Shanghai Raises $10 Million to Develop Brain Cancer Drug
$5.00
Available
Shanghai's Harbour BioMed in $81 Million Deal for Two HanAll Biologic Drugs
$5.00
Available
Wellem Raises $30 Million for China Pediatric Clinics
$5.00
Available
Suzhou Basecare Raises $15.3 Million for Pre-Implantation Genetic Screening Tests
$5.00
Available
Fosun In-Licenses Female Sexual Desire Disorder Drug in $106 Million Deal
$5.00
Available
HitGen to Discover Lead Molecules for Takeda
$5.00
Available
China Medical Systems Invests $8 Million in Destiny; Will Acquire Asia Rights for MRSA Candidate
$5.00
Available
TPG Asia Acquires Majority Stake in Taiwan-Asia Clinical CRO
$5.00
Available
Lilly Announces Plans to Close its Shanghai R&D Center
$5.00
Available
Suzhou's Innovent Strikes $457 Million Deal with CAS for Immuno-Oncology Candidate
$5.00
Available
WuXi NextCODE, a Genomics CRO, Closes $240 Million Series B Round
$5.00
Available
Shanghai Sanyou Medical Raises $14 Million for Spinal/Trauma Implants
$5.00
Available
SinoVision Technologies Raises $29 Million for CT Scanners
$5.00
Available
Wuxi Fortune Partners with Andarix to Develop Radiotherapeutic in China
$5.00
Available
OrbiMed Raises $551 Million for Third Asia Healthcare Fund
$5.00
Available
Sisram, a Fosun Pharma Device Company, Staging a $200 Million Hong Kong IPO
$5.00
Available
Fidelity's Eight Roads Launches $250 Million China Healthcare Venture Fund
$5.00
Available
3SBio Acquires CDMO Business from Canada's Therapure for $290 Million
$5.00
Available
Yisheng Biopharma Reports "Breakthrough" Efficacy of Lead Immuno-Oncology Drug
$5.00
Available
Fosun Pharma Acquires 65% Stake In SinoMedCare for $40 Million
$5.00
Available
iCAD Gains CFDA Approval to Market Brachytherapy Device in China
$5.00
Available
Berry Genomics Completes $648 Million Reverse Merger in Shenzhen
$5.00
Available
Shuidi Raises $24 Million for Healthcare Crowdfunding App
$5.00
Available
China's iPharma in $120 Million Deal for Mologen's Immunotherapy Candidate
$5.00
Available
Akeso Biopharma of Zhongshan Closes $45 Million B Round
$5.00
Available
CF PharmaTech of Suzhou Raises $65 Million for Inhaled Drug Products
$5.00
Available
aTyr Pharma, a Public US-Hong Kong Biotech, Announces $46 Million Private Placement
$5.00
Available
Distinct Healthcare Closes $40 Million Round for China Clinics
$5.00
Available
GSK Teams Up with Ali Health to Promote HPV Vaccine in China
$5.00
Available
Zhejiang Hisun Partners with Seattle's IDRI on Treatment for Drug-Resistant TB
$5.00
Available
GSK Teams Up with Ali Health to Promote HPV Vaccine in China
$5.00
Available
Columbia China Building $150 Million Hospital in Jiaxing, China
$5.00
Available
South Korea's EDGC and China's GPBio Form Genomics Partnership
$5.00
Available
Samsung Bioepis Forms Novel Biologics JV with Takeda Pharma
$5.00
Available
NovaBay
$5.00
Available
Hengrui and Crown Bioscience Announce Antibody Partnership
$5.00
Available
Amerigen Pharma Announces Two China-US Deals
$5.00
Available
Aeras and CNBG Partner on TB Vaccine
$5.00
Available
Shanghai Pharma Subsidiary Buys 51% of Jinhe Biotech
$5.00
Available
Mindray Climbs on Improved 2011 Revenues
$5.00
Available
China Kanghui Granted FDA Approval for Two Joint Replacements
$5.00
Available
AstraZeneca Wants to Build its Portfolio of Generic Drugs in China
$5.00
Available
Darren Ji Steps Down as PharmaLegacy CEO
$5.00
Available
Ascletis Lands $1.6 Million R&D Grant from Hangzhou Park
$5.00
Available
ProteoTech and GSK (China) Collaborate on Parkinson
$5.00
Available
Vivo Ventures Closes $375 Million US-China Life Science Fund
$5.00
Available
China Supports Foreign Direct Investment in Biotechnology
$5.00
Available
Harbin Pharma Trades $870 Million of Stock for Assets from Parent
$5.00
Available
China Health Resource, a TCM Maker, Ready to Start M&A Hunt
$5.00
Available
Yunnan Baiyao Opens New Production Facility
$5.00
Available
BioTime Options Cell Lines from USCN Life Science China
$5.00
Available
Frontage Labs Opens Clinical-Stage CRO in Jilin Hospital
$5.00
Available
Beijing Double-Crane Buys Transfusion Maker Huali
$5.00
Available
Sanjiu Expected to Acquire Shunfeng Pharma through Auction
$5.00
Available
ForteBio Acquired by Pall Corporation
$5.00
Available
Hutchison MediPharma Inks $140 Million Cancer Deal with AstraZeneca
$5.00
Available
Hengrui Gains FDA Approval for Cancer Drug
$5.00
Available
Hua Medicine In-licenses Diabetes Drug Candidate from Roche
$5.00
Available
Beijing SL Pharma Forms US-based Diabetes JV
$5.00
Available
DSM Sinochem JV Building Second China Anti-Infective Facility
$5.00
Available
China Sky One Partners Up to Form New Stem Cell Company
$5.00
Available
Jilin Aodong Defers Investment in Vital Therapies
$5.00
Available
Boehringer Ingelheim Sets $91 Million Shanghai Expansion
$5.00
Available
Sihuan Pharma Building $110 Million Facility in Beijing
$5.00
Available
Quintiles, a Clinical-Stage CRO, will Double China Headcount
$5.00
Available
China Will Regulate TCM Products to Improve Their Purity
$5.00
Available
Pfizer's Dual R&D Strategy for China
$5.00
Available
ICON Builds China Presence by Acquiring BeijingWits, a Clinical CRO
$5.00
Available
Mindray Medical Invests in Healthcare IT Company
$5.00
Available
Beijing SL Pharma Buys Stake in Forwell Biopharm
$5.00
Available
AstraZeneca Buys China Generic Drug Firm; Announces US Layoffs
$5.00
Available
Conba Buys 84% of Yunnan Xiogye Pharma
$5.00
Available
Aoxing Pharma Secures $3.2 Million from Bank Loan
$5.00
Available
Merck Will Build Beijing R&D Center; Invest $1.5 Billion in China
$5.00
Available
Foci Pharma to IPO in Shenzhen
$5.00
Available
Taiantang Pharma Pays $21.4 Million for Stake in TCM Company
$5.00
Available
LDR Given China Approval for Two Medical Devices
$5.00
Available
Haibin Pharma Announces European Approval for Bulk Antibiotic
$5.00
Available
WHO Certification a Shot-in-the-Arm for China Vaccine Makers
$5.00
Available
PRC Increases Goals of Healthcare Reform
$5.00
Available
Ascletis Nominated for Financing Deal of the Year
$5.00
Available
Sihuan Bioengineering Sues Vitapharm to Unwind Deal
$5.00
Available
Regeneron/Bayer Start China Trial of Wet AMD Drug
$5.00
Available
Zhejiang Huahai Pharma to Raise $204 Million
$5.00
Available
Fosun Pharma to Float up to $470 Million in Bonds
$5.00
Available
Kunming and ZBD to Collaborate on TCM Injection
$5.00
Available
A Second Life for Bayer
$5.00
Available
Lilly Concerned about IP Protection in China
$5.00
Available
China Plans $1.7 Trillion Investment in Hi-Tech, including Biotechnology
$5.00
Available
Tasly Pharma Selects ICON for Global Phase III Trial of TCM Heart Drug
$5.00
Available
BGI Forms Children
$5.00
Available
SFDA Will Inspect Foreign Drug Makers
$5.00
Available
Novartis Will Invest $25 Million in Zhongshan Facility
$5.00
Available
Italian Pharma Menarini Buys Invida of Singapore
$5.00
Available
Pfizer
$5.00
Available
Lepu Medical Buys Controlling Interest in Dutch Device Maker
$5.00
Available
Hutchison MediPharma Starts Clinical Trial of Cancer Drug
$5.00
Available
WuXi PharmaTech to Form $50 Million Venture Fund
$5.00
Available
Fosun Pharma Buys 6.5% Stake in Simcere for $30 Million
$5.00
Available
China Resources Medications Forms $158 Million JV with Pientzehuang
$5.00
Available
Former Head of Shanghai Pharma Given Death Sentence for Accepting Bribes
$5.00
Available
Sinovac Biotech
$5.00
Available
Kunming Pharma will Raise $110 Million to Boost Capacity
$5.00
Available
China Biotech
$5.00
Available
Jennerex/Lee
$5.00
Available
Yabao Pharma Raises $74 Million in Secondary Offering
$5.00
Available
Sanofi Says China Sales Grew 47% to $370 Million in Q3
$5.00
Available
China National Biotechnology to IPO on the Hong Kong Exchange
$5.00
Available
ImmBio Strikes China Deal with CNBG Unit for TB Vaccine
$5.00
Available
Aslan Pharma In-licenses China Rights to BMS Cancer Drug
$5.00
Available
Novo Nordisk Rejects China M&A; Will Grow through Innovation
$5.00
Available
The FDA Improves Tracking of Foreign-Sourced Drugs
$5.00
Available
Healthgen, a China Startup, Announces Rice-Derived Human Serum Albumin
$5.00
Available
Alios Signs Flu Treatment Deal with Univ. of Hong Kong
$5.00
Available
Gates Foundation and China Form $300 Million Drug and Agriculture Partnership
$5.00
Available
China to Up Vaccine Protection against Epidemics
$5.00
Available
Lansen Pharma In-licenses China Rights to Rheumatoid Drug
$5.00
Available
Lepu Medical Invests $15.6 Million to Increase Medical Device Capacity
$5.00
Available
Novartis Transferring Jobs from Europe/US to China and India
$5.00
Available
Modern Hasen Pharma Building $43.6 Million Essential Drug Facility
$5.00
Available
BioBay, Roche and Harvard Form Novel Cancer Drug Partnership
$5.00
Available
WuXi PharmaTech Makes Clinical-Stage CRO Acquisition
$5.00
Available
ShangPharma Buys Charles River
$5.00
Available
Simcere Partners Up with Suzhou NeuPharma on Cancer Drug
$5.00
Available
Medicilon to Complete Pre-Clinical Work on South Korean Anti-Depressant
$5.00
Available
Hepalink Pharma Posts Lower Q3 Results
$5.00
Available
Zhuhai Hokai Medical Instruments Completes ChiNext IPO
$5.00
Available
Lundbeck Sets Up Research Center in Shanghai
$5.00
Available
Sinocom Pharma Withdraws Nasdaq IPO
$5.00
Available
WuXi Buys Abgent, a US-China Antibody Maker
$5.00
Available
BeiGene In-Licenses Two Potential Cancer Drugs from Janssen
$5.00
Available
ViroMed
$5.00
Available
Sinovac Lands Flu Vaccine Order from Beijing CDC
$5.00
Available
SemBioSys Genetics of Canada Forms JV with Tasly Pharma
$5.00
Available
Chiva Pharma Acquires Global Rights to Osteoporosis Drug from Ligand
$5.00
Available
Biostar Announces $9.6 Million China Acquisition
$5.00
Available
University of Hong Kong and Sinopharm Sign Cooperation Agreement
$5.00
Available
AstraZeneca to Build $200 Million Manufacturing Plant in China Medical City
$5.00
Available
China Attacks Antibiotic Overuse, Putting Pressure on Makers
$5.00
Available
India Takes Aim at China Pharma's Inroads into the Indian Market
$5.00
Available
SciClone Announces $20 Million Stock Buyback
$5.00
Available
GSK Seeking Up to $2B Bolt-on Acquisitions in India
$5.00
Available
Guizhou Bailing Buys Another Ethnic-Miao TCM Company
$5.00
Available
Nycomed/Takeda Adds Antihistamine to China Portfolio
$5.00
Available
China
$5.00
Available
Sanjiu Medical Buys Four Small Pharmas
$5.00
Available
Merck Names China Expert as Directory of Strategy
$5.00
Available
Newsummit Launches $100 Million Fund for US Medical Device Makers
$5.00
Available
Cardinal Health Seeking to Acquire China Drug Distributors
$5.00
Available
Sinovac Given Final Go-Ahead for Animal Rabies Vaccine
$5.00
Available
Zhongsheng Pharma Commits $3 Million to Three Novel Drugs
$5.00
Available
AstraZeneca Remains Committed to Partnering in China
$5.00
Available
China Grand Pharma Pays $17 Million for Wuhan Kernel Biotech
$5.00
Available
ProMetic Sells Biotech Product in China
$5.00
Available
Daiichi Sankyo Given OK for Prostatic Hyperplasia Drug in China
$5.00
Available
Cipla, with Plants in China and India, Goes After Biosimilar Market
$5.00
Available
Lingrui Pharma Raises $60 Million to Expand Capacity
$5.00
Available
Pfizer Signs Jointown to Distribute its Drugs in China
$5.00
Available
Avenue Capital Plans $313 Million Fund for China Medical City
$5.00
Available
China Scientist Given Lasker Award for TCM-based Malaria Drug
$5.00
Available
Covidien to Build Medical Device R&D Center in Shanghai
$5.00
Available
ShangPharma Forms mAb Partnership with Hengrui Medicine
$5.00
Available
Merck Serono and Pharmaron Partner in Beijing Lab
$5.00
Available
China
$5.00
Available
Merck Partners with China
$5.00
Available
HealthLinx and CytogenDx to Develop New Ovarian Cancer IVD for China
$5.00
Available
Pfizer Starts Animal Health JV with Jilin Guoyuan
$5.00
Available
Fosun Pharma Buys 70% of Jinzhou Ahon Pharma fo $219 Million
$5.00
Available
Four China Vitamin C Makers to Face Price Fixing Charges in US
$5.00
Available
Fosun Pharma and Lonza to Start Generic Drug JV
$5.00
Available
AllCells Expands Primary Cell Services in Shanghai
$5.00
Available
GlaxoSmithKline to Use Three Vaccine Distributors to Cover China
$5.00
Available
SinoCubate Signs on Biotech Startup Veteran for Incubator
$5.00
Available
Merck Serono Opens Beijing Lab
$5.00
Available
Royal DSM and Sinochem Close Antibiotics JV Deal
$5.00
Available
NexBio Reports Positive Data from Test of Biologic Flu Drug
$5.00
Available
Nycomed Says Growth in China Helped Revenues
$5.00
Available
Sinopharm Beats Estimates for First Half of 2011
$5.00
Available
China
$5.00
Available
SFDA Issues Anti-Counterfeiting Rules for CMOs
$5.00
Available
Simcere Obtains SFDA Approval for Rheumatoid Arthritis Treatment
$5.00
Available
Vasomedical Buys Two China Medical Device Manufacturers
$5.00
Available
WuXi AppTec Certified by European Authorities for Bioanalytical Services
$5.00
Available
Simcere Passes EU-GMP Inspection for OTC Diarrhea Treatment
$5.00
Available
Life Technologies
$5.00
Available
Asymchem Announces $39 Million in VC Funds
$5.00
Available
Shanghai Pharma Acquires Jiangsu Drug Distributor
$5.00
Available
Epitomics Plans Taiwan IPO Later in 2011
$5.00
Available
WuXi PharmaTech to Add Clinical Trial CRO Services
$5.00
Available
3SBio Forms Investment Partnership with China Medical City
$5.00
Available
Shanghai Pharma Wants to Acquire US or European Pharma
$5.00
Available
Sinopharm Acquires Wuhan Zhongliang Pharma
$5.00
Available
Beijing SL Pharma Forms Canadian Vaccine JV
$5.00
Available
New FDA Plan to Increase Foreign Drugmaker Inspections
$5.00
Available
ShangPharma Bumps Stock Price 28% Higher with Share Buyback
$5.00
Available
WuXi PharmaTech Reports Big Jump in Q2 Manufacturing Revenues
$5.00
Available
ShangPharma Touts Growth in its Biologics Division
$5.00
Available
Bohai Pharma Acquires Yantai Tianzheng Pharma, a TCM Maker
$5.00
Available
NDRC Mandates Price Cuts on 82 Drugs
$5.00
Available
Mingyuan Medicare Buys Diagnostic Company for $55 Million
$5.00
Available
China Medical Technology and Leica to Form IVD Collaboration
$5.00
Available
Changshan Biochemical Sets Price for ChiNext IPO
$5.00
Available
Hisun Pharma Makes Another US Investment; This One with PharmTek
$5.00
Available
Global Pharm Acquires Drug Distributor for $9 Million
$5.00
Available
VWR Buys China
$5.00
Available
Simcere Plans to Triple Headcount in New R&D Facility
$5.00
Available
BGI and GT Life Sciences Publish Chinese Hamster Ovary Genome
$5.00
Available
Shionogi of Japan to Take Control of China
$5.00
Available
Merck Reduces Workforce Globally while Building in China
$5.00
Available
Shanxi C&Y Pharma to IPO on the ChiNext Exchange
$5.00
Available
Hepalink Pharma
$5.00
Available
Yiling Pharma Climbs in Post-IPO Trading
$5.00
Available
Boston Scientific to Spend $150 Million in China
$5.00
Available
Meheco Signs Contract for Controlling Interest in Tianshan
$5.00
Available
BGI Work on Structural Variations Published in Journal
$5.00
Available
Aeras and China National Biotech Sign MOU for TB Vaccine
$5.00
Available
Chi-Med Forming an OTC Drug Distribution JV
$5.00
Available
Merck and Simcere Form China JV to Develop and Sell Branded Drugs
$5.00
Available
Ascletis Adds Support to $100 Million in Startup Capital
$5.00
Available
Biolight Meditech and D.A. Diagnostics Debut on ChiNext Exchange
$5.00
Available
Shijiazhuang Yiling Pharma Raises Offering Price of ChiNext IPO
$5.00
Available
Sihuan Pharma Sells 50% of Drug Distribution Subsidiary to Shandong Buchang
$5.00
Available
Chongqing Zhifei Nixes Plan to Buy Bilthoven Biologicals
$5.00
Available
BeiLu Pharma Gives Up on Melatonin-based Depression Drug
$5.00
Available
China Takes Dramatic Step to Curb TCM Speculation
$5.00
Available
Bristol-Myers Squibb Ups its Plans for China
$5.00
Available
China Leads India on Drug Patents and Academic Drug Research
$5.00
Available
Guizhou Bailing Buys Majority Stake in Guizhou Herentang
$5.00
Available
Shanghai Pharma Spending to Build Drug Distribution Business
$5.00
Available
Novartis May IPO in China
$5.00
Available
3SBio Given OK for High-Dose EPIAO
$5.00
Available
Sagent Pharma Adds Lummy Pharma to its List of China Collaborators
$5.00
Available
Hikma Pharma Buys Stake in Hubei Haosun Pharma
$5.00
Available
Bimeda Sets Up Veterinary JV with Rainbow Labs
$5.00
Available
BeiGene Plans a $100 Million to $150 Million Capital Raise
$5.00
Available
Guangzhou Biotech Island Holds Official Opening
$5.00
Available
Baotou Dongbao and Grandhope Biotech Soar after ChiNext IPOs
$5.00
Available
Baiyunshan Pharma Expands Production Facility
$5.00
Available
MingSight and Relin Medicine Form China Ophthalmology JV
$5.00
Available
China May Subject HIV/AIDS Treatments to Mandatory Licensing
$5.00
Available
Mindray Medical Buys Majority Stake in Urinalysis Company
$5.00
Available
ARC Capital Invests $13 Million in Buchang Pharma Group
$5.00
Available
Boston Therapeutics and Advance Pharma in China Deal for Glucose Product
$5.00
Available
Gloria Pharma Loses Out on Bid to Acquire Dilong Pharma
$5.00
Available
Jointown Pharma and 360buy.com to Form Online China Pharmacy
$5.00
Available
MedicaNova and Zhejiang Medicine Announce Asthma-focused JV
$5.00
Available
Wuhan Kindstar Diagnostics Raises $11 Million in Series B Funding
$5.00
Available
Walvax Will Spend $112 Million to Up Vaccine Capacity
$5.00
Available
Biotech a Priority in China
$5.00
Available
Sinovac Starts Phase II Trial of EV71 Vaccine
$5.00
Available
Microbix and Hunan Influenza JV Looking Doubtful
$5.00
Available
Medivir Licenses China Rights for Cold Sore Treatment to Daewoong
$5.00
Available
J&J Opens Innovation Center for Medical Devices in Suzhou
$5.00
Available
Sirnaomics Names China Partner for siRNA Therapeutic
$5.00
Available
Sihuan Pharma Acquires TCM Cardiovascular Drug Maker for $120 Million
$5.00
Available
Shandong Jincheng Pharma Completes $72 Million IPO
$5.00
Available
China Medical Technology Signs Diagnostic Test Partnership
$5.00
Available
Britain and China Announce $155 Million Drug Development Partnership
$5.00
Available
BGI and Shenzhen Set Up National Gene Bank
$5.00
Available
Biomatters Partners with Genewiz; Plans Entry into China
$5.00
Available
SFDA Orders China Recall of GlaxoSmithKline Antibiotic
$5.00
Available
CRO ClinTec Making Push into China and Asia Pacific Region
$5.00
Available
Rhei Pharma Gaining on SFDA Approval of MuGard
$5.00
Available
PKU Southwest Synthetic Pharma to Acquire 100% of Distribution Subsidiary
$5.00
Available
LabCorp Buys Clearstone Labs, Giving it Access to China
$5.00
Available
Nycomed to Market Roche Osteoporosis Drug in China and Asia-Pacific
$5.00
Available
GlaxoSmithKline to Buy Out China Vaccine JV Partner
$5.00
Available
Conba Pharma Forms Cancer JV with Kite Pharma, a US Startup
$5.00
Available
Unigene Ends China Peptide JV; Will Out-License Technology
$5.00
Available
Luoxin Pharmacy to Develop Narrow-Spectrum Antibiotic
$5.00
Available
NDAs and INDs Quantify the Innovation in China
$5.00
Available
Harbor BioSciences in Deal for ex-China Distribution of Sinopharm Generics
$5.00
Available
BGI and U. of California, Davis Announce Partnership
$5.00
Available
Selected Value Therapeutics Acquires China Rights to Cancer Drug
$5.00
Available
Agenix Discloses Plans for Clinical Trial of Hepatitis B Drug
$5.00
Available
Simcere Receives Settlement for Shuttered Rabies Vaccine Facility
$5.00
Available
Northeast Pharma Announces $370 million Private Placement
$5.00
Available
China Medical System Buys 51% of Drug Maker
$5.00
Available
Foci Pharma Seeks EU Approval of TCM
$5.00
Available
KingMed Diagnostics Strikes Second Opinions Deal with U. of Pennsylvania
$5.00
Available
Zhejiang Huahai Obtains FDA Approval for Alzheimer
$5.00
Available
Tasly Pharma to Make $40 Million Investment in US Facility
$5.00
Available
Pfizer and Zhejiang Hisun Sign MOU for Branded Generics JV
$5.00
Available
First China Pharma Progressing on Acquisition of Drug Distributor
$5.00
Available
Livzon Pharma to Spend $154 Million on New API Facilities
$5.00
Available
All 11 Defendants Plead Guilty in Fake Avastin Case
$5.00
Available
D-Pharm Out-licenses China Rights for Epilepsy Drug to Nhwa Pharma
$5.00
Available
CAS and Univ. of Pennsylvania Set up Brain Mapping Center
$5.00
Available
Sinocom Releases Q1 Report before its IPO
$5.00
Available
Sinovac Announces Success for Phase I Trial of EV71 Vaccine
$5.00
Available
BeiGene Makes Key Hires in Clinical Research and Regulatory Affairs
$5.00
Available
Hainan Honz Pharma
$5.00
Available
Q1 Earnings Review: Healthy Revenue Increases, Smaller Profit Growth
$5.00
Available
ShangPharma Reports 26% Increase in Q1 Revenues
$5.00
Available
Qiming Shows China Venture Capital Running Strong
$5.00
Available
Shanghai Pharma Affiliate Hit with Allegations of Poor Quality
$5.00
Available
Walvax
$5.00
Available
Takeda Taking Steps for 10-Fold Increase in China Revenues
$5.00
Available
Shanghai Pharma Prices Hong Kong IPO at $2 Billion
$5.00
Available
Naviscan Signs Up Chindex as China Distributor of Breast-PET Scanner
$5.00
Available
Chongqing Zhifei Bidding to Buy Dutch Vaccine Company
$5.00
Available
Tianyin Pharma Approved to Launch Diabetes Treatment
$5.00
Available
Sanofi Expects China to be its Number Two Market by 2015
$5.00
Available
ChChina Stresses Consolidation in Five-Year Plan for Drug Distribution
$5.00
Available
China Meheco to Sell $939 Million of Drugs to Venezuela
$5.00
Available
WuXi Beats Financial Estimates in Q1
$5.00
Available
AstraZeneca
$5.00
Available
Sinopharm Xinjiang Unloads Seven Non-operating Subsidiaries
$5.00
Available
Simcere Subsidiary Given SFDA Approval for anti-TNF Biosimilar
$5.00
Available
Sinocom Pharma Plans $58 Million IPO on Nasdaq
$5.00
Available
Crown BioScience Raises $28.8 Million in C Round
$5.00
Available
C3 Jian to Form Clinical Research Facility with Sichuan Univ.
$5.00
Available
Beijing Second Pharma Wins US Approval for Anti- Hypertensive
$5.00
Available
Pfizer to Take Stake in $2.2 Billion Shanghai Pharma IPO
$5.00
Available
Shenzhen Edan Instruments Stages $146 Million ChiNext IPO
$5.00
Available
Columbia University Licenses Autoimmune IP to China Group
$5.00
Available
Roche Expects China to be #3 Market by 2015
$5.00
Available
Aslan Pharma of Singapore Raises $12 Million for In-licensing
$5.00
Available
Mitsui Gains Interest in Shenzhen Main Luck Pharma
$5.00
Available
Shanghai Pharma Reports Earnings Doubled in Q1
$5.00
Available
Sinopharm Will Raise $440 Million to Build Distribution Network
$5.00
Available
Cash-strapped Lotus Pharma Explains CapEx Decisions
$5.00
Available
Neuralstem and BaYi Brain Hospital Plan Stem Cell Trial in Stroke Patients
$5.00
Available
Shanghai Pharma and Pfizer Sign MOU to Expand Collaboration
$5.00
Available
Kinex Licenses China Rights for Cancer Molecule to Hanmi Pharma
$5.00
Available
Morningside Invests in Aduro Biotech, a US Cancer Immunotherapy Co.
$5.00
Available
SciClone to Acquire NovaMed Pharma for up to $105 Million
$5.00
Available
Jiangbo Commits Some of its Large Cash Hoard to buy Drug Distributor
$5.00
Available
Roche Expands Shanghai Facility into Third Global Operations Center
$5.00
Available
Standard Chemical (Taiwan) and DIA Pharma (Japan) Form China JV
$5.00
Available
Cachet Pharma Adds to Capacity of Beijing Drug Logistics Center
$5.00
Available
Shanghai Pharma
$5.00
Available
Greek Pharma Alapis Signs MoU with CSPC Pharma
$5.00
Available
Aoxing Pharma: An Exercise in Patience
$5.00
Available
India Tops China in Big Pharma-Generic Deals: Merck Signs up with Sun Pharma
$5.00
Available
China Regulates Antibiotics to Curb Abuse
$5.00
Available
China Life Science 2010: A Giant Leap Forward
$5.00
Available
Jilin Aodong Makes $2 Million Initial Investment in Vital Therapies
$5.00
Available
China Medical System Joins PRC
$5.00
Available
Pfizer and Daiichi Sankyo Team Up in China
$5.00
Available
Lilly Sees Big Opportunity in China
$5.00
Available
Shanghai Pharma Bumps Size of Hong Kong IPO by 50%
$5.00
Available
Huamin Pharma Plans $168 Million Antibiotic Facility
$5.00
Available
China YCT Bets Company on Botanical Flu Treatment
$5.00
Available
Merck Serono Expects M&A to Build China Sales
$5.00
Available
Kang Sheng Bao to Develop Immune System Diagnostic Test for SuperNova
$5.00
Available
ICON Ups China Presence and Posits Double-Standard in China Trials
$5.00
Available
Merck Expects to Garner 25% of its Revenues in China by 2013
$5.00
Available
Latest Round of Cuts in Drug Prices Takes Effect in China
$5.00
Available
Zhejiang Hisun Pharma Invests in US Biotech Startup
$5.00
Available
China Kanghui Acquires Stake in Orthopedic Implant Company
$5.00
Available
Competition between Drug Distributors Heats Up in Zhejiang Province
$5.00
Available
Takeda Pharma Ups Commitment to China
$5.00
Available
American Oriental Bioengineering: All Dressed Up, Nowhere to Go
$5.00
Available
Chongqing Fuan Pharma Makes Its Debut on ChiNext Exchange
$5.00
Available
Novartis Will Add China Sales Reps to Gain Market Share
$5.00
Available
China Touts Quick Identification of Novel Deadly Pathogen
$5.00
Available
Jilin Jian Yisheng Pharma IPOs on Shenzhen Exchange
$5.00
Available
SuperNova Diagnostics to Partner with Kang Sheng Bao Bio-Tech
$5.00
Available
Novo Nordisk Wins China Approval for Diabetes Drug
$5.00
Available
Shenogen Signs Up ShangPharma to Help Develop Cancer Drug
$5.00
Available
Pfizer Moving Antibacterial R&D from US to Shanghai
$5.00
Available
Pharmaron Signs CMO Contract with Isis Pharma
$5.00
Available
First China Pharma Acquires Fellow Drug Distributor
$5.00
Available
Four China Vitamin C Producers Charged in US Antitrust Suit
$5.00
Available
China Orders More Price Cuts for Drugs
$5.00
Available
Mindray Medical Buys China Infusion Pump Maker
$5.00
Available
Life Technologies Opens Asia-Pacific Distribution Center
$5.00
Available